drug1_db
stringlengths 7
7
| drug2_db
stringlengths 7
7
| drug1_id
int64 0
1.69k
| drug2_id
int64 0
1.69k
| drug_pair
sequencelengths 2
2
| drug1_name
stringlengths 4
85
| drug2_name
stringlengths 4
85
| drug1_desc
stringlengths 27
1.09k
| drug2_desc
stringlengths 27
6.14k
| label
stringclasses 3
values | label_idx
int64 0
2
| all_paths
sequencelengths 1
10
| all_paths_str
sequencelengths 1
10
| path_str
stringlengths 0
3.57k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00342 | DB00640 | 1,181 | 1,585 | [
"DDInter1770",
"DDInter31"
] | Terfenadine | Adenosine | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole] and [regadenson].[A229833,A229838] Adenosine is also indicated in the treatment of supraventricular tachycardia. Adenosine was granted FDA approval on 30 October 1989. | Major | 2 | [
[
[
1181,
25,
1585
]
],
[
[
1181,
24,
578
],
[
578,
62,
1585
]
],
[
[
1181,
24,
477
],
[
477,
63,
1585
]
],
[
[
1181,
63,
521
],
[
521,
24,
1585
]
],
[
[
1181,
24,
79
],
[
79,
24,
1585
]
],
[
[
1181,
25,
918
],
[
918,
63,
1585
]
],
[
[
1181,
64,
600
],
[
600,
24,
1585
]
],
[
[
1181,
25,
351
],
[
351,
64,
1585
]
],
[
[
1181,
25,
1424
],
[
1424,
25,
1585
]
],
[
[
1181,
24,
985
],
[
985,
64,
1585
]
]
] | [
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Adenosine"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Adenosine"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Adenosine"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Adenosine"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Adenosine"
]
],
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bicalutamide"
],
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Adenosine"
]
],
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Adenosine"
]
],
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Adenosine"
]
],
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Adenosine"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Adenosine"
]
]
] | Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Adenosine
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Adenosine
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Adenosine
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Adenosine
Terfenadine may lead to a major life threatening interaction when taken with Bicalutamide and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Adenosine
Terfenadine may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Adenosine
Terfenadine may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Adenosine
Terfenadine may lead to a major life threatening interaction when taken with Quinine and Quinine may lead to a major life threatening interaction when taken with Adenosine
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Adenosine |
DB01045 | DB01142 | 463 | 1,264 | [
"DDInter1590",
"DDInter593"
] | Rifampicin | Doxepin | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160) | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline], [clomipramine], [desipramine], [imipramine], [nortriptyline], [protriptyline] and [trimipramine]. Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant. However, in 2010 it was approved for the treatment of insomnia. The latter indication was presented by Pernix Therapeutics. | Minor | 0 | [
[
[
463,
23,
1264
]
],
[
[
463,
6,
4973
],
[
4973,
45,
1264
]
],
[
[
463,
63,
112
],
[
112,
23,
1264
]
],
[
[
463,
64,
600
],
[
600,
24,
1264
]
],
[
[
463,
25,
741
],
[
741,
63,
1264
]
],
[
[
463,
23,
1228
],
[
1228,
63,
1264
]
],
[
[
463,
63,
542
],
[
542,
24,
1264
]
],
[
[
463,
24,
392
],
[
392,
63,
1264
]
],
[
[
463,
24,
1411
],
[
1411,
24,
1264
]
],
[
[
463,
62,
1387
],
[
1387,
24,
1264
]
]
] | [
[
[
"Rifampicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doxepin"
]
],
[
[
"Rifampicin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Doxepin"
]
],
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doxepin"
]
],
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rolapitant"
],
[
"Rolapitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Rifampicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lenvatinib"
],
[
"Lenvatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levothyroxine"
],
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Rifampicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Terbinafine"
],
[
"Terbinafine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
]
] | Rifampicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Doxepin (Compound)
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Doxepin
Rifampicin may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Rifampicin may lead to a major life threatening interaction when taken with Rolapitant and Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Rifampicin may cause a minor interaction that can limit clinical effects when taken with Lenvatinib and Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Rifampicin may cause a minor interaction that can limit clinical effects when taken with Terbinafine and Terbinafine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin |
DB00313 | DB08938 | 556 | 1,384 | [
"DDInter1913",
"DDInter1112"
] | Valproic acid | Magaldrate | Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investigations into the anticonvulsant effects of khelline when he found that all of his samples, dissolved in valproic acid, exerted a similar degree of anticonvulsive activity. It first received approval on February 28, 1978 from the FDA under the trade name Depakene. Since then, it has been investigated for neuroprotective, anti-manic, and anti-migraine effects. It is currently a compound of interest in the field of oncology for its anti-proliferative effects and is the subject of many clinical trials in a variety of cancer types. | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Minor | 0 | [
[
[
556,
23,
1384
]
],
[
[
556,
23,
752
],
[
752,
23,
1384
]
],
[
[
556,
24,
401
],
[
401,
23,
1384
]
],
[
[
556,
24,
1487
],
[
1487,
24,
1384
]
],
[
[
556,
23,
1411
],
[
1411,
24,
1384
]
],
[
[
556,
23,
752
],
[
752,
24,
699
],
[
699,
23,
1384
]
],
[
[
556,
24,
401
],
[
401,
74,
1178
],
[
1178,
23,
1384
]
],
[
[
556,
24,
1487
],
[
1487,
64,
1178
],
[
1178,
23,
1384
]
],
[
[
556,
23,
1411
],
[
1411,
63,
167
],
[
167,
23,
1384
]
],
[
[
556,
24,
303
],
[
303,
40,
167
],
[
167,
23,
1384
]
]
] | [
[
[
"Valproic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Valproic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
]
],
[
[
"Valproic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
]
],
[
[
"Valproic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nadolol"
],
[
"Nadolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
],
[
"Trifluoperazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trifluoperazine"
],
[
"Trifluoperazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Valproic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Medroxyprogesterone acetate"
],
[
"Medroxyprogesterone acetate",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
]
] | Valproic acid may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate
Valproic acid may cause a minor interaction that can limit clinical effects when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate
Valproic acid may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine (Compound) resembles Trifluoperazine (Compound) and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Trifluoperazine and Trifluoperazine may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Valproic acid may cause a minor interaction that can limit clinical effects when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate |
DB00792 | DB06077 | 832 | 879 | [
"DDInter1878",
"DDInter1102"
] | Tripelennamine | Lumateperone | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumateperone is a newly approved 2nd generation antipsychotic currently indicated for the treatment of schizophrenia. It has a unique receptor binding profile and differs from other antipsychotics in that it modulates glutamate, serotonin and dopamine, which are all neurotransmitters that contribute to the pathophysiology of schizophrenia.[A189093,A189174] The data so far indicates that lumateperone can alleviate both positive and negative symptoms of schizophrenia. Further, not only is the new antipsychotic selective for dopamine (D2) receptors in the mesolimbic and mesocortical brain regions, but it also has minimal off-target activity. Both characteristics lend to a more favourable adverse effect profile and ultimately safer drug.[A189093,L10908] | Moderate | 1 | [
[
[
832,
24,
879
]
],
[
[
832,
24,
407
],
[
407,
63,
879
]
],
[
[
832,
24,
1511
],
[
1511,
24,
879
]
],
[
[
832,
63,
352
],
[
352,
24,
879
]
],
[
[
832,
40,
649
],
[
649,
24,
879
]
],
[
[
832,
35,
272
],
[
272,
24,
879
]
],
[
[
832,
74,
662
],
[
662,
24,
879
]
],
[
[
832,
63,
475
],
[
475,
25,
879
]
],
[
[
832,
24,
1311
],
[
1311,
25,
879
]
],
[
[
832,
24,
407
],
[
407,
63,
1511
],
[
1511,
24,
879
]
]
] | [
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Tripelennamine",
"{u} (Compound) resembles {v} (Compound)",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Tripelennamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Tripelennamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumateperone"
]
],
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumateperone"
]
],
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
]
] | Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Tripelennamine (Compound) resembles Clofedanol (Compound) and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Tripelennamine (Compound) resembles Chlorpheniramine (Compound) and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Tripelennamine (Compound) resembles Carbinoxamine (Compound) and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Lumateperone
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may lead to a major life threatening interaction when taken with Lumateperone
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone |
DB01035 | DB06589 | 1,401 | 1,250 | [
"DDInter1524",
"DDInter1400"
] | Procainamide | Pazopanib | A derivative of procaine with less CNS action. | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Major | 2 | [
[
[
1401,
25,
1250
]
],
[
[
1401,
6,
12523
],
[
12523,
45,
1250
]
],
[
[
1401,
21,
28658
],
[
28658,
60,
1250
]
],
[
[
1401,
62,
112
],
[
112,
23,
1250
]
],
[
[
1401,
36,
1151
],
[
1151,
24,
1250
]
],
[
[
1401,
63,
455
],
[
455,
24,
1250
]
],
[
[
1401,
24,
28
],
[
28,
63,
1250
]
],
[
[
1401,
24,
4
],
[
4,
24,
1250
]
],
[
[
1401,
64,
1557
],
[
1557,
24,
1250
]
],
[
[
1401,
25,
913
],
[
913,
63,
1250
]
]
] | [
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
]
],
[
[
"Procainamide",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Pazopanib"
]
],
[
[
"Procainamide",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Pazopanib"
]
],
[
[
"Procainamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pazopanib"
]
],
[
[
"Procainamide",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Sunitinib"
],
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Procainamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Procainamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
],
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Procainamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Astemizole"
],
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
]
] | Procainamide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pazopanib (Compound)
Procainamide (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Pazopanib (Compound)
Procainamide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pazopanib
Procainamide (Compound) resembles Sunitinib (Compound) and Procainamide may lead to a major life threatening interaction when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Procainamide may lead to a major life threatening interaction when taken with Astemizole and Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Procainamide may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib |
DB00015 | DB00208 | 582 | 1,018 | [
"DDInter1585",
"DDInter1804"
] | Reteplase | Ticlopidine | Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF). | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke. The FDA label includes a black-box warning of neutropenia, aplastic anemia, thrombotic thrombocytopenia purpura, and agranulocytosis, so it is necessary to monitor patients' WBC and platelets when they are taking ticlopidine. | Moderate | 1 | [
[
[
582,
24,
1018
]
],
[
[
582,
24,
1347
],
[
1347,
64,
1018
]
],
[
[
582,
23,
1631
],
[
1631,
62,
1018
]
],
[
[
582,
24,
643
],
[
643,
63,
1018
]
],
[
[
582,
25,
126
],
[
126,
63,
1018
]
],
[
[
582,
64,
942
],
[
942,
24,
1018
]
],
[
[
582,
24,
940
],
[
940,
24,
1018
]
],
[
[
582,
25,
365
],
[
365,
64,
1018
]
],
[
[
582,
25,
834
],
[
834,
25,
1018
]
],
[
[
582,
64,
1578
],
[
1578,
25,
1018
]
]
] | [
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticlopidine"
]
],
[
[
"Reteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
],
[
"Turmeric",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticlopidine"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
],
[
"Desvenlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bivalirudin"
],
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Icosapent"
],
[
"Icosapent",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalteparin"
],
[
"Dalteparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticlopidine"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Drotrecogin alfa"
],
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticlopidine"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticlopidine"
]
]
] | Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may lead to a major life threatening interaction when taken with Ticlopidine
Reteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Ticlopidine
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine
Reteplase may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine
Reteplase may lead to a major life threatening interaction when taken with Bivalirudin and Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Icosapent and Icosapent may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine
Reteplase may lead to a major life threatening interaction when taken with Dalteparin and Dalteparin may lead to a major life threatening interaction when taken with Ticlopidine
Reteplase may lead to a major life threatening interaction when taken with Drotrecogin alfa and Drotrecogin alfa may lead to a major life threatening interaction when taken with Ticlopidine
Reteplase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may lead to a major life threatening interaction when taken with Ticlopidine |
DB00674 | DB06589 | 1,516 | 1,250 | [
"DDInter802",
"DDInter1400"
] | Galantamine | Pazopanib | Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sources, such as _Galanthus nivalis_. Galantamine was first studied in paralytic and neuropathic conditions, such as myopathies and postpolio paralytic conditions, and for reversal of neuromuscular blockade.[A182993,A201968] Following the discovery of its AChE-inhibiting properties, the cognitive effects of galantamine were studied in a wide variety of psychiatric disorders such as mild cognitive impairment, cognitive impairment in schizophrenia and bipolar disorder, and autism; however, re-development of the drug for Alzheimer’s disease did not commence until the early 1990s due to difficulties in extraction and | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
1516,
24,
1250
]
],
[
[
1516,
7,
10365
],
[
10365,
45,
1250
]
],
[
[
1516,
6,
12523
],
[
12523,
45,
1250
]
],
[
[
1516,
18,
6072
],
[
6072,
57,
1250
]
],
[
[
1516,
21,
28658
],
[
28658,
60,
1250
]
],
[
[
1516,
24,
112
],
[
112,
23,
1250
]
],
[
[
1516,
24,
1151
],
[
1151,
24,
1250
]
],
[
[
1516,
63,
1419
],
[
1419,
24,
1250
]
],
[
[
1516,
24,
214
],
[
214,
63,
1250
]
],
[
[
1516,
63,
11
],
[
11,
25,
1250
]
]
] | [
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Galantamine",
"{u} (Compound) upregulates {v} (Gene)",
"STK10"
],
[
"STK10",
"{u} (Gene) is bound by {v} (Compound)",
"Pazopanib"
]
],
[
[
"Galantamine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Pazopanib"
]
],
[
[
"Galantamine",
"{u} (Compound) downregulates {v} (Gene)",
"MBOAT7"
],
[
"MBOAT7",
"{u} (Gene) is downregulated by {v} (Compound)",
"Pazopanib"
]
],
[
[
"Galantamine",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Pazopanib"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pazopanib"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
],
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
]
]
] | Galantamine (Compound) upregulates STK10 (Gene) and STK10 (Gene) is bound by Pazopanib (Compound)
Galantamine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pazopanib (Compound)
Galantamine (Compound) downregulates MBOAT7 (Gene) and MBOAT7 (Gene) is downregulated by Pazopanib (Compound)
Galantamine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Pazopanib (Compound)
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pazopanib
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Pazopanib |
DB08882 | DB14509 | 1,281 | 1,399 | [
"DDInter1070",
"DDInter1081"
] | Linagliptin | Lithium carbonate | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes. Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 2011. | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
1281,
24,
1399
]
],
[
[
1281,
63,
874
],
[
874,
23,
1399
]
],
[
[
1281,
63,
820
],
[
820,
24,
1399
]
],
[
[
1281,
24,
927
],
[
927,
24,
1399
]
],
[
[
1281,
40,
1002
],
[
1002,
24,
1399
]
],
[
[
1281,
24,
982
],
[
982,
64,
1399
]
],
[
[
1281,
63,
121
],
[
121,
25,
1399
]
],
[
[
1281,
63,
874
],
[
874,
40,
1636
],
[
1636,
23,
1399
]
],
[
[
1281,
63,
1636
],
[
1636,
1,
874
],
[
874,
23,
1399
]
],
[
[
1281,
63,
820
],
[
820,
63,
874
],
[
874,
23,
1399
]
]
] | [
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
],
[
"Epinephrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Linagliptin",
"{u} (Compound) resembles {v} (Compound)",
"Alogliptin"
],
[
"Alogliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
],
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
],
[
"Epinephrine",
"{u} (Compound) resembles {v} (Compound)",
"Phenylephrine"
],
[
"Phenylephrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylephrine"
],
[
"Phenylephrine",
"{u} (Compound) resembles {v} (Compound)",
"Epinephrine"
],
[
"Epinephrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
],
[
"Epinephrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lithium carbonate"
]
]
] | Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Linagliptin (Compound) resembles Alogliptin (Compound) and Alogliptin may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Lithium carbonate
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may lead to a major life threatening interaction when taken with Lithium carbonate
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine (Compound) resembles Phenylephrine (Compound) and Phenylephrine may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine and Phenylephrine (Compound) resembles Epinephrine (Compound) and Epinephrine may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate |
DB00556 | DB09078 | 1,262 | 1,228 | [
"DDInter1429",
"DDInter1036"
] | Perflutren | Lenvatinib | Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultrasound machine. The difference in density between the gas-filled bubbles and the blood around them creates an increased level of contrast visible in the resulting ultrasound image. During echocardiography, activated Perflutren enhances images of the inner edges or borders of the heart, producing an improved image that may enable physicians to better diagnose patients. | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression. In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers. Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer. Most patients with thyroid cancer have a very good prognosis with treatment (98% 5 year survival rate) involving surgery and hormone therapy. However, for patients with RAI-refractory thyroid cancer, treatment options are limited and the prognosis is poor, leading to a push for the development of more targeted therapies such as lenvatinib. | Moderate | 1 | [
[
[
1262,
24,
1228
]
],
[
[
1262,
23,
112
],
[
112,
23,
1228
]
],
[
[
1262,
24,
609
],
[
609,
24,
1228
]
],
[
[
1262,
24,
603
],
[
603,
63,
1228
]
],
[
[
1262,
63,
521
],
[
521,
24,
1228
]
],
[
[
1262,
40,
679
],
[
679,
24,
1228
]
],
[
[
1262,
25,
1069
],
[
1069,
25,
1228
]
],
[
[
1262,
25,
982
],
[
982,
64,
1228
]
],
[
[
1262,
24,
877
],
[
877,
64,
1228
]
],
[
[
1262,
24,
1487
],
[
1487,
25,
1228
]
]
] | [
[
[
"Perflutren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Perflutren",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lenvatinib"
]
],
[
[
"Perflutren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Perflutren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
],
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Perflutren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Perflutren",
"{u} (Compound) resembles {v} (Compound)",
"Sevoflurane"
],
[
"Sevoflurane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Perflutren",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
]
],
[
[
"Perflutren",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
]
],
[
[
"Perflutren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
]
],
[
[
"Perflutren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
]
]
] | Perflutren may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Perflutren (Compound) resembles Sevoflurane (Compound) and Sevoflurane may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Perflutren may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may lead to a major life threatening interaction when taken with Lenvatinib
Perflutren may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Lenvatinib
Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Lenvatinib
Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Lenvatinib |
DB00035 | DB00636 | 1,314 | 429 | [
"DDInter507",
"DDInter408"
] | Desmopressin | Clofibrate | Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release from the stimulation of increased plasma osmolarity or decreased circulating blood volume, ADH mainly acts on the cells of the distal part of the nephron and the collecting tubules in the kidney. The hormone interacts with V1, V2 or V3 receptors with differing signal cascade systems. Desmopressin displays enhanced antidiuretic potency, fewer pressor effects due to V2-selective actions, and a prolonged half-life and duration of action compared to endogenous ADH. It has been employed clinically since 1972 | A fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986) | Moderate | 1 | [
[
[
1314,
24,
429
]
],
[
[
1314,
21,
28787
],
[
28787,
60,
11538
],
[
11538,
40,
429
]
],
[
[
1314,
21,
28787
],
[
28787,
60,
11254
],
[
11254,
1,
429
]
],
[
[
1314,
21,
28974
],
[
28974,
60,
467
],
[
467,
64,
429
]
],
[
[
1314,
21,
28845
],
[
28845,
60,
473
],
[
473,
63,
429
]
],
[
[
1314,
21,
28787
],
[
28787,
60,
245
],
[
245,
24,
429
]
],
[
[
1314,
24,
831
],
[
831,
40,
11254
],
[
11254,
1,
429
]
],
[
[
1314,
24,
831
],
[
831,
1,
535
],
[
535,
40,
429
]
],
[
[
1314,
24,
831
],
[
831,
6,
6664
],
[
6664,
45,
429
]
],
[
[
1314,
24,
831
],
[
831,
24,
1411
],
[
1411,
63,
429
]
]
] | [
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofibrate"
]
],
[
[
"Desmopressin",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Benzocaine"
],
[
"Benzocaine",
"{u} (Compound) resembles {v} (Compound)",
"Clofibrate"
]
],
[
[
"Desmopressin",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bezafibrate"
],
[
"Bezafibrate",
"{u} (Compound) resembles {v} (Compound)",
"Clofibrate"
]
],
[
[
"Desmopressin",
"{u} (Compound) causes {v} (Side Effect)",
"Swelling"
],
[
"Swelling",
"{u} (Side Effect) is caused by {v} (Compound)",
"Simvastatin"
],
[
"Simvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clofibrate"
]
],
[
[
"Desmopressin",
"{u} (Compound) causes {v} (Side Effect)",
"Oedema"
],
[
"Oedema",
"{u} (Side Effect) is caused by {v} (Compound)",
"Repaglinide"
],
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofibrate"
]
],
[
[
"Desmopressin",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofibrate"
]
],
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indomethacin"
],
[
"Indomethacin",
"{u} (Compound) resembles {v} (Compound)",
"Bezafibrate"
],
[
"Bezafibrate",
"{u} (Compound) resembles {v} (Compound)",
"Clofibrate"
]
],
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indomethacin"
],
[
"Indomethacin",
"{u} (Compound) resembles {v} (Compound)",
"Fenofibrate"
],
[
"Fenofibrate",
"{u} (Compound) resembles {v} (Compound)",
"Clofibrate"
]
],
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indomethacin"
],
[
"Indomethacin",
"{u} (Compound) binds {v} (Gene)",
"PPARA"
],
[
"PPARA",
"{u} (Gene) is bound by {v} (Compound)",
"Clofibrate"
]
],
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indomethacin"
],
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofibrate"
]
]
] | Desmopressin (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Benzocaine (Compound) and Benzocaine (Compound) resembles Clofibrate (Compound)
Desmopressin (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Bezafibrate (Compound) and Bezafibrate (Compound) resembles Clofibrate (Compound)
Desmopressin (Compound) causes Swelling (Side Effect) and Swelling (Side Effect) is caused by Simvastatin (Compound) and Simvastatin may lead to a major life threatening interaction when taken with Clofibrate
Desmopressin (Compound) causes Oedema (Side Effect) and Oedema (Side Effect) is caused by Repaglinide (Compound) and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Clofibrate
Desmopressin (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Clofibrate
Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin (Compound) resembles Bezafibrate (Compound) and Bezafibrate (Compound) resembles Clofibrate (Compound)
Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin (Compound) resembles Fenofibrate (Compound) and Fenofibrate (Compound) resembles Clofibrate (Compound)
Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin (Compound) binds PPARA (Gene) and PPARA (Gene) is bound by Clofibrate (Compound)
Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Clofibrate |
DB00363 | DB01206 | 695 | 37 | [
"DDInter419",
"DDInter1086"
] | Clozapine | Lomustine | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine receptors results in fewer extrapyramidal side effects, especially tardive dyskinesia. However, its promiscuity toward the muscarinic and adrenergic receptors can result in other side effects, notably gastrointestinal hypomotility and orthostatic hypotension. [L905,A215552]. Despite its effectiveness in treating both positive and negative symptoms of schizophrenia, clozapine was briefly removed from the market in various jurisdictions in 1970 due to severe agranulocytosis.[A256713,A256718] However, continued evidence of its effectiveness led to clozapine's eventual reintroduction, although | An alkylating agent of value against both hematologic malignancies and solid tumors. | Major | 2 | [
[
[
695,
25,
37
]
],
[
[
695,
6,
8374
],
[
8374,
45,
37
]
],
[
[
695,
25,
147
],
[
147,
23,
37
]
],
[
[
695,
64,
141
],
[
141,
24,
37
]
],
[
[
695,
25,
51
],
[
51,
24,
37
]
],
[
[
695,
25,
384
],
[
384,
63,
37
]
],
[
[
695,
25,
375
],
[
375,
64,
37
]
],
[
[
695,
25,
1377
],
[
1377,
25,
37
]
],
[
[
695,
24,
752
],
[
752,
25,
37
]
],
[
[
695,
64,
1057
],
[
1057,
25,
37
]
]
] | [
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomustine"
]
],
[
[
"Clozapine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Lomustine"
]
],
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomustine"
]
],
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Floxuridine"
],
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
]
],
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Daunorubicin"
],
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
]
],
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
]
],
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomustine"
]
],
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomustine"
]
],
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomustine"
]
],
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomustine"
]
]
] | Clozapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lomustine (Compound)
Clozapine may lead to a major life threatening interaction when taken with Vinblastine and Vinblastine may cause a minor interaction that can limit clinical effects when taken with Lomustine
Clozapine may lead to a major life threatening interaction when taken with Floxuridine and Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Lomustine
Clozapine may lead to a major life threatening interaction when taken with Daunorubicin and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Lomustine
Clozapine may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Lomustine
Clozapine may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Lomustine
Clozapine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Lomustine
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may lead to a major life threatening interaction when taken with Lomustine
Clozapine may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Lomustine |
DB00434 | DB00470 | 13 | 530 | [
"DDInter459",
"DDInter601"
] | Cyproheptadine | Dronabinol | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction with cannabinoid receptors that are found throughout the body . While both CBD and THC are used for medicinal purposes, they have different receptor activity, function, and physiological effects. If not provided in their activated form (such as through synthetic forms like Dronabinol or ), THC and CBD are obtained through conversion from their precursors, tetrahydrocannabinolic acid-A (THCA-A) and cannabidiolic acid (CBDA), through decarboxylation reactions. This can be achieved through heating, smoking, vaporization, or baking of dried unfertilized female cannabis flowers. From a pharmacological perspective, Cannabis' diverse receptor profile explains its potential application for such a wide variety of medical conditions. Cannabis contains more than 400 different chemical compounds, of which 61 are considered cannabinoids, a class of compounds that act upon endogenous cannabinoid receptors of the body . The endocannabinoid system is widely distributed throughout the central and peripheral nervous system (via the Cannabinoid Receptors CB1 and CB2) and plays a role in many physiological processes such as inflammation, cardiovascular function, learning, pain, memory, stress and emotional regulation, and the sleep/wake cycle among many others . CB1 receptors are found in both the central and peripheral nervous system, and are most abundant in the hippocampus and amygdala, which are the areas of the brain responsible for short-term memory storage and emotional regulation. CB2 receptors are mainly located in the peripheral nervous system and can be found on lymphoid tissue where they are involved in regulation of immune function . | Moderate | 1 | [
[
[
13,
24,
530
]
],
[
[
13,
24,
1614
],
[
1614,
40,
530
]
],
[
[
13,
21,
29118
],
[
29118,
60,
530
]
],
[
[
13,
63,
701
],
[
701,
24,
530
]
],
[
[
13,
24,
358
],
[
358,
63,
530
]
],
[
[
13,
25,
306
],
[
306,
63,
530
]
],
[
[
13,
74,
21
],
[
21,
24,
530
]
],
[
[
13,
24,
1349
],
[
1349,
24,
530
]
],
[
[
13,
35,
1405
],
[
1405,
63,
530
]
],
[
[
13,
24,
1301
],
[
1301,
64,
530
]
]
] | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} (Compound) resembles {v} (Compound)",
"Dronabinol"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) causes {v} (Side Effect)",
"Tachycardia"
],
[
"Tachycardia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dronabinol"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
]
],
[
[
"Cyproheptadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zonisamide"
],
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amitriptyline"
],
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meperidine"
],
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levacetylmethadol"
],
[
"Levacetylmethadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronabinol"
]
]
] | Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone (Compound) resembles Dronabinol (Compound)
Cyproheptadine (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Dronabinol (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol
Cyproheptadine may lead to a major life threatening interaction when taken with Zonisamide and Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol
Cyproheptadine (Compound) resembles Amitriptyline (Compound) and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Amitriptyline and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Meperidine and Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol
Cyproheptadine (Compound) resembles Cyclobenzaprine (Compound) and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Levacetylmethadol and Levacetylmethadol may lead to a major life threatening interaction when taken with Dronabinol |
DB04932 | DB09079 | 1,564 | 1,496 | [
"DDInter491",
"DDInter1296"
] | Defibrotide | Nintedanib | Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). It is marketed under the brand names Dasovas (FM), Noravid, and Prociclide in a variety of countries. In the USA it is was approved in March, 2016 as Defitelio. | Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one of only two disease-modifying therapies available and indicated for the condition (the other being [Pirfenidone]) and as such is used as a first-line treatment following diagnosis to slow down the progressive loss of lung function. As a chemotherapeutic agent for NSCLC, nintedanib, in combination with [Docetaxel], is reserved for patients who have tried and failed first-line chemotherapeutic options. | Moderate | 1 | [
[
[
1564,
24,
1496
]
],
[
[
1564,
25,
707
],
[
707,
24,
1496
]
],
[
[
1564,
64,
20
],
[
20,
24,
1496
]
],
[
[
1564,
63,
765
],
[
765,
24,
1496
]
],
[
[
1564,
25,
235
],
[
235,
63,
1496
]
],
[
[
1564,
64,
834
],
[
834,
25,
1496
]
],
[
[
1564,
25,
707
],
[
707,
64,
20
],
[
20,
24,
1496
]
],
[
[
1564,
64,
20
],
[
20,
25,
707
],
[
707,
24,
1496
]
],
[
[
1564,
63,
765
],
[
765,
63,
20
],
[
20,
24,
1496
]
],
[
[
1564,
64,
25
],
[
25,
24,
1317
],
[
1317,
24,
1496
]
]
] | [
[
[
"Defibrotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Defibrotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
],
[
"Danaparoid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Defibrotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Defibrotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hemin"
],
[
"Hemin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Defibrotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Defibrotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Drotrecogin alfa"
],
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nintedanib"
]
],
[
[
"Defibrotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
],
[
"Danaparoid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Defibrotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
],
[
"Danaparoid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Defibrotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hemin"
],
[
"Hemin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Defibrotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anistreplase"
],
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dipyridamole"
],
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
]
] | Defibrotide may lead to a major life threatening interaction when taken with Danaparoid and Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Defibrotide may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Defibrotide may cause a moderate interaction that could exacerbate diseases when taken with Hemin and Hemin may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Defibrotide may lead to a major life threatening interaction when taken with Desirudin and Desirudin may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Defibrotide may lead to a major life threatening interaction when taken with Drotrecogin alfa and Drotrecogin alfa may lead to a major life threatening interaction when taken with Nintedanib
Defibrotide may lead to a major life threatening interaction when taken with Danaparoid and Danaparoid may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Defibrotide may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may lead to a major life threatening interaction when taken with Danaparoid and Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Defibrotide may cause a moderate interaction that could exacerbate diseases when taken with Hemin and Hemin may cause a moderate interaction that could exacerbate diseases when taken with Tenecteplase and Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Defibrotide may lead to a major life threatening interaction when taken with Anistreplase and Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Dipyridamole and Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib |
DB00252 | DB01156 | 362 | 593 | [
"DDInter1460",
"DDInter252"
] | Phenytoin | Bupropion | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for several other indications such as bipolar disorder, retina protection, and wound healing.[A188826,A188832] Clinicians are advised to initiate therapeutic drug monitoring in patients who require phenytoin since even small deviations from the recommended therapeutic range can lead to suboptimal treatment, or adverse effects.[A189219,A35884] Both parenteral and oral formulations of phenytoin are available on the market. | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the uptake of the neurotransmitters norepinephrine and dopamine from the synaptic cleft, therefore prolonging their duration of action within the neuronal synapse and the downstream effects of these neurotransmitters. More specifically, bupropion binds to the norepinephrine transporter (NET) and the dopamine transporter (DAT).[A6399,A178810] Bupropion was originally classified as an "atypical" antidepressant because it does not exert the same effects as the classical antidepressants such as Monoamine Oxidase Inhibitors (MAOIs), Tricyclic Antidepressants (TCAs), or Selective Serotonin Reuptake Inhibitors (SSRIs). While it has comparable effectiveness to typical first-line options for the treatment of depression such as SSRIs,[A178798,A178804] bupropion is a unique option for the treatment of MDD as it lacks any clinically relevant serotonergic effects, typical of other mood medications, or any effects on histamine or adrenaline receptors.[A6399,A178840] Lack of activity at these receptors results in a more tolerable side effect profile; bupropion is less likely to cause sexual side effects, sedation, or weight gain as compared to SSRIs or TCAs, for example.[A178804,A178807] When used as an aid to smoking cessation, bupropion is thought to confer its anti-craving and anti-withdrawal effects by inhibiting dopamine reuptake, which is thought to be involved in the reward pathways associated with nicotine, and through the antagonism of the nicotinic acetylcholinergic receptor.[A178825,A1966,A16508] A Cochrane Review of meta-analyses of available treatment modalities for smoking cessation found that abstinence rates approximately doubled when bupropion was used as compared to placebo, and was found to have similar rates of smoking cessation as [nicotine] replacement therapy (NRT). Bupropion is sometimes used as an add-on agent to first-line treatments of depression such as selective serotonin reuptake inhibitor (SSRI) medications when there is a treatment-failure or only partial response. Bupropion is also used off-label for the management of Attention/Deficit-Hyperactivity Disorder (ADHD) in adults with comorbid bipolar depression to avoid mood destabilization caused by typical stimulant medications used for the treatment of ADHD. When used in combination with [naltrexone] in the marketed product ContraveⓇ for chronic weight management, the two components are thought to have effects on areas of the brain involved in the regulation of food intake. This includes the hypothalamus, which is involved in appetite regulation, and the mesolimbic dopamine circuit, which is involved in reward pathways. Studies have shown that the combined activity of bupropion and [naltrexone] increase the firing rate of hypothalamic pro-opiomelanocortin (POMC) neurons and blockade of opioid receptor-mediated POMC auto-inhibition, which are associated with a reduction in food intake and increased energy expenditure.[L6562,A179038,A179050] The combination of naltrexone and bupropion was shown to result in a statistically significant weight loss, with a mean change in body weight of -6.3% compared to -1.3% for placebo. | Moderate | 1 | [
[
[
362,
24,
593
]
],
[
[
362,
6,
3486
],
[
3486,
45,
593
]
],
[
[
362,
21,
29220
],
[
29220,
60,
593
]
],
[
[
362,
25,
752
],
[
752,
23,
593
]
],
[
[
362,
24,
126
],
[
126,
24,
593
]
],
[
[
362,
25,
1033
],
[
1033,
63,
593
]
],
[
[
362,
1,
759
],
[
759,
24,
593
]
],
[
[
362,
24,
1040
],
[
1040,
63,
593
]
],
[
[
362,
1,
651
],
[
651,
63,
593
]
],
[
[
362,
35,
1376
],
[
1376,
24,
593
]
]
] | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Phenytoin",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Bupropion"
]
],
[
[
"Phenytoin",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain upper"
],
[
"Abdominal pain upper",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bupropion"
]
],
[
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bupropion"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alpelisib"
],
[
"Alpelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Primidone"
],
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
]
] | Phenytoin (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Bupropion (Compound)
Phenytoin (Compound) causes Abdominal pain upper (Side Effect) and Abdominal pain upper (Side Effect) is caused by Bupropion (Compound)
Phenytoin may lead to a major life threatening interaction when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Bupropion
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Bupropion
Phenytoin may lead to a major life threatening interaction when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Bupropion
Phenytoin (Compound) resembles Primidone (Compound) and Primidone may cause a moderate interaction that could exacerbate diseases when taken with Bupropion
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Bupropion
Phenytoin (Compound) resembles Fosphenytoin (Compound) and Fos
Phenytoin (Compound) resembles Diphenhydramine (Compound) and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Bupropion |
DB00468 | DB01044 | 1,424 | 246 | [
"DDInter1557",
"DDInter809"
] | Quinine | Gatifloxacin | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood. | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. It is also available as eye drops under the brand name Zymar® marketed by Allergan. The FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence of hyperglycemic and hypoglycemic episodes in patients taking gatifloxacin compared to those on macrolide antibiotics.[L43942,L44037] | Major | 2 | [
[
[
1424,
25,
246
]
],
[
[
1424,
24,
739
],
[
739,
1,
246
]
],
[
[
1424,
64,
1176
],
[
1176,
1,
246
]
],
[
[
1424,
25,
945
],
[
945,
40,
246
]
],
[
[
1424,
24,
872
],
[
872,
40,
246
]
],
[
[
1424,
21,
28741
],
[
28741,
60,
246
]
],
[
[
1424,
23,
112
],
[
112,
23,
246
]
],
[
[
1424,
24,
973
],
[
973,
62,
246
]
],
[
[
1424,
24,
603
],
[
603,
63,
246
]
],
[
[
1424,
24,
688
],
[
688,
24,
246
]
]
] | [
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gatifloxacin"
]
],
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gatifloxacin"
]
],
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sparfloxacin"
],
[
"Sparfloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gatifloxacin"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gatifloxacin"
]
],
[
[
"Quinine",
"{u} (Compound) causes {v} (Side Effect)",
"Agitation"
],
[
"Agitation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Gatifloxacin"
]
],
[
[
"Quinine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
],
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gatifloxacin"
]
]
] | Quinine may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gatifloxacin (Compound)
Quinine may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Gatifloxacin (Compound)
Quinine may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Gatifloxacin (Compound)
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Gatifloxacin (Compound)
Quinine (Compound) causes Agitation (Side Effect) and Agitation (Side Effect) is caused by Gatifloxacin (Compound)
Quinine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gatifloxacin
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a minor interaction that can limit clinical effects when taken with Gatifloxacin
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Gatifloxacin
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Gatifloxacin |
DB01416 | DB05351 | 1,024 | 101 | [
"DDInter326",
"DDInter519"
] | Cefpodoxime | Dexlansoprazole | Cefpodoxime is an oral third generation cephalosporin antibiotic with effectiveness against most Gram positive and Gram negative bacteria. Commonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime. | Dexlansoprazole is a new-generation proton pump inhibitor (PPI) used for the management of symptoms associated with gastroesophageal reflux disease (GERD) and erosive esophagitis. Dexlansoprazole is the R-enantiomer of , which is composed of a racemic mixture of the R- and S-enantiomers. Compared to the older generation of PPIs (which includes , , and ), dexlansoprazole has a unique pharmacokinetic profile due to its delayed-release and dual-delivery release system: This aims to address some limitations of the older-generation PPIs, such as short plasma half-life and the need for meal-associated dosing.[A19566, A19568, A178084, A174244] Dexlansoprazole inhibits the final step in gastric acid production by blocking the (H+, K+)-ATPase enzyme. | Moderate | 1 | [
[
[
1024,
24,
101
]
],
[
[
1024,
63,
361
],
[
361,
24,
101
]
],
[
[
1024,
1,
665
],
[
665,
24,
101
]
],
[
[
1024,
40,
1462
],
[
1462,
24,
101
]
],
[
[
1024,
63,
361
],
[
361,
63,
589
],
[
589,
24,
101
]
],
[
[
1024,
63,
1448
],
[
1448,
63,
1479
],
[
1479,
23,
101
]
],
[
[
1024,
63,
1132
],
[
1132,
24,
1479
],
[
1479,
23,
101
]
],
[
[
1024,
1,
665
],
[
665,
63,
361
],
[
361,
24,
101
]
],
[
[
1024,
40,
1462
],
[
1462,
1,
665
],
[
665,
24,
101
]
],
[
[
1024,
63,
126
],
[
126,
25,
256
],
[
256,
62,
101
]
]
] | [
[
[
"Cefpodoxime",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Cefpodoxime",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neomycin"
],
[
"Neomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Cefpodoxime",
"{u} (Compound) resembles {v} (Compound)",
"Cefuroxime"
],
[
"Cefuroxime",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Cefpodoxime",
"{u} (Compound) resembles {v} (Compound)",
"Cefditoren"
],
[
"Cefditoren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Cefpodoxime",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neomycin"
],
[
"Neomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
],
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Cefpodoxime",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
],
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Cefpodoxime",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gentamicin"
],
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Cefpodoxime",
"{u} (Compound) resembles {v} (Compound)",
"Cefuroxime"
],
[
"Cefuroxime",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neomycin"
],
[
"Neomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Cefpodoxime",
"{u} (Compound) resembles {v} (Compound)",
"Cefditoren"
],
[
"Cefditoren",
"{u} (Compound) resembles {v} (Compound)",
"Cefuroxime"
],
[
"Cefuroxime",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Cefpodoxime",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
],
[
"Prasugrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexlansoprazole"
]
]
] | Cefpodoxime may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole
Cefpodoxime (Compound) resembles Cefuroxime (Compound) and Cefuroxime may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole
Cefpodoxime (Compound) resembles Cefditoren (Compound) and Cefditoren may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole
Cefpodoxime may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole
Cefpodoxime may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin and Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Dexlansoprazole
Cefpodoxime may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Dexlansoprazole
Cefpodoxime (Compound) resembles Cefuroxime (Compound) and Cefuroxime may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole
Cefpodoxime (Compound) resembles Cefditoren (Compound) and Cefditoren (Compound) resembles Cefuroxime (Compound) and Cefuroxime may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole
Cefpodoxime may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Dexlansoprazole |
DB00745 | DB01268 | 307 | 1,151 | [
"DDInter1236",
"DDInter1731"
] | Modafinil | Sunitinib | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with psychoactivation and euphoria. The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular dopamine. Modafinil activates glutamatergic circuits while inhibiting GABA. | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3. | Moderate | 1 | [
[
[
307,
24,
1151
]
],
[
[
307,
6,
8374
],
[
8374,
45,
1151
]
],
[
[
307,
18,
10375
],
[
10375,
57,
1151
]
],
[
[
307,
21,
28868
],
[
28868,
60,
1151
]
],
[
[
307,
24,
1148
],
[
1148,
24,
1151
]
],
[
[
307,
23,
1250
],
[
1250,
63,
1151
]
],
[
[
307,
24,
659
],
[
659,
63,
1151
]
],
[
[
307,
1,
847
],
[
847,
24,
1151
]
],
[
[
307,
62,
1424
],
[
1424,
24,
1151
]
],
[
[
307,
63,
1324
],
[
1324,
24,
1151
]
]
] | [
[
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Modafinil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Sunitinib"
]
],
[
[
"Modafinil",
"{u} (Compound) downregulates {v} (Gene)",
"RPS4Y1"
],
[
"RPS4Y1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Sunitinib"
]
],
[
[
"Modafinil",
"{u} (Compound) causes {v} (Side Effect)",
"Stomatitis"
],
[
"Stomatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sunitinib"
]
],
[
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Modafinil",
"{u} (Compound) resembles {v} (Compound)",
"Atomoxetine"
],
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
]
] | Modafinil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sunitinib (Compound)
Modafinil (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Sunitinib (Compound)
Modafinil (Compound) causes Stomatitis (Side Effect) and Stomatitis (Side Effect) is caused by Sunitinib (Compound)
Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Modafinil may cause a minor interaction that can limit clinical effects when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Modafinil (Compound) resembles Atomoxetine (Compound) and Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Modafinil may cause a minor interaction that can limit clinical effects when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib |
DB00283 | DB00782 | 701 | 1,123 | [
"DDInter395",
"DDInter1535"
] | Clemastine | Propantheline | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | Moderate | 1 | [
[
[
701,
24,
1123
]
],
[
[
701,
21,
28898
],
[
28898,
60,
1123
]
],
[
[
701,
24,
551
],
[
551,
23,
1123
]
],
[
[
701,
24,
768
],
[
768,
63,
1123
]
],
[
[
701,
24,
999
],
[
999,
24,
1123
]
],
[
[
701,
63,
534
],
[
534,
24,
1123
]
],
[
[
701,
25,
675
],
[
675,
24,
1123
]
],
[
[
701,
35,
1594
],
[
1594,
24,
1123
]
],
[
[
701,
35,
1511
],
[
1511,
63,
1123
]
],
[
[
701,
25,
1621
],
[
1621,
25,
1123
]
]
] | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
]
],
[
[
"Clemastine",
"{u} (Compound) causes {v} (Side Effect)",
"Constipation"
],
[
"Constipation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Propantheline"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
],
[
"Phenelzine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Propantheline"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tapentadol"
],
[
"Tapentadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tramadol"
],
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
]
],
[
[
"Clemastine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
]
],
[
[
"Clemastine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
]
],
[
[
"Clemastine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
]
],
[
[
"Clemastine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
],
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Propantheline"
]
]
] | Clemastine (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Propantheline (Compound)
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine and Phenelzine may cause a minor interaction that can limit clinical effects when taken with Propantheline
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Tapentadol and Tapentadol may cause a moderate interaction that could exacerbate diseases when taken with Propantheline
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Propantheline
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Tramadol and Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Propantheline
Clemastine may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Propantheline
Clemastine (Compound) resembles Doxylamine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Propantheline
Clemastine (Compound) resembles Mepenzolate (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Propantheline
Clemastine may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may lead to a major life threatening interaction when taken with Propantheline |
DB00250 | DB08913 | 10 | 1,186 | [
"DDInter475",
"DDInter1561"
] | Dapsone | Radium Ra 223 dichloride | A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8) | Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first approved by the FDA in May 2013 and is currently marketed under the brand name Xofigo, which was formerly called Alpharadin. Xofigo is indicated in patients who have metastatic bone cancer that is symptomatic with no visceral metastases and patients who have prostate cancer that is castration resistant. The FDA label includes a warning that Radium Ra 223 Dichloride should not be used in women who are pregnant or may become pregnant due to the high risk of fetal harm. | Moderate | 1 | [
[
[
10,
24,
1186
]
],
[
[
10,
21,
28722
],
[
28722,
60,
1186
]
],
[
[
10,
24,
134
],
[
134,
24,
1186
]
],
[
[
10,
24,
1619
],
[
1619,
63,
1186
]
],
[
[
10,
63,
168
],
[
168,
24,
1186
]
],
[
[
10,
64,
1064
],
[
1064,
24,
1186
]
],
[
[
10,
21,
28722
],
[
28722,
60,
37
],
[
37,
24,
1186
]
],
[
[
10,
24,
134
],
[
134,
21,
28872
],
[
28872,
60,
1186
]
],
[
[
10,
24,
1619
],
[
1619,
63,
134
],
[
134,
24,
1186
]
],
[
[
10,
63,
168
],
[
168,
21,
28872
],
[
28872,
60,
1186
]
]
] | [
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Dapsone",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Radium Ra 223 dichloride"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Dapsone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Dapsone",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lomustine"
],
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} (Compound) causes {v} (Side Effect)",
"Extravasation"
],
[
"Extravasation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Radium Ra 223 dichloride"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} (Compound) causes {v} (Side Effect)",
"Extravasation"
],
[
"Extravasation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Radium Ra 223 dichloride"
]
]
] | Dapsone (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Radium Ra 223 dichloride (Compound)
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Dapsone may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Dapsone (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Lomustine (Compound) and Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine (Compound) causes Extravasation (Side Effect) and Extravasation (Side Effect) is caused by Radium Ra 223 dichloride (Compound)
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib (Compound) causes Extravasation (Side Effect) and Extravasation (Side Effect) is caused by Radium Ra 223 dichloride (Compound) |
DB00261 | DB10897 | 702 | 539 | [
"DDInter93",
"DDInter291"
] | Anagrelide | Capsicum | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated. | Capsicum (Chili pepper) allergenic extract is used in allergenic testing. | Minor | 0 | [
[
[
702,
23,
539
]
],
[
[
702,
24,
885
],
[
885,
23,
539
]
],
[
[
702,
63,
1018
],
[
1018,
23,
539
]
],
[
[
702,
25,
1226
],
[
1226,
23,
539
]
],
[
[
702,
64,
1432
],
[
1432,
23,
539
]
],
[
[
702,
25,
1421
],
[
1421,
62,
539
]
],
[
[
702,
24,
885
],
[
885,
63,
1018
],
[
1018,
23,
539
]
],
[
[
702,
63,
1018
],
[
1018,
24,
885
],
[
885,
23,
539
]
],
[
[
702,
25,
1226
],
[
1226,
24,
885
],
[
885,
23,
539
]
],
[
[
702,
25,
553
],
[
553,
25,
885
],
[
885,
23,
539
]
]
] | [
[
[
"Anagrelide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tirofiban"
],
[
"Tirofiban",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abciximab"
],
[
"Abciximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tirofiban"
],
[
"Tirofiban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fondaparinux"
],
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
]
]
] | Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Capsicum
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Capsicum
Anagrelide may lead to a major life threatening interaction when taken with Tirofiban and Tirofiban may cause a minor interaction that can limit clinical effects when taken with Capsicum
Anagrelide may lead to a major life threatening interaction when taken with Abciximab and Abciximab may cause a minor interaction that can limit clinical effects when taken with Capsicum
Anagrelide may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a minor interaction that can limit clinical effects when taken with Capsicum
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Capsicum
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Capsicum
Anagrelide may lead to a major life threatening interaction when taken with Tirofiban and Tirofiban may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Capsicum
Anagrelide may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux may lead to a major life threatening interaction when taken with Epoprostenol and Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Capsicum |
DB00661 | DB01229 | 122 | 973 | [
"DDInter1928",
"DDInter1377"
] | Verapamil | Paclitaxel | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes drugs like [diltiazem] and [flunarizine], but is chemically unrelated to other cardioactive medications. Verapamil is administered as a racemic mixture containing equal amounts of the S- and R-enantiomer, each of which is pharmacologically distinct - the S-enantiomer carries approximately 20-fold greater potency than the R-enantiomer, but is metabolized at a higher rate. | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane. | Moderate | 1 | [
[
[
122,
24,
973
]
],
[
[
122,
24,
310
],
[
310,
63,
973
]
],
[
[
122,
6,
7524
],
[
7524,
45,
973
]
],
[
[
122,
7,
6952
],
[
6952,
46,
973
]
],
[
[
122,
21,
28779
],
[
28779,
60,
973
]
],
[
[
122,
23,
36
],
[
36,
63,
973
]
],
[
[
122,
25,
1362
],
[
1362,
63,
973
]
],
[
[
122,
63,
752
],
[
752,
24,
973
]
],
[
[
122,
24,
609
],
[
609,
24,
973
]
],
[
[
122,
62,
1101
],
[
1101,
24,
973
]
]
] | [
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Verapamil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Verapamil",
"{u} (Compound) upregulates {v} (Gene)",
"MCOLN1"
],
[
"MCOLN1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Verapamil",
"{u} (Compound) causes {v} (Side Effect)",
"Dry mouth"
],
[
"Dry mouth",
"{u} (Side Effect) is caused by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Verapamil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Eribulin"
],
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Verapamil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Verapamil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
]
] | Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Verapamil (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Paclitaxel (Compound)
Verapamil (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Paclitaxel (Compound)
Verapamil (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Paclitaxel (Compound)
Verapamil may cause a minor interaction that can limit clinical effects when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Verapamil may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Verapamil may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel |
DB09331 | DB10429 | 745 | 200 | [
"DDInter478",
"DDInter282"
] | Daratumumab | Candida albicans | Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind. Daratumumab was granted FDA approval on 16 November 2015. It is approved for the treatment of multiple myeloma as monotherapy or combination therapy and light chain (AL) amyloidosis in combination with other drugs.[L13290,L13296] | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Moderate | 1 | [
[
[
745,
24,
200
]
],
[
[
745,
63,
1683
],
[
1683,
24,
200
]
],
[
[
745,
64,
976
],
[
976,
24,
200
]
],
[
[
745,
24,
738
],
[
738,
63,
200
]
],
[
[
745,
25,
676
],
[
676,
63,
200
]
],
[
[
745,
63,
1683
],
[
1683,
63,
1096
],
[
1096,
24,
200
]
],
[
[
745,
64,
976
],
[
976,
64,
1096
],
[
1096,
24,
200
]
],
[
[
745,
63,
869
],
[
869,
24,
1683
],
[
1683,
24,
200
]
],
[
[
745,
24,
738
],
[
738,
63,
1683
],
[
1683,
24,
200
]
],
[
[
745,
64,
1064
],
[
1064,
25,
1096
],
[
1096,
24,
200
]
]
] | [
[
[
"Daratumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Daratumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Daratumumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Daratumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Daratumumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Daratumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Daratumumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Daratumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Daratumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Daratumumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
]
] | Daratumumab may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Daratumumab may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Daratumumab may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Daratumumab may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Daratumumab may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Daratumumab may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Daratumumab may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Daratumumab may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Daratumumab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans |
DB00443 | DB00827 | 251 | 646 | [
"DDInter195",
"DDInter383"
] | Betamethasone | Cinoxacin | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity. | Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections. | Major | 2 | [
[
[
251,
25,
646
]
],
[
[
251,
21,
28722
],
[
28722,
60,
646
]
],
[
[
251,
63,
1648
],
[
1648,
23,
646
]
],
[
[
251,
24,
589
],
[
589,
23,
646
]
],
[
[
251,
24,
433
],
[
433,
63,
646
]
],
[
[
251,
23,
1193
],
[
1193,
63,
646
]
],
[
[
251,
24,
127
],
[
127,
24,
646
]
],
[
[
251,
63,
1031
],
[
1031,
24,
646
]
],
[
[
251,
25,
593
],
[
593,
64,
646
]
],
[
[
251,
24,
959
],
[
959,
64,
646
]
]
] | [
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cinoxacin"
]
],
[
[
"Betamethasone",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cinoxacin"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cinoxacin"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
],
[
"Cisplatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cinoxacin"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
],
[
"Ertugliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cinoxacin"
]
],
[
[
"Betamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cinoxacin"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"
],
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cinoxacin"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cinoxacin"
]
],
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cinoxacin"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cinoxacin"
]
]
] | Betamethasone (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Cinoxacin (Compound)
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Cinoxacin
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a minor interaction that can limit clinical effects when taken with Cinoxacin
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin and Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Cinoxacin
Betamethasone may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a moderate interaction that could exacerbate diseases when taken with Cinoxacin
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Cinoxacin
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Cinoxacin
Betamethasone may lead to a major life threatening interaction when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Cinoxacin
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may lead to a major life threatening interaction when taken with Cinoxacin |
DB06589 | DB11113 | 1,250 | 657 | [
"DDInter1400",
"DDInter307"
] | Pazopanib | Castor oil | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic, and less than 1% linolenic fatty acids . has a hydroxyl group that provides a functional group location for various chemical reactions, making it a favourable substance in industrial applications . Castor oil does not contain ricin, which is a natural poison found in the castor oil plant; the toxic lectin remains in the bean pulp following oil isolation . Due to its renewability and high versatility in addition to being the only commercial source of a hydroxylated fatty acid , castor oil has been used as a vital raw material for the chemical industry . Castor oil was mainly used in the manufacturing of soaps, lubricants, and coatings . It is an FDA-approved food additive directly added to food products for human consumption. It can also be found in hard candies as a release agent and anti-sticking agent, or supplementary vitamins and mineral oral tablets as an ingredient for protective coatings. Castor oil is found in over-the-counter oral liquids as a stimulant laxative, and is also added in commercial cosmetic, hair, and skincare products. | Moderate | 1 | [
[
[
1250,
24,
657
]
],
[
[
1250,
63,
1079
],
[
1079,
24,
657
]
],
[
[
1250,
24,
927
],
[
927,
63,
657
]
],
[
[
1250,
64,
540
],
[
540,
24,
657
]
],
[
[
1250,
24,
1491
],
[
1491,
24,
657
]
],
[
[
1250,
25,
985
],
[
985,
24,
657
]
],
[
[
1250,
25,
351
],
[
351,
63,
657
]
],
[
[
1250,
35,
786
],
[
786,
24,
657
]
],
[
[
1250,
63,
1079
],
[
1079,
24,
927
],
[
927,
63,
657
]
],
[
[
1250,
24,
927
],
[
927,
63,
1079
],
[
1079,
24,
657
]
]
] | [
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
],
[
"Telavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Pazopanib",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
],
[
"Rilpivirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
],
[
"Telavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
],
[
"Telavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
]
] | Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Pazopanib may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Pazopanib may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Pazopanib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Pazopanib (Compound) resembles Rilpivirine (Compound) and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine and Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil |
DB00230 | DB00514 | 784 | 506 | [
"DDInter1516",
"DDInter527"
] | Pregabalin | Dextromethorphan | Pregabalin is structurally similar to gamma-aminobutyric acid (GABA) - an inhibitory neurotransmitter. It may be used to manage neuropathic pain, postherpetic neuralgia, and fibromyalgia among other conditions. Although as per the FDA Label the mechanism of action has not been definitively characterized, there is evidence that pregabalin exerts its effects by binding to the α2δ subunit of voltage-dependent calcium channels.[A187190,L7066] Pregabalin is marketed by Pfizer under the trade name Lyrica and Lyrica Cr (extended release).[L1006,L7066] It may have dependence liability if misused but the risk appears to be highest in patients with current or past substance use disorders. | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Moderate | 1 | [
[
[
784,
24,
506
]
],
[
[
784,
10,
11594
],
[
11594,
49,
506
]
],
[
[
784,
21,
28810
],
[
28810,
60,
506
]
],
[
[
784,
63,
1324
],
[
1324,
24,
506
]
],
[
[
784,
24,
13
],
[
13,
24,
506
]
],
[
[
784,
24,
717
],
[
717,
63,
506
]
],
[
[
784,
25,
475
],
[
475,
24,
506
]
],
[
[
784,
24,
222
],
[
222,
64,
506
]
],
[
[
784,
10,
11594
],
[
11594,
47,
11565
],
[
11565,
49,
506
]
],
[
[
784,
21,
28810
],
[
28810,
60,
197
],
[
197,
40,
506
]
]
] | [
[
[
"Pregabalin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
]
],
[
[
"Pregabalin",
"{u} (Compound) palliates {v} (Disease)",
"multiple sclerosis"
],
[
"multiple sclerosis",
"{u} (Disease) is palliated by {v} (Compound)",
"Dextromethorphan"
]
],
[
[
"Pregabalin",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal pain"
],
[
"Gastrointestinal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dextromethorphan"
]
],
[
[
"Pregabalin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
]
],
[
[
"Pregabalin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
]
],
[
[
"Pregabalin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
],
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
]
],
[
[
"Pregabalin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
]
],
[
[
"Pregabalin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextromethorphan"
]
],
[
[
"Pregabalin",
"{u} (Compound) palliates {v} (Disease)",
"multiple sclerosis"
],
[
"multiple sclerosis",
"{u} (Disease) resembles {v} (Disease)",
"amyotrophic lateral sclerosis"
],
[
"amyotrophic lateral sclerosis",
"{u} (Disease) is palliated by {v} (Compound)",
"Dextromethorphan"
]
],
[
[
"Pregabalin",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal pain"
],
[
"Gastrointestinal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Levorphanol"
],
[
"Levorphanol",
"{u} (Compound) resembles {v} (Compound)",
"Dextromethorphan"
]
]
] | Pregabalin (Compound) palliates multiple sclerosis (Disease) and multiple sclerosis (Disease) is palliated by Dextromethorphan (Compound)
Pregabalin (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Dextromethorphan (Compound)
Pregabalin may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan
Pregabalin may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan
Pregabalin may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide and Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan
Pregabalin may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan
Pregabalin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may lead to a major life threatening interaction when taken with Dextromethorphan
Pregabalin (Compound) palliates multiple sclerosis (Disease) and multiple sclerosis (Disease) resembles amyotrophic lateral sclerosis (Disease) and amyotrophic lateral sclerosis (Disease) is palliated by Dextromethorphan (Compound)
Pregabalin (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Levorphanol (Compound) and Levorphanol (Compound) resembles Dextromethorphan (Compound) |
DB00968 | DB01222 | 1,551 | 617 | [
"DDInter1185",
"DDInter246"
] | Methyldopa | Budesonide | Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent. It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects. Methyldopa works by binding to alpha(α)-2 adrenergic receptors as an agonist, leading to the inhibition of adrenergic neuronal outflow and reduction of vasoconstrictor adrenergic signals. Methyldopa exists in two isomers D-α-methyldopa and L-α-methyldopa, which is the active form. First introduced in 1960 as an antihypertensive agent, methyldopa was considered to be useful in certain patient populations, such as pregnant women and patients with renal insufficiency. Since | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product with [formoterol]. | Moderate | 1 | [
[
[
1551,
24,
617
]
],
[
[
1551,
63,
251
],
[
251,
1,
617
]
],
[
[
1551,
24,
1220
],
[
1220,
1,
617
]
],
[
[
1551,
7,
2592
],
[
2592,
46,
617
]
],
[
[
1551,
18,
10737
],
[
10737,
46,
617
]
],
[
[
1551,
18,
5527
],
[
5527,
57,
617
]
],
[
[
1551,
21,
29221
],
[
29221,
60,
617
]
],
[
[
1551,
1,
1148
],
[
1148,
23,
617
]
],
[
[
1551,
63,
1674
],
[
1674,
23,
617
]
],
[
[
1551,
24,
688
],
[
688,
23,
617
]
]
] | [
[
[
"Methyldopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Methyldopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Budesonide"
]
],
[
[
"Methyldopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Budesonide"
]
],
[
[
"Methyldopa",
"{u} (Compound) upregulates {v} (Gene)",
"CEBPD"
],
[
"CEBPD",
"{u} (Gene) is upregulated by {v} (Compound)",
"Budesonide"
]
],
[
[
"Methyldopa",
"{u} (Compound) downregulates {v} (Gene)",
"DNAJC15"
],
[
"DNAJC15",
"{u} (Gene) is upregulated by {v} (Compound)",
"Budesonide"
]
],
[
[
"Methyldopa",
"{u} (Compound) downregulates {v} (Gene)",
"HAT1"
],
[
"HAT1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Budesonide"
]
],
[
[
"Methyldopa",
"{u} (Compound) causes {v} (Side Effect)",
"Infestation"
],
[
"Infestation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Budesonide"
]
],
[
[
"Methyldopa",
"{u} (Compound) resembles {v} (Compound)",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Budesonide"
]
],
[
[
"Methyldopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Budesonide"
]
],
[
[
"Methyldopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Budesonide"
]
]
] | Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Budesonide (Compound)
Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Budesonide (Compound)
Methyldopa (Compound) upregulates CEBPD (Gene) and CEBPD (Gene) is upregulated by Budesonide (Compound)
Methyldopa (Compound) downregulates DNAJC15 (Gene) and DNAJC15 (Gene) is upregulated by Budesonide (Compound)
Methyldopa (Compound) downregulates HAT1 (Gene) and HAT1 (Gene) is downregulated by Budesonide (Compound)
Methyldopa (Compound) causes Infestation (Side Effect) and Infestation (Side Effect) is caused by Budesonide (Compound)
Methyldopa (Compound) resembles Isoprenaline (Compound) and Isoprenaline may cause a minor interaction that can limit clinical effects when taken with Budesonide
Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a minor interaction that can limit clinical effects when taken with Budesonide
Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a minor interaction that can limit clinical effects when taken with Budesonide |
DB00872 | DB12130 | 1,080 | 1,017 | [
"DDInter438",
"DDInter1094"
] | Conivaptan | Lorlatinib | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. | Major | 2 | [
[
[
1080,
25,
1017
]
],
[
[
1080,
64,
608
],
[
608,
23,
1017
]
],
[
[
1080,
62,
1101
],
[
1101,
23,
1017
]
],
[
[
1080,
64,
175
],
[
175,
24,
1017
]
],
[
[
1080,
25,
976
],
[
976,
24,
1017
]
],
[
[
1080,
25,
1421
],
[
1421,
63,
1017
]
],
[
[
1080,
62,
126
],
[
126,
24,
1017
]
],
[
[
1080,
63,
888
],
[
888,
24,
1017
]
],
[
[
1080,
24,
309
],
[
309,
24,
1017
]
],
[
[
1080,
1,
165
],
[
165,
24,
1017
]
]
] | [
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
],
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lorlatinib"
]
],
[
[
"Conivaptan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lorlatinib"
]
],
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Conivaptan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
],
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Conivaptan",
"{u} (Compound) resembles {v} (Compound)",
"Tolvaptan"
],
[
"Tolvaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
]
] | Conivaptan may lead to a major life threatening interaction when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Conivaptan may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Conivaptan may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Conivaptan may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Conivaptan may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Conivaptan may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Conivaptan (Compound) resembles Tolvaptan (Compound) and Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib |
DB00544 | DB05273 | 970 | 507 | [
"DDInter757",
"DDInter1638"
] | Fluorouracil | Samarium (153Sm) lexidronam | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium Sm 153 lexidronam is used to help relieve the bone pain that may occur with certain kinds of cancer. The radioactive samarium is taken up in the bone cancer area and gives off radiation that helps provide relief of pain. | Major | 2 | [
[
[
970,
25,
507
]
],
[
[
970,
24,
248
],
[
248,
24,
507
]
],
[
[
970,
24,
270
],
[
270,
63,
507
]
],
[
[
970,
24,
1686
],
[
1686,
25,
507
]
],
[
[
970,
40,
132
],
[
132,
25,
507
]
],
[
[
970,
64,
1064
],
[
1064,
25,
507
]
],
[
[
970,
23,
147
],
[
147,
25,
507
]
],
[
[
970,
63,
134
],
[
134,
25,
507
]
],
[
[
970,
24,
1330
],
[
1330,
64,
507
]
],
[
[
970,
25,
1259
],
[
1259,
64,
507
]
]
] | [
[
[
"Fluorouracil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
],
[
"Valganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Temozolomide"
],
[
"Temozolomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Fluorouracil",
"{u} (Compound) resembles {v} (Compound)",
"Uracil mustard"
],
[
"Uracil mustard",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Fluorouracil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Fluorouracil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
],
[
"Naxitamab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Fluorouracil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
]
] | Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Temozolomide and Temozolomide may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Fluorouracil (Compound) resembles Uracil mustard (Compound) and Uracil mustard may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Fluorouracil may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Fluorouracil may cause a minor interaction that can limit clinical effects when taken with Vinblastine and Vinblastine may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab and Naxitamab may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Fluorouracil may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam |
DB09312 | DB14783 | 967 | 287 | [
"DDInter106",
"DDInter574"
] | Antithymocyte immunoglobulin (rabbit) | Diroximel fumarate | Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of T-cells. | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting forms of MS lead to neurological symptoms that resolve and recur periodically. More than 80% of patients suffering from this disease have relapsing-remitting MS. Diroximel fumarate is a new drug from the fumarate class formulated to treat various relapsing forms of MS. This drug is bioequivalent to [Dimethyl fumarate][A187544,L9626](initially manufactured in 2013), but is less likely to cause gastrointestinal side effects, owing to its unique chemical structure. Diroximel fumarate was formulated by Alkermes in collaboration with Biogen, and was approved by the FDA in October 2019 and by the EMA in November 2021. | Moderate | 1 | [
[
[
967,
24,
287
]
],
[
[
967,
63,
599
],
[
599,
24,
287
]
],
[
[
967,
24,
270
],
[
270,
24,
287
]
],
[
[
967,
25,
1510
],
[
1510,
25,
287
]
],
[
[
967,
64,
908
],
[
908,
25,
287
]
],
[
[
967,
25,
676
],
[
676,
64,
287
]
],
[
[
967,
63,
713
],
[
713,
25,
287
]
],
[
[
967,
63,
599
],
[
599,
24,
1101
],
[
1101,
24,
287
]
],
[
[
967,
24,
270
],
[
270,
63,
1101
],
[
1101,
24,
287
]
],
[
[
967,
63,
259
],
[
259,
63,
1101
],
[
1101,
24,
287
]
]
] | [
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
],
[
"Dimethyl fumarate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
]
] | Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Diroximel fumarate
Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Diroximel fumarate
Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Diroximel fumarate
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may lead to a major life threatening interaction when taken with Diroximel fumarate
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate |
DB00307 | DB00820 | 1,101 | 402 | [
"DDInter202",
"DDInter1736"
] | Bexarotene | Tadalafil | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy.[L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. In contrast to other PDE5 inhibitors like [sildenafil], tadalafil has greater selectivity for PDE5 and a longer half-life which has made it a more suitable option for chronic once-daily dosing in the treatment of PAH. | Moderate | 1 | [
[
[
1101,
24,
402
]
],
[
[
1101,
6,
8374
],
[
8374,
45,
402
]
],
[
[
1101,
21,
28669
],
[
28669,
60,
402
]
],
[
[
1101,
24,
159
],
[
159,
63,
402
]
],
[
[
1101,
23,
982
],
[
982,
63,
402
]
],
[
[
1101,
23,
1419
],
[
1419,
24,
402
]
],
[
[
1101,
25,
98
],
[
98,
63,
402
]
],
[
[
1101,
62,
1324
],
[
1324,
24,
402
]
],
[
[
1101,
6,
8374
],
[
8374,
45,
1250
],
[
1250,
63,
402
]
],
[
[
1101,
21,
28669
],
[
28669,
60,
1419
],
[
1419,
24,
402
]
]
] | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tadalafil"
]
],
[
[
"Bexarotene",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Tadalafil"
]
],
[
[
"Bexarotene",
"{u} (Compound) causes {v} (Side Effect)",
"Conjunctivitis"
],
[
"Conjunctivitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tadalafil"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tadalafil"
]
],
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tadalafil"
]
],
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tadalafil"
]
],
[
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tadalafil"
]
],
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tadalafil"
]
],
[
[
"Bexarotene",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tadalafil"
]
],
[
[
"Bexarotene",
"{u} (Compound) causes {v} (Side Effect)",
"Conjunctivitis"
],
[
"Conjunctivitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tadalafil"
]
]
] | Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tadalafil (Compound)
Bexarotene (Compound) causes Conjunctivitis (Side Effect) and Conjunctivitis (Side Effect) is caused by Tadalafil (Compound)
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Tadalafil
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Tadalafil
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Tadalafil
Bexarotene may lead to a major life threatening interaction when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Tadalafil
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Tadalafil
Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pazopanib (Compound) and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Tadalafil
Bexarotene (Compound) causes Conjunctivitis (Side Effect) and Conjunctivitis (Side Effect) is caused by Imatinib (Compound) and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Tadalafil |
DB00009 | DB01050 | 1,271 | 848 | [
"DDInter56",
"DDInter900"
] | Alteplase | Ibuprofen | Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and fibrin.[A252330,L43125] Alteplase is a purified glycoprotein of 527 amino acids expressed in Chinese hamster ovary (CHO) cells.[A252345,L43125] It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI). The use of alteplase to manage AMI has decreased thanks to the availability of safer treatments such as angioplasty and stenting. However, its use for the treatment of acute ischem | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID. On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer. | Moderate | 1 | [
[
[
1271,
24,
848
]
],
[
[
1271,
23,
297
],
[
297,
62,
848
]
],
[
[
1271,
24,
831
],
[
831,
24,
848
]
],
[
[
1271,
64,
1578
],
[
1578,
24,
848
]
],
[
[
1271,
24,
643
],
[
643,
63,
848
]
],
[
[
1271,
25,
936
],
[
936,
63,
848
]
],
[
[
1271,
25,
1432
],
[
1432,
24,
848
]
],
[
[
1271,
25,
1650
],
[
1650,
64,
848
]
],
[
[
1271,
25,
202
],
[
202,
25,
848
]
],
[
[
1271,
24,
886
],
[
886,
25,
848
]
]
] | [
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Alteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ibuprofen"
]
],
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indomethacin"
],
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
],
[
"Desvenlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cangrelor"
],
[
"Cangrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abciximab"
],
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
],
[
"Avapritinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibuprofen"
]
],
[
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ardeparin"
],
[
"Ardeparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibuprofen"
]
],
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketorolac"
],
[
"Ketorolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibuprofen"
]
]
] | Alteplase may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Ibuprofen
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen
Alteplase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen
Alteplase may lead to a major life threatening interaction when taken with Cangrelor and Cangrelor may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen
Alteplase may lead to a major life threatening interaction when taken with Abciximab and Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen
Alteplase may lead to a major life threatening interaction when taken with Avapritinib and Avapritinib may lead to a major life threatening interaction when taken with Ibuprofen
Alteplase may lead to a major life threatening interaction when taken with Ardeparin and Ardeparin may lead to a major life threatening interaction when taken with Ibuprofen
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Ketorolac and Ketorolac may lead to a major life threatening interaction when taken with Ibuprofen |
DB01041 | DB01101 | 770 | 60 | [
"DDInter1789",
"DDInter285"
] | Thalidomide | Capecitabine | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence. | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Major | 2 | [
[
[
770,
25,
60
]
],
[
[
770,
6,
6017
],
[
6017,
45,
60
]
],
[
[
770,
21,
28906
],
[
28906,
60,
60
]
],
[
[
770,
24,
872
],
[
872,
62,
60
]
],
[
[
770,
63,
1176
],
[
1176,
23,
60
]
],
[
[
770,
24,
246
],
[
246,
23,
60
]
],
[
[
770,
64,
147
],
[
147,
23,
60
]
],
[
[
770,
63,
112
],
[
112,
24,
60
]
],
[
[
770,
24,
810
],
[
810,
63,
60
]
],
[
[
770,
64,
869
],
[
869,
24,
60
]
]
] | [
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Capecitabine"
]
],
[
[
"Thalidomide",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Capecitabine"
]
],
[
[
"Thalidomide",
"{u} (Compound) causes {v} (Side Effect)",
"Gastroenteritis"
],
[
"Gastroenteritis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Capecitabine"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capecitabine"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capecitabine"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capecitabine"
]
],
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capecitabine"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
],
[
"Strontium chloride Sr-89",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
]
],
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
]
]
] | Thalidomide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Capecitabine (Compound)
Thalidomide (Compound) causes Gastroenteritis (Side Effect) and Gastroenteritis (Side Effect) is caused by Capecitabine (Compound)
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin and Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Capecitabine
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Capecitabine
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Gatifloxacin and Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Capecitabine
Thalidomide may lead to a major life threatening interaction when taken with Vinblastine and Vinblastine may cause a minor interaction that can limit clinical effects when taken with Capecitabine
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89 and Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine
Thalidomide may lead to a major life threatening interaction when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine |
DB00182 | DB00431 | 80 | 1,503 | [
"DDInter84",
"DDInter1072"
] | Amphetamine | Lindane | Amphetamine, a compound discovered over 100 years ago, is one of the more restricted controlled drugs. It was previously used for a large variety of conditions and this changed until this point where its use is highly restricted. Amphetamine, with the chemical formula alpha-methylphenethylamine, was discovered in 1910 and first synthesized by 1927. After being proven to reduce drug-induced anesthesia and produce arousal and insomnia, amphetamine racemic mix was registered by Smith, Kline and French in 1935. Amphetamine structure presents one chiral center and it exists in the form of dextro- and levo-isomers. The first product of Smith, Kline and French was approved by the FDA on 1976. During World War II, amphetamine was used to promote wakefulness in the soldiers. This use derived into a large overproduction of amphetamine and all the surplus after the war finalized ended up in the black market, producing the initiation of the illicit | An organochlorine insecticide that has been used as a pediculicide and a scabicide. Lindane has been banned in California, United Kingdom, Australia, and many western countries due to concerns about neurotoxicity and adverse effects on the environment. In Canada, Lindane is not recommmended as a first-line therapy due to reports of resistance, neurotoxicity, and bone marrow suppression, but has been approved by the FDA as a second-line therapy for topical treatment of pediculosis capitis (head lice), pediculosis pubis (pubic lice), or scabies in patients greater than two years of age who cannot tolerate or have failed first-line treatment. Lindane is still allowed for pharmaceutical use until 2015. | Moderate | 1 | [
[
[
80,
24,
1503
]
],
[
[
80,
21,
28921
],
[
28921,
60,
1503
]
],
[
[
80,
40,
939
],
[
939,
63,
1503
]
],
[
[
80,
24,
104
],
[
104,
63,
1503
]
],
[
[
80,
25,
222
],
[
222,
63,
1503
]
],
[
[
80,
24,
999
],
[
999,
24,
1503
]
],
[
[
80,
40,
73
],
[
73,
24,
1503
]
],
[
[
80,
25,
593
],
[
593,
64,
1503
]
],
[
[
80,
21,
28921
],
[
28921,
60,
939
],
[
939,
63,
1503
]
],
[
[
80,
21,
28751
],
[
28751,
60,
475
],
[
475,
24,
1503
]
]
] | [
[
[
"Amphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lindane"
]
],
[
[
"Amphetamine",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lindane"
]
],
[
[
"Amphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Benzphetamine"
],
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lindane"
]
],
[
[
"Amphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lindane"
]
],
[
[
"Amphetamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lindane"
]
],
[
[
"Amphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lindane"
]
],
[
[
"Amphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Phentermine"
],
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lindane"
]
],
[
[
"Amphetamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lindane"
]
],
[
[
"Amphetamine",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Benzphetamine"
],
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lindane"
]
],
[
[
"Amphetamine",
"{u} (Compound) causes {v} (Side Effect)",
"Convulsion"
],
[
"Convulsion",
"{u} (Side Effect) is caused by {v} (Compound)",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lindane"
]
]
] | Amphetamine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Lindane (Compound)
Amphetamine (Compound) resembles Benzphetamine (Compound) and Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Lindane
Amphetamine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Lindane
Amphetamine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Lindane
Amphetamine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Lindane
Amphetamine (Compound) resembles Phentermine (Compound) and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Lindane
Amphetamine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Lindane
Amphetamine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Benzphetamine (Compound) and Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Lindane
Amphetamine (Compound) causes Convulsion (Side Effect) and Convulsion (Side Effect) is caused by Morphine (Compound) and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Lindane |
DB01169 | DB09104 | 57 | 286 | [
"DDInter120",
"DDInter1118"
] | Arsenic trioxide | Magnesium hydroxide | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide. | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used commercially as a fire retardant. It can also be used topically as a deodorant or for the relief of canker sores (aphthous ulcers). | Moderate | 1 | [
[
[
57,
24,
286
]
],
[
[
57,
25,
820
],
[
820,
23,
286
]
],
[
[
57,
64,
401
],
[
401,
23,
286
]
],
[
[
57,
63,
1559
],
[
1559,
23,
286
]
],
[
[
57,
64,
1326
],
[
1326,
24,
286
]
],
[
[
57,
25,
859
],
[
859,
24,
286
]
],
[
[
57,
63,
688
],
[
688,
24,
286
]
],
[
[
57,
25,
730
],
[
730,
63,
286
]
],
[
[
57,
24,
28
],
[
28,
24,
286
]
],
[
[
57,
25,
1231
],
[
1231,
25,
286
]
]
] | [
[
[
"Arsenic trioxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Arsenic trioxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diclofenamide"
],
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Posaconazole"
],
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Arsenic trioxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deutetrabenazine"
],
[
"Deutetrabenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Arsenic trioxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
],
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tolevamer"
],
[
"Tolevamer",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Magnesium hydroxide"
]
]
] | Arsenic trioxide may lead to a major life threatening interaction when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Arsenic trioxide may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Arsenic trioxide may lead to a major life threatening interaction when taken with Diclofenamide and Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Arsenic trioxide may lead to a major life threatening interaction when taken with Posaconazole and Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Arsenic trioxide may lead to a major life threatening interaction when taken with Deutetrabenazine and Deutetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Arsenic trioxide may lead to a major life threatening interaction when taken with Tolevamer and Tolevamer may lead to a major life threatening interaction when taken with Magnesium hydroxide |
DB00055 | DB00208 | 834 | 1,018 | [
"DDInter605",
"DDInter1804"
] | Drotrecogin alfa | Ticlopidine | Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective in improving outcomes in patients with sepsis. | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke. The FDA label includes a black-box warning of neutropenia, aplastic anemia, thrombotic thrombocytopenia purpura, and agranulocytosis, so it is necessary to monitor patients' WBC and platelets when they are taking ticlopidine. | Major | 2 | [
[
[
834,
25,
1018
]
],
[
[
834,
25,
1347
],
[
1347,
64,
1018
]
],
[
[
834,
23,
539
],
[
539,
62,
1018
]
],
[
[
834,
64,
1271
],
[
1271,
24,
1018
]
],
[
[
834,
24,
643
],
[
643,
63,
1018
]
],
[
[
834,
25,
1027
],
[
1027,
63,
1018
]
],
[
[
834,
24,
940
],
[
940,
24,
1018
]
],
[
[
834,
25,
1167
],
[
1167,
24,
1018
]
],
[
[
834,
25,
273
],
[
273,
25,
1018
]
],
[
[
834,
64,
1432
],
[
1432,
25,
1018
]
]
] | [
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticlopidine"
]
],
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticlopidine"
]
],
[
[
"Drotrecogin alfa",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticlopidine"
]
],
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alteplase"
],
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
]
],
[
[
"Drotrecogin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
],
[
"Desvenlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
]
],
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Piroxicam"
],
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
]
],
[
[
"Drotrecogin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Icosapent"
],
[
"Icosapent",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
]
],
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Streptokinase"
],
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
]
],
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tositumomab"
],
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticlopidine"
]
],
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abciximab"
],
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticlopidine"
]
]
] | Drotrecogin alfa may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel may lead to a major life threatening interaction when taken with Ticlopidine
Drotrecogin alfa may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Ticlopidine
Drotrecogin alfa may lead to a major life threatening interaction when taken with Alteplase and Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine
Drotrecogin alfa may lead to a major life threatening interaction when taken with Piroxicam and Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Icosapent and Icosapent may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine
Drotrecogin alfa may lead to a major life threatening interaction when taken with Streptokinase and Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine
Drotrecogin alfa may lead to a major life threatening interaction when taken with Tositumomab and Tositumomab may lead to a major life threatening interaction when taken with Ticlopidine
Drotrecogin alfa may lead to a major life threatening interaction when taken with Abciximab and Abciximab may lead to a major life threatening interaction when taken with Ticlopidine |
DB01142 | DB01175 | 1,264 | 318 | [
"DDInter593",
"DDInter672"
] | Doxepin | Escitalopram | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline], [clomipramine], [desipramine], [imipramine], [nortriptyline], [protriptyline] and [trimipramine]. Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant. However, in 2010 it was approved for the treatment of insomnia. The latter | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.[A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.[A185825,A185726,A185822] | Major | 2 | [
[
[
1264,
25,
318
]
],
[
[
1264,
64,
1230
],
[
1230,
1,
318
]
],
[
[
1264,
6,
8374
],
[
8374,
45,
318
]
],
[
[
1264,
21,
29461
],
[
29461,
60,
318
]
],
[
[
1264,
62,
112
],
[
112,
23,
318
]
],
[
[
1264,
63,
1419
],
[
1419,
23,
318
]
],
[
[
1264,
24,
760
],
[
760,
62,
318
]
],
[
[
1264,
63,
999
],
[
999,
24,
318
]
],
[
[
1264,
74,
1376
],
[
1376,
24,
318
]
],
[
[
1264,
24,
1609
],
[
1609,
63,
318
]
]
] | [
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Escitalopram"
]
],
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Citalopram"
],
[
"Citalopram",
"{u} (Compound) resembles {v} (Compound)",
"Escitalopram"
]
],
[
[
"Doxepin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Escitalopram"
]
],
[
[
"Doxepin",
"{u} (Compound) causes {v} (Side Effect)",
"Dysmenorrhoea"
],
[
"Dysmenorrhoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Escitalopram"
]
],
[
[
"Doxepin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Escitalopram"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Escitalopram"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Escitalopram"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Doxepin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
],
[
"Pentoxyverine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
]
] | Doxepin may lead to a major life threatening interaction when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Doxepin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Escitalopram (Compound)
Doxepin (Compound) causes Dysmenorrhoea (Side Effect) and Dysmenorrhoea (Side Effect) is caused by Escitalopram (Compound)
Doxepin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Escitalopram
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a minor interaction that can limit clinical effects when taken with Escitalopram
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may cause a minor interaction that can limit clinical effects when taken with Escitalopram
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram
Doxepin (Compound) resembles Diphenhydramine (Compound) and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram |
DB00938 | DB01193 | 455 | 819 | [
"DDInter1635",
"DDInter12"
] | Salmeterol | Acebutolol | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine. Salmeterol was granted FDA approval on 4 February 1994. | A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. | Moderate | 1 | [
[
[
455,
24,
819
]
],
[
[
455,
25,
887
],
[
887,
1,
819
]
],
[
[
455,
63,
1121
],
[
1121,
1,
819
]
],
[
[
455,
6,
3576
],
[
3576,
45,
819
]
],
[
[
455,
21,
28762
],
[
28762,
60,
819
]
],
[
[
455,
63,
1674
],
[
1674,
24,
819
]
],
[
[
455,
62,
251
],
[
251,
24,
819
]
],
[
[
455,
24,
1450
],
[
1450,
63,
819
]
],
[
[
455,
24,
688
],
[
688,
24,
819
]
],
[
[
455,
23,
617
],
[
617,
63,
819
]
]
] | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
]
],
[
[
"Salmeterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pindolol"
],
[
"Pindolol",
"{u} (Compound) resembles {v} (Compound)",
"Acebutolol"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisoprolol"
],
[
"Bisoprolol",
"{u} (Compound) resembles {v} (Compound)",
"Acebutolol"
]
],
[
[
"Salmeterol",
"{u} (Compound) binds {v} (Gene)",
"ADRB2"
],
[
"ADRB2",
"{u} (Gene) is bound by {v} (Compound)",
"Acebutolol"
]
],
[
[
"Salmeterol",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Acebutolol"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
]
],
[
[
"Salmeterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Betamethasone"
],
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
]
],
[
[
"Salmeterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
]
]
] | Salmeterol may lead to a major life threatening interaction when taken with Pindolol and Pindolol (Compound) resembles Acebutolol (Compound)
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Bisoprolol and Bisoprolol (Compound) resembles Acebutolol (Compound)
Salmeterol (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is bound by Acebutolol (Compound)
Salmeterol (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Acebutolol (Compound)
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol
Salmeterol may cause a minor interaction that can limit clinical effects when taken with Betamethasone and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol
Salmeterol may cause a minor interaction that can limit clinical effects when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol |
DB00497 | DB09268 | 828 | 1,662 | [
"DDInter1366",
"DDInter1464"
] | Oxycodone | Picosulfuric acid | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The first oxycodone containing product, Percodan, was approved by the FDA on April 12, 1950. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been used in European countries for many years. | Moderate | 1 | [
[
[
828,
24,
1662
]
],
[
[
828,
24,
1619
],
[
1619,
63,
1662
]
],
[
[
828,
64,
597
],
[
597,
24,
1662
]
],
[
[
828,
24,
250
],
[
250,
24,
1662
]
],
[
[
828,
25,
913
],
[
913,
63,
1662
]
],
[
[
828,
63,
1494
],
[
1494,
24,
1662
]
],
[
[
828,
25,
129
],
[
129,
24,
1662
]
],
[
[
828,
40,
421
],
[
421,
24,
1662
]
],
[
[
828,
1,
560
],
[
560,
24,
1662
]
],
[
[
828,
24,
1166
],
[
1166,
25,
1662
]
]
] | [
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Oxycodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
],
[
"Blinatumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Oxycodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palonosetron"
],
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Oxycodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Oxycodone",
"{u} (Compound) resembles {v} (Compound)",
"Hydromorphone"
],
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Oxycodone",
"{u} (Compound) resembles {v} (Compound)",
"Oxymorphone"
],
[
"Oxymorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Picosulfuric acid"
]
]
] | Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Oxycodone may lead to a major life threatening interaction when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab and Blinatumomab may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Oxycodone may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron and Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Oxycodone may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Oxycodone (Compound) resembles Hydromorphone (Compound) and Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Oxycodone (Compound) resembles Oxymorphone (Compound) and Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Dolasetron and Dolasetron may lead to a major life threatening interaction when taken with Picosulfuric acid |
DB00488 | DB11943 | 196 | 255 | [
"DDInter57",
"DDInter495"
] | Altretamine | Delafloxacin | An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects. | Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in the treatment of acute bacterial skin and skin structure infections. | Minor | 0 | [
[
[
196,
23,
255
]
],
[
[
196,
24,
869
],
[
869,
23,
255
]
],
[
[
196,
5,
11583
],
[
11583,
44,
322
],
[
322,
23,
255
]
],
[
[
196,
24,
869
],
[
869,
63,
63
],
[
63,
23,
255
]
],
[
[
196,
7,
18110
],
[
18110,
46,
63
],
[
63,
23,
255
]
],
[
[
196,
54,
19138
],
[
19138,
15,
1053
],
[
1053,
23,
255
]
],
[
[
196,
18,
2995
],
[
2995,
57,
973
],
[
973,
23,
255
]
],
[
[
196,
21,
28852
],
[
28852,
60,
141
],
[
141,
23,
255
]
],
[
[
196,
24,
869
],
[
869,
24,
60
],
[
60,
23,
255
]
],
[
[
196,
21,
28722
],
[
28722,
60,
761
],
[
761,
24,
255
]
]
] | [
[
[
"Altretamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Delafloxacin"
]
],
[
[
"Altretamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Delafloxacin"
]
],
[
[
"Altretamine",
"{u} (Compound) treats {v} (Disease)",
"ovarian cancer"
],
[
"ovarian cancer",
"{u} (Disease) is treated by {v} (Compound)",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Delafloxacin"
]
],
[
[
"Altretamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teniposide"
],
[
"Teniposide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Delafloxacin"
]
],
[
[
"Altretamine",
"{u} (Compound) upregulates {v} (Gene)",
"ST6GALNAC2"
],
[
"ST6GALNAC2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Teniposide"
],
[
"Teniposide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Delafloxacin"
]
],
[
[
"Altretamine",
"{u} (Compound) is included by {v} (Pharmacologic Class)",
"Alkylating Activity"
],
[
"Alkylating Activity",
"{u} (Pharmacologic Class) includes {v} (Compound)",
"Procarbazine"
],
[
"Procarbazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Delafloxacin"
]
],
[
[
"Altretamine",
"{u} (Compound) downregulates {v} (Gene)",
"KRT7"
],
[
"KRT7",
"{u} (Gene) is downregulated by {v} (Compound)",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Delafloxacin"
]
],
[
[
"Altretamine",
"{u} (Compound) causes {v} (Side Effect)",
"Leukopenia"
],
[
"Leukopenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Floxuridine"
],
[
"Floxuridine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Delafloxacin"
]
],
[
[
"Altretamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
],
[
"Capecitabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Delafloxacin"
]
],
[
[
"Altretamine",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Saxagliptin"
],
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delafloxacin"
]
]
] | Altretamine may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Altretamine (Compound) treats ovarian cancer (Disease) and ovarian cancer (Disease) is treated by Epirubicin (Compound) and Epirubicin may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Altretamine may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Teniposide and Teniposide may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Altretamine (Compound) upregulates ST6GALNAC2 (Gene) and ST6GALNAC2 (Gene) is upregulated by Teniposide (Compound) and Teniposide may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Altretamine (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Procarbazine (Compound) and Procarbazine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Altretamine (Compound) downregulates KRT7 (Gene) and KRT7 (Gene) is downregulated by Paclitaxel (Compound) and Paclitaxel may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Altretamine (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Floxuridine (Compound) and Floxuridine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Altretamine may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine and Capecitabine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Altretamine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Saxagliptin (Compound) and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Delafloxacin |
DB00365 | DB01206 | 839 | 37 | [
"DDInter842",
"DDInter1086"
] | Grepafloxacin | Lomustine | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | An alkylating agent of value against both hematologic malignancies and solid tumors. | Minor | 0 | [
[
[
839,
23,
37
]
],
[
[
839,
24,
147
],
[
147,
23,
37
]
],
[
[
839,
62,
141
],
[
141,
24,
37
]
],
[
[
839,
25,
51
],
[
51,
24,
37
]
],
[
[
839,
24,
384
],
[
384,
63,
37
]
],
[
[
839,
23,
328
],
[
328,
24,
37
]
],
[
[
839,
24,
1419
],
[
1419,
24,
37
]
],
[
[
839,
25,
1011
],
[
1011,
64,
37
]
],
[
[
839,
24,
770
],
[
770,
25,
37
]
],
[
[
839,
62,
552
],
[
552,
35,
37
]
]
] | [
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomustine"
]
],
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomustine"
]
],
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Floxuridine"
],
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
]
],
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Daunorubicin"
],
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
]
],
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
]
],
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mercaptopurine"
],
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
]
],
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
]
],
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomustine"
]
],
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomustine"
]
],
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Carmustine"
],
[
"Carmustine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
]
]
] | Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a minor interaction that can limit clinical effects when taken with Lomustine
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Floxuridine and Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Lomustine
Grepafloxacin may lead to a major life threatening interaction when taken with Daunorubicin and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Lomustine
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Lomustine
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Mercaptopurine and Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Lomustine
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Lomustine
Grepafloxacin may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Lomustine
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Lomustine
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Carmustine and Carmustine (Compound) resembles Lomustine (Compound) and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Lomustine |
DB00218 | DB00364 | 1,176 | 417 | [
"DDInter1247",
"DDInter1717"
] | Moxifloxacin | Sucralfate | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia . It is considered a _cytoprotective agent_, protecting cells in the gastrointestinal tract from damage caused by agents such as gastric acid, bile salts, alcohol, and acetylsalicylic acid (aspirin), among other substances [A177655, F4519]. Sucralfate has been shown to be a well-tolerated and safe drug. It is sold under many brands and is available in both tablet and suspension forms. It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form [L6073, L6076]. | Moderate | 1 | [
[
[
1176,
24,
417
]
],
[
[
1176,
21,
28882
],
[
28882,
60,
417
]
],
[
[
1176,
24,
1512
],
[
1512,
62,
417
]
],
[
[
1176,
25,
820
],
[
820,
62,
417
]
],
[
[
1176,
25,
702
],
[
702,
23,
417
]
],
[
[
1176,
24,
1647
],
[
1647,
24,
417
]
],
[
[
1176,
25,
959
],
[
959,
63,
417
]
],
[
[
1176,
24,
5
],
[
5,
63,
417
]
],
[
[
1176,
1,
956
],
[
956,
63,
417
]
],
[
[
1176,
64,
1685
],
[
1685,
24,
417
]
]
] | [
[
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
]
],
[
[
"Moxifloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sucralfate"
]
],
[
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sucralfate"
]
],
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sucralfate"
]
],
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sucralfate"
]
],
[
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
]
],
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
]
],
[
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
],
[
"Liraglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
]
],
[
[
"Moxifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Norfloxacin"
],
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
]
],
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Insulin human"
],
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
]
]
] | Moxifloxacin (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Sucralfate (Compound)
Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a minor interaction that can limit clinical effects when taken with Sucralfate
Moxifloxacin may lead to a major life threatening interaction when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Sucralfate
Moxifloxacin may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may cause a minor interaction that can limit clinical effects when taken with Sucralfate
Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate
Moxifloxacin may lead to a major life threatening interaction when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate
Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate
Moxifloxacin (Compound) resembles Norfloxacin (Compound) and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate
Moxifloxacin may lead to a major life threatening interaction when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate |
DB00313 | DB01083 | 556 | 1,142 | [
"DDInter1913",
"DDInter1348"
] | Valproic acid | Orlistat | Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investigations into the anticonvulsant effects of khelline when he found that all of his samples, dissolved in valproic acid, exerted a similar degree of anticonvulsive activity. It first received approval on February 28, 1978 from the FDA under the trade name Depakene. Since then, it has been investigated for neuroprotective, anti-manic, and anti-migraine effects. It is currently a compound of interest in the field of oncology for its anti-proliferative effects and is the subject of many clinical trials in a variety of cancer types. | The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical intervention is required. Orlistat is a lipase inhibitor used in the treatment of obesity that works by inhibiting fat-metabolizing enzymes. It was approved by the FDA for use in combination with a reduced-calorie diet in 1999. This drug is a generally well-tolerated and effective weight-loss aid and is now available in both over-the-counter and prescription preparations, depending on the dosage quantity. | Moderate | 1 | [
[
[
556,
24,
1142
]
],
[
[
556,
6,
8374
],
[
8374,
45,
1142
]
],
[
[
556,
21,
29317
],
[
29317,
60,
1142
]
],
[
[
556,
24,
850
],
[
850,
63,
1142
]
],
[
[
556,
24,
1144
],
[
1144,
24,
1142
]
],
[
[
556,
23,
1411
],
[
1411,
63,
1142
]
],
[
[
556,
63,
912
],
[
912,
24,
1142
]
],
[
[
556,
25,
1510
],
[
1510,
64,
1142
]
],
[
[
556,
6,
8374
],
[
8374,
48,
11640
],
[
11640,
44,
1142
]
],
[
[
556,
21,
29317
],
[
29317,
60,
549
],
[
549,
63,
1142
]
]
] | [
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orlistat"
]
],
[
[
"Valproic acid",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Orlistat"
]
],
[
[
"Valproic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Multiple fractures"
],
[
"Multiple fractures",
"{u} (Side Effect) is caused by {v} (Compound)",
"Orlistat"
]
],
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orlistat"
]
],
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orlistat"
]
],
[
[
"Valproic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orlistat"
]
],
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orlistat"
]
],
[
[
"Valproic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Orlistat"
]
],
[
[
"Valproic acid",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is associated with {v} (Disease)",
"type 2 diabetes mellitus"
],
[
"type 2 diabetes mellitus",
"{u} (Disease) is treated by {v} (Compound)",
"Orlistat"
]
],
[
[
"Valproic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Multiple fractures"
],
[
"Multiple fractures",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orlistat"
]
]
] | Valproic acid (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Orlistat (Compound)
Valproic acid (Compound) causes Multiple fractures (Side Effect) and Multiple fractures (Side Effect) is caused by Orlistat (Compound)
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Orlistat
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Orlistat
Valproic acid may cause a minor interaction that can limit clinical effects when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Orlistat
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Orlistat
Valproic acid may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Orlistat
Valproic acid (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is associated with type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Orlistat (Compound)
Valproic acid (Compound) causes Multiple fractures (Side Effect) and Multiple fractures (Side Effect) is caused by Dapagliflozin (Compound) and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Orlistat |
DB00563 | DB01157 | 663 | 304 | [
"DDInter1174",
"DDInter1875"
] | Methotrexate | Trimetrexate | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953. | A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect. | Moderate | 1 | [
[
[
663,
24,
304
]
],
[
[
663,
64,
1548
],
[
1548,
40,
304
]
],
[
[
663,
6,
2946
],
[
2946,
45,
304
]
],
[
[
663,
21,
28703
],
[
28703,
60,
304
]
],
[
[
663,
63,
600
],
[
600,
23,
304
]
],
[
[
663,
62,
706
],
[
706,
23,
304
]
],
[
[
663,
63,
58
],
[
58,
24,
304
]
],
[
[
663,
24,
1270
],
[
1270,
63,
304
]
],
[
[
663,
24,
869
],
[
869,
24,
304
]
],
[
[
663,
25,
1070
],
[
1070,
64,
304
]
]
] | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimetrexate"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trimethoprim"
],
[
"Trimethoprim",
"{u} (Compound) resembles {v} (Compound)",
"Trimetrexate"
]
],
[
[
"Methotrexate",
"{u} (Compound) binds {v} (Gene)",
"DHFR"
],
[
"DHFR",
"{u} (Gene) is bound by {v} (Compound)",
"Trimetrexate"
]
],
[
[
"Methotrexate",
"{u} (Compound) causes {v} (Side Effect)",
"Pruritus"
],
[
"Pruritus",
"{u} (Side Effect) is caused by {v} (Compound)",
"Trimetrexate"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trimetrexate"
]
],
[
[
"Methotrexate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lamotrigine"
],
[
"Lamotrigine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trimetrexate"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimetrexate"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
],
[
"Tuberculin purified protein derivative",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimetrexate"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimetrexate"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
],
[
"Mipomersen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trimetrexate"
]
]
] | Methotrexate may lead to a major life threatening interaction when taken with Trimethoprim and Trimethoprim (Compound) resembles Trimetrexate (Compound)
Methotrexate (Compound) binds DHFR (Gene) and DHFR (Gene) is bound by Trimetrexate (Compound)
Methotrexate (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Trimetrexate (Compound)
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Trimetrexate
Methotrexate may cause a minor interaction that can limit clinical effects when taken with Lamotrigine and Lamotrigine may cause a minor interaction that can limit clinical effects when taken with Trimetrexate
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Trimetrexate
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative and Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Trimetrexate
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Trimetrexate
Methotrexate may lead to a major life threatening interaction when taken with Mipomersen and Mipomersen may lead to a major life threatening interaction when taken with Trimetrexate |
DB00321 | DB01105 | 21 | 222 | [
"DDInter78",
"DDInter1665"
] | Amitriptyline | Sibutramine | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States. In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease. | Major | 2 | [
[
[
21,
25,
222
]
],
[
[
21,
6,
8374
],
[
8374,
45,
222
]
],
[
[
21,
18,
9385
],
[
9385,
57,
222
]
],
[
[
21,
21,
28852
],
[
28852,
60,
222
]
],
[
[
21,
63,
600
],
[
600,
23,
222
]
],
[
[
21,
24,
86
],
[
86,
62,
222
]
],
[
[
21,
25,
351
],
[
351,
62,
222
]
],
[
[
21,
24,
752
],
[
752,
23,
222
]
],
[
[
21,
24,
659
],
[
659,
63,
222
]
],
[
[
21,
24,
128
],
[
128,
24,
222
]
]
] | [
[
[
"Amitriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
]
],
[
[
"Amitriptyline",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Sibutramine"
]
],
[
[
"Amitriptyline",
"{u} (Compound) downregulates {v} (Gene)",
"MRPL19"
],
[
"MRPL19",
"{u} (Gene) is downregulated by {v} (Compound)",
"Sibutramine"
]
],
[
[
"Amitriptyline",
"{u} (Compound) causes {v} (Side Effect)",
"Leukopenia"
],
[
"Leukopenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sibutramine"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
],
[
"Miconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
]
],
[
[
"Amitriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
]
] | Amitriptyline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound)
Amitriptyline (Compound) downregulates MRPL19 (Gene) and MRPL19 (Gene) is downregulated by Sibutramine (Compound)
Amitriptyline (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Sibutramine (Compound)
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Amitriptyline may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine |
DB00011 | DB14730 | 1,451 | 1,412 | [
"DDInter944",
"DDInter264"
] | Interferon alfa-n1 | Calaspargase pegol | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparaginase treatment in ALL , , . Calaspargase pegol, also known as _asparlas_, is an asparagine specific enzyme which is indicated as a part of a multi-agent chemotherapy regimen for the treatment of ALL . The asparagine specific enzyme is derived from Escherichia coli, as a conjugate of L-asparaginase (L-asparagine amidohydrolase) and monomethoxypolyethylene glycol (mPEG) with a succinimidyl carbonate (SC) linker to create a stable molecule which increases the half-life and decreases the dosing frequency [FDA label], . Calaspargase pegol, by _Shire_ pharmaceuticals, was approved by the FDA on December 20, 2018 for acute lymphoblastic anemia (ALL) . | Moderate | 1 | [
[
[
1451,
24,
1412
]
],
[
[
1451,
24,
1439
],
[
1439,
24,
1412
]
],
[
[
1451,
63,
491
],
[
491,
24,
1412
]
],
[
[
1451,
25,
593
],
[
593,
24,
1412
]
],
[
[
1451,
24,
770
],
[
770,
25,
1412
]
],
[
[
1451,
25,
1101
],
[
1101,
25,
1412
]
],
[
[
1451,
24,
1439
],
[
1439,
25,
792
],
[
792,
24,
1412
]
],
[
[
1451,
24,
268
],
[
268,
24,
1439
],
[
1439,
24,
1412
]
],
[
[
1451,
63,
491
],
[
491,
24,
1439
],
[
1439,
24,
1412
]
],
[
[
1451,
25,
593
],
[
593,
25,
250
],
[
250,
24,
1412
]
]
] | [
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
],
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2a"
],
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Interferon alfa-n1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Interferon alfa-n1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
],
[
"Ipilimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
],
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2b"
],
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
],
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2a"
],
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
],
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Interferon alfa-n1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Blinatumomab"
],
[
"Blinatumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
]
] | Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab and Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Interferon alfa-n1 may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Calaspargase pegol
Interferon alfa-n1 may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Calaspargase pegol
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab and Ipilimumab may lead to a major life threatening interaction when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab and Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab and Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Interferon alfa-n1 may lead to a major life threatening interaction when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Blinatumomab and Blinatumomab may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol |
DB00910 | DB11730 | 1,041 | 351 | [
"DDInter1394",
"DDInter1588"
] | Paricalcitol | Ribociclib | Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali. | Moderate | 1 | [
[
[
1041,
24,
351
]
],
[
[
1041,
24,
283
],
[
283,
62,
351
]
],
[
[
1041,
63,
288
],
[
288,
24,
351
]
],
[
[
1041,
24,
1654
],
[
1654,
63,
351
]
],
[
[
1041,
24,
98
],
[
98,
24,
351
]
],
[
[
1041,
24,
129
],
[
129,
25,
351
]
],
[
[
1041,
63,
1622
],
[
1622,
25,
351
]
],
[
[
1041,
24,
1619
],
[
1619,
64,
351
]
],
[
[
1041,
24,
283
],
[
283,
62,
271
],
[
271,
23,
351
]
],
[
[
1041,
63,
288
],
[
288,
24,
466
],
[
466,
62,
351
]
]
] | [
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ribociclib"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Butalbital"
],
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
],
[
"Somapacitan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
],
[
"Voriconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ribociclib"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Butalbital"
],
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ribociclib"
]
]
] | Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Butalbital and Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan and Somapacitan may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Ribociclib
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole and Voriconazole may lead to a major life threatening interaction when taken with Ribociclib
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may lead to a major life threatening interaction when taken with Ribociclib
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Butalbital and Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Ribociclib |
DB00791 | DB01610 | 132 | 248 | [
"DDInter1902",
"DDInter1912"
] | Uracil mustard | Valganciclovir | Nitrogen mustard derivative of uracil. It is a alkylating antineoplastic agent that is used in lymphatic malignancies, and causes mainly gastrointestinal and bone marrow damage. | Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. | Moderate | 1 | [
[
[
132,
24,
248
]
],
[
[
132,
24,
563
],
[
563,
1,
248
]
],
[
[
132,
25,
507
],
[
507,
63,
248
]
],
[
[
132,
25,
770
],
[
770,
24,
248
]
],
[
[
132,
24,
738
],
[
738,
63,
248
]
],
[
[
132,
63,
1287
],
[
1287,
24,
248
]
],
[
[
132,
1,
970
],
[
970,
24,
248
]
],
[
[
132,
24,
869
],
[
869,
24,
248
]
],
[
[
132,
25,
375
],
[
375,
64,
248
]
],
[
[
132,
64,
581
],
[
581,
25,
248
]
]
] | [
[
[
"Uracil mustard",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Uracil mustard",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
],
[
"Ganciclovir",
"{u} (Compound) resembles {v} (Compound)",
"Valganciclovir"
]
],
[
[
"Uracil mustard",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
],
[
"Samarium (153Sm) lexidronam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Uracil mustard",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Uracil mustard",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Uracil mustard",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphotericin B"
],
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Uracil mustard",
"{u} (Compound) resembles {v} (Compound)",
"Fluorouracil"
],
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Uracil mustard",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Uracil mustard",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Valganciclovir"
]
],
[
[
"Uracil mustard",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Valganciclovir"
]
]
] | Uracil mustard may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir (Compound) resembles Valganciclovir (Compound)
Uracil mustard may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam and Samarium (153Sm) lexidronam may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir
Uracil mustard may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir
Uracil mustard may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir
Uracil mustard may cause a moderate interaction that could exacerbate diseases when taken with Amphotericin B and Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir
Uracil mustard (Compound) resembles Fluorouracil (Compound) and Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir
Uracil mustard may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir
Uracil mustard may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Valganciclovir
Uracil mustard may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Valganciclovir |
DB00860 | DB08873 | 891 | 74 | [
"DDInter1513",
"DDInter221"
] | Prednisolone | Boceprevir | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients . Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as Boceprevir. Boceprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 [synthesis]. These enzymes are essential for viral replication and serve to cleave the virally encoded polyprotein into mature proteins like NS4A, NS4B, NS5A and NS5B [FDA Label]. The barrier for develoment of resistance to NS3/4A inhibitors is lower than that of NS5B inhibitors, another class of DAAs . Subtitutions at amino acid positions 155, 156, or 168 are known to confer resistance. The substitutions of the enzyme's catalytic triad consisting of H58, D82, and S139 are also likely to alter the affinity of the drug for NS3/4A or the activity of the enzyme itself. Despite this disadvantage Boceprevir is still effective against HCV when paired with , , and . In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) do not reccomend Boceprevir in combination with , , and as first line therapy for Hepatitis C . Boceprevir, , , and are used with the intent to cure, or achieve a sustained virologic response (SVR), after 48 weeks of daily therapy. SVR and eradication of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause mortality . Boceprevir is available as a fixed dose product (tradename Victrelis) used for the treatment of chronic Hepatitis C. Approved in May 2011 by the FDA, Victrelis is indicated for the treatment of HCV genotype 1 in combination with , , and [FDA Label]. Victrelis is no longer widely used as interferon-free therapies have been developed. | Moderate | 1 | [
[
[
891,
24,
74
]
],
[
[
891,
6,
4973
],
[
4973,
45,
74
]
],
[
[
891,
21,
28769
],
[
28769,
60,
74
]
],
[
[
891,
24,
473
],
[
473,
24,
74
]
],
[
[
891,
1,
1351
],
[
1351,
24,
74
]
],
[
[
891,
40,
1220
],
[
1220,
24,
74
]
],
[
[
891,
63,
1419
],
[
1419,
24,
74
]
],
[
[
891,
24,
1619
],
[
1619,
63,
74
]
],
[
[
891,
23,
659
],
[
659,
63,
74
]
],
[
[
891,
1,
1486
],
[
1486,
25,
74
]
]
] | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Prednisolone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Boceprevir"
]
],
[
[
"Prednisolone",
"{u} (Compound) causes {v} (Side Effect)",
"Feeling abnormal"
],
[
"Feeling abnormal",
"{u} (Side Effect) is caused by {v} (Compound)",
"Boceprevir"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Flunisolide"
],
[
"Flunisolide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Prednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Boceprevir"
]
]
] | Prednisolone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Boceprevir (Compound)
Prednisolone (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Boceprevir (Compound)
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Prednisolone (Compound) resembles Flunisolide (Compound) and Flunisolide may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Prednisolone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Prednisolone may cause a minor interaction that can limit clinical effects when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Prednisolone (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone may lead to a major life threatening interaction when taken with Boceprevir |
DB01044 | DB01124 | 246 | 1,411 | [
"DDInter809",
"DDInter1828"
] | Gatifloxacin | Tolbutamide | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. It is also available as eye drops under the brand name Zymar® marketed by Allergan. The FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence of hyperglycemic and hypoglycemic episodes in patients taking gatifloxacin compared to those on macrolide antibiotics.[L43942,L44037] | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Tolbutamide appears to be metabolized in the liver. Tolbutamide and its metabolites are excreted in urine (75-85%) and feces. | Major | 2 | [
[
[
246,
25,
1411
]
],
[
[
246,
25,
959
],
[
959,
40,
1411
]
],
[
[
246,
64,
245
],
[
245,
40,
1411
]
],
[
[
246,
21,
28746
],
[
28746,
60,
1411
]
],
[
[
246,
24,
1475
],
[
1475,
62,
1411
]
],
[
[
246,
25,
1296
],
[
1296,
63,
1411
]
],
[
[
246,
64,
126
],
[
126,
24,
1411
]
],
[
[
246,
63,
1274
],
[
1274,
24,
1411
]
],
[
[
246,
24,
286
],
[
286,
63,
1411
]
],
[
[
246,
23,
1532
],
[
1532,
63,
1411
]
]
] | [
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tolbutamide"
]
],
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} (Compound) resembles {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} (Compound) resembles {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Gatifloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Erythema"
],
[
"Erythema",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Gatifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium citrate"
],
[
"Sodium citrate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tolbutamide"
]
],
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Gatifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Gatifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Gatifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
]
] | Gatifloxacin may lead to a major life threatening interaction when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Gatifloxacin may lead to a major life threatening interaction when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compound)
Gatifloxacin (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Tolbutamide (Compound)
Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Sodium citrate and Sodium citrate may cause a minor interaction that can limit clinical effects when taken with Tolbutamide
Gatifloxacin may lead to a major life threatening interaction when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Gatifloxacin may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide |
DB00314 | DB01249 | 894 | 258 | [
"DDInter288",
"DDInter958"
] | Capreomycin | Iodixanol | Cyclic peptide antibiotic similar to viomycin. It is produced by Streptomyces capreolus. | Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents. | Major | 2 | [
[
[
894,
25,
258
]
],
[
[
894,
25,
497
],
[
497,
1,
258
]
],
[
[
894,
21,
28748
],
[
28748,
60,
258
]
],
[
[
894,
24,
712
],
[
712,
64,
258
]
],
[
[
894,
25,
416
],
[
416,
25,
258
]
],
[
[
894,
24,
1481
],
[
1481,
25,
258
]
],
[
[
894,
25,
497
],
[
497,
7,
18008
],
[
18008,
46,
258
]
],
[
[
894,
21,
28748
],
[
28748,
60,
178
],
[
178,
63,
258
]
],
[
[
894,
21,
28719
],
[
28719,
60,
497
],
[
497,
1,
258
]
],
[
[
894,
21,
29035
],
[
29035,
60,
772
],
[
772,
24,
258
]
]
] | [
[
[
"Capreomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iodixanol"
]
],
[
[
"Capreomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} (Compound) resembles {v} (Compound)",
"Iodixanol"
]
],
[
[
"Capreomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Vertigo"
],
[
"Vertigo",
"{u} (Side Effect) is caused by {v} (Compound)",
"Iodixanol"
]
],
[
[
"Capreomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olsalazine"
],
[
"Olsalazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iodixanol"
]
],
[
[
"Capreomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Kanamycin"
],
[
"Kanamycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iodixanol"
]
],
[
[
"Capreomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polymyxin B"
],
[
"Polymyxin B",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iodixanol"
]
],
[
[
"Capreomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} (Compound) upregulates {v} (Gene)",
"BAMBI"
],
[
"BAMBI",
"{u} (Gene) is upregulated by {v} (Compound)",
"Iodixanol"
]
],
[
[
"Capreomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Vertigo"
],
[
"Vertigo",
"{u} (Side Effect) is caused by {v} (Compound)",
"Polythiazide"
],
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodixanol"
]
],
[
[
"Capreomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Pain"
],
[
"Pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Iohexol"
],
[
"Iohexol",
"{u} (Compound) resembles {v} (Compound)",
"Iodixanol"
]
],
[
[
"Capreomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Hearing impaired"
],
[
"Hearing impaired",
"{u} (Side Effect) is caused by {v} (Compound)",
"Carvedilol"
],
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodixanol"
]
]
] | Capreomycin may lead to a major life threatening interaction when taken with Iohexol and Iohexol (Compound) resembles Iodixanol (Compound)
Capreomycin (Compound) causes Vertigo (Side Effect) and Vertigo (Side Effect) is caused by Iodixanol (Compound)
Capreomycin may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine may lead to a major life threatening interaction when taken with Iodixanol
Capreomycin may lead to a major life threatening interaction when taken with Kanamycin and Kanamycin may lead to a major life threatening interaction when taken with Iodixanol
Capreomycin may cause a moderate interaction that could exacerbate diseases when taken with Polymyxin B and Polymyxin B may lead to a major life threatening interaction when taken with Iodixanol
Capreomycin may lead to a major life threatening interaction when taken with Iohexol and Iohexol (Compound) upregulates BAMBI (Gene) and BAMBI (Gene) is upregulated by Iodixanol (Compound)
Capreomycin (Compound) causes Vertigo (Side Effect) and Vertigo (Side Effect) is caused by Polythiazide (Compound) and Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Iodixanol
Capreomycin (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Iohexol (Compound) and Iohexol (Compound) resembles Iodixanol (Compound)
Capreomycin (Compound) causes Hearing impaired (Side Effect) and Hearing impaired (Side Effect) is caused by Carvedilol (Compound) and Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Iodixanol |
DB01087 | DB01268 | 1,520 | 1,151 | [
"DDInter1520",
"DDInter1731"
] | Primaquine | Sunitinib | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404) | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3. | Moderate | 1 | [
[
[
1520,
24,
1151
]
],
[
[
1520,
6,
8374
],
[
8374,
45,
1151
]
],
[
[
1520,
21,
28757
],
[
28757,
60,
1151
]
],
[
[
1520,
62,
1247
],
[
1247,
23,
1151
]
],
[
[
1520,
63,
1148
],
[
1148,
24,
1151
]
],
[
[
1520,
24,
1250
],
[
1250,
63,
1151
]
],
[
[
1520,
64,
876
],
[
876,
24,
1151
]
],
[
[
1520,
24,
419
],
[
419,
24,
1151
]
],
[
[
1520,
62,
479
],
[
479,
24,
1151
]
],
[
[
1520,
25,
1327
],
[
1327,
25,
1151
]
]
] | [
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Primaquine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Sunitinib"
]
],
[
[
"Primaquine",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspepsia"
],
[
"Dyspepsia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sunitinib"
]
],
[
[
"Primaquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sunitinib"
]
],
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Primaquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tizanidine"
],
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Halothane"
],
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Primaquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Primaquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Saquinavir"
],
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sunitinib"
]
]
] | Primaquine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sunitinib (Compound)
Primaquine (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Sunitinib (Compound)
Primaquine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Sunitinib
Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Primaquine may lead to a major life threatening interaction when taken with Tizanidine and Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Halothane and Halothane may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Primaquine may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Primaquine may lead to a major life threatening interaction when taken with Saquinavir and Saquinavir may lead to a major life threatening interaction when taken with Sunitinib |
DB00063 | DB00533 | 366 | 1,416 | [
"DDInter659",
"DDInter1613"
] | Eptifibatide | Rofecoxib | Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics. | Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids. Rofecoxib has a half-life of 17 hours and its mean oral bioavailability at therapeutically recommended doses of 125, 25, and 50 mg is approximately 93%. The proteins that rofecoxib target include elastin and prostaglandin G/H synthase 2. Cytochrome P450 1A2, Cytochrome P450 3A4, Cytochrome P450 2C9, Cytochrome P450 2C8, and Prostaglandin G/H synthase 1 are known to metabolize rofecoxib. On September 30, 2004, Merck voluntarily withdrew rofecoxib from the market because of concerns about increased risk of heart attack and stroke associated with long-term, high-dosage use. | Moderate | 1 | [
[
[
366,
24,
1416
]
],
[
[
366,
25,
1409
],
[
1409,
63,
1416
]
],
[
[
366,
64,
1578
],
[
1578,
24,
1416
]
],
[
[
366,
24,
714
],
[
714,
63,
1416
]
],
[
[
366,
24,
1061
],
[
1061,
24,
1416
]
],
[
[
366,
63,
942
],
[
942,
24,
1416
]
],
[
[
366,
25,
291
],
[
291,
24,
1416
]
],
[
[
366,
25,
1409
],
[
1409,
64,
1578
],
[
1578,
24,
1416
]
],
[
[
366,
64,
1578
],
[
1578,
25,
1409
],
[
1409,
63,
1416
]
],
[
[
366,
25,
553
],
[
553,
25,
1409
],
[
1409,
63,
1416
]
]
] | [
[
[
"Eptifibatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rofecoxib"
]
],
[
[
"Eptifibatide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
],
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rofecoxib"
]
],
[
[
"Eptifibatide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rofecoxib"
]
],
[
[
"Eptifibatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rofecoxib"
]
],
[
[
"Eptifibatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rofecoxib"
]
],
[
[
"Eptifibatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bivalirudin"
],
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rofecoxib"
]
],
[
[
"Eptifibatide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Argatroban"
],
[
"Argatroban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rofecoxib"
]
],
[
[
"Eptifibatide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
],
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rofecoxib"
]
],
[
[
"Eptifibatide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
],
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rofecoxib"
]
],
[
[
"Eptifibatide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fondaparinux"
],
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
],
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rofecoxib"
]
]
] | Eptifibatide may lead to a major life threatening interaction when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Rofecoxib
Eptifibatide may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Rofecoxib
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Rofecoxib
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Rofecoxib
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Bivalirudin and Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Rofecoxib
Eptifibatide may lead to a major life threatening interaction when taken with Argatroban and Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Rofecoxib
Eptifibatide may lead to a major life threatening interaction when taken with Apixaban and Apixaban may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Rofecoxib
Eptifibatide may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may lead to a major life threatening interaction when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Rofecoxib
Eptifibatide may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux may lead to a major life threatening interaction when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Rofecoxib |
DB00640 | DB11718 | 1,585 | 927 | [
"DDInter31",
"DDInter640"
] | Adenosine | Encorafenib | The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole] and [regadenson].[A229833,A229838] Adenosine is also indicated in the treatment of supraventricular tachycardia. Adenosine was granted FDA approval on 30 October 1989. | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of the lung. On June 27, 2018, the Food and Drug Administration approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. | Moderate | 1 | [
[
[
1585,
24,
927
]
],
[
[
1585,
40,
372
],
[
372,
24,
927
]
],
[
[
1585,
24,
1491
],
[
1491,
24,
927
]
],
[
[
1585,
63,
1010
],
[
1010,
24,
927
]
],
[
[
1585,
24,
484
],
[
484,
63,
927
]
],
[
[
1585,
23,
578
],
[
578,
24,
927
]
],
[
[
1585,
64,
1424
],
[
1424,
24,
927
]
],
[
[
1585,
25,
39
],
[
39,
25,
927
]
],
[
[
1585,
24,
129
],
[
129,
25,
927
]
],
[
[
1585,
63,
600
],
[
600,
25,
927
]
]
] | [
[
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Adenosine",
"{u} (Compound) resembles {v} (Compound)",
"Clofarabine"
],
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Adenosine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Adenosine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Adenosine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
]
] | Adenosine (Compound) resembles Clofarabine (Compound) and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Adenosine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Adenosine may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Adenosine may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Encorafenib
Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Encorafenib
Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Encorafenib |
DB00282 | DB00681 | 641 | 1,287 | [
"DDInter1383",
"DDInter85"
] | Pamidronic acid | Amphotericin B | Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to [neridronic acid] and [alendronic acid]. Pamidronic acid was first described in the literature in 1977. The second generation bisphosphonates are less common as third generation bisphosphonates, such as [ibandronic acid], [zoledronic acid], [minodronic acid], and [risedronic acid] are becoming more popular. Pamidronic acid was granted FDA approval on 31 October 1991. | Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL in vitro. While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible. Pseudallescheria boydii and Fusarium sp. are often resistant to amphotericin B. The antibiotic is without effect on bacteria, rickettsiae, and viruses. | Moderate | 1 | [
[
[
641,
24,
1287
]
],
[
[
641,
21,
29876
],
[
29876,
60,
1287
]
],
[
[
641,
24,
663
],
[
663,
24,
1287
]
],
[
[
641,
24,
50
],
[
50,
63,
1287
]
],
[
[
641,
1,
1199
],
[
1199,
63,
1287
]
],
[
[
641,
1,
963
],
[
963,
24,
1287
]
],
[
[
641,
25,
497
],
[
497,
64,
1287
]
],
[
[
641,
21,
29876
],
[
29876,
60,
251
],
[
251,
24,
1287
]
],
[
[
641,
21,
29026
],
[
29026,
60,
1622
],
[
1622,
23,
1287
]
],
[
[
641,
21,
29196
],
[
29196,
60,
11554
],
[
11554,
40,
1287
]
]
] | [
[
[
"Pamidronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphotericin B"
]
],
[
[
"Pamidronic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Epilepsy"
],
[
"Epilepsy",
"{u} (Side Effect) is caused by {v} (Compound)",
"Amphotericin B"
]
],
[
[
"Pamidronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphotericin B"
]
],
[
[
"Pamidronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
],
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphotericin B"
]
],
[
[
"Pamidronic acid",
"{u} (Compound) resembles {v} (Compound)",
"Ibandronate"
],
[
"Ibandronate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphotericin B"
]
],
[
[
"Pamidronic acid",
"{u} (Compound) resembles {v} (Compound)",
"Zoledronic acid"
],
[
"Zoledronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphotericin B"
]
],
[
[
"Pamidronic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amphotericin B"
]
],
[
[
"Pamidronic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Epilepsy"
],
[
"Epilepsy",
"{u} (Side Effect) is caused by {v} (Compound)",
"Betamethasone"
],
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphotericin B"
]
],
[
[
"Pamidronic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Bone pain"
],
[
"Bone pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Voriconazole"
],
[
"Voriconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amphotericin B"
]
],
[
[
"Pamidronic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Paraesthesia"
],
[
"Paraesthesia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Natamycin"
],
[
"Natamycin",
"{u} (Compound) resembles {v} (Compound)",
"Amphotericin B"
]
]
] | Pamidronic acid (Compound) causes Epilepsy (Side Effect) and Epilepsy (Side Effect) is caused by Amphotericin B (Compound)
Pamidronic acid may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Amphotericin B
Pamidronic acid may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Amphotericin B
Pamidronic acid (Compound) resembles Ibandronate (Compound) and Ibandronate may cause a moderate interaction that could exacerbate diseases when taken with Amphotericin B
Pamidronic acid (Compound) resembles Zoledronic acid (Compound) and Zoledronic acid may cause a moderate interaction that could exacerbate diseases when taken with Amphotericin B
Pamidronic acid may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Amphotericin B
Pamidronic acid (Compound) causes Epilepsy (Side Effect) and Epilepsy (Side Effect) is caused by Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Amphotericin B
Pamidronic acid (Compound) causes Bone pain (Side Effect) and Bone pain (Side Effect) is caused by Voriconazole (Compound) and Voriconazole may cause a minor interaction that can limit clinical effects when taken with Amphotericin B
Pamidronic acid (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Natamycin (Compound) and Natamycin (Compound) resembles Amphotericin B (Compound) |
DB00851 | DB08868 | 611 | 1,011 | [
"DDInter463",
"DDInter737"
] | Dacarbazine | Fingolimod | An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma. | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.[L12654,L12657] | Major | 2 | [
[
[
611,
25,
1011
]
],
[
[
611,
6,
6365
],
[
6365,
45,
1011
]
],
[
[
611,
24,
242
],
[
242,
63,
1011
]
],
[
[
611,
24,
1136
],
[
1136,
24,
1011
]
],
[
[
611,
63,
267
],
[
267,
24,
1011
]
],
[
[
611,
25,
976
],
[
976,
64,
1011
]
],
[
[
611,
64,
1066
],
[
1066,
25,
1011
]
],
[
[
611,
63,
1555
],
[
1555,
25,
1011
]
],
[
[
611,
24,
259
],
[
259,
25,
1011
]
],
[
[
611,
24,
1362
],
[
1362,
64,
1011
]
]
] | [
[
[
"Dacarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Dacarbazine",
"{u} (Compound) binds {v} (Gene)",
"CYP2E1"
],
[
"CYP2E1",
"{u} (Gene) is bound by {v} (Compound)",
"Fingolimod"
]
],
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
],
[
"Remdesivir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
],
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
]
],
[
[
"Dacarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Dacarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
]
] | Dacarbazine (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Fingolimod (Compound)
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Dacarbazine may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Fingolimod
Dacarbazine may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Fingolimod
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may lead to a major life threatening interaction when taken with Fingolimod
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may lead to a major life threatening interaction when taken with Fingolimod
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may lead to a major life threatening interaction when taken with Fingolimod |
DB06335 | DB11255 | 761 | 1,371 | [
"DDInter1646",
"DDInter374"
] | Saxagliptin | Chromium picolinate | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Chromium picolinate has a chemical formula CrPic3 and reddish-pink color. It is a coordination complex consisting of chromium(III) and picolinic acid. Chromium picolinate is used as a nutritional supplement for optimal insulin function in patients with Type 2 diabetes or promotion of weight loss. Chromium ions are shown to regulate insulin by promoting glucose utilization and increasing the sensitivity of the insulin receptor . | Moderate | 1 | [
[
[
761,
24,
1371
]
],
[
[
761,
63,
245
],
[
245,
24,
1371
]
],
[
[
761,
24,
1296
],
[
1296,
24,
1371
]
],
[
[
761,
63,
245
],
[
245,
24,
5
],
[
5,
24,
1371
]
],
[
[
761,
24,
1296
],
[
1296,
63,
245
],
[
245,
24,
1371
]
],
[
[
761,
63,
959
],
[
959,
1,
245
],
[
245,
24,
1371
]
],
[
[
761,
63,
1254
],
[
1254,
63,
245
],
[
245,
24,
1371
]
],
[
[
761,
21,
28757
],
[
28757,
60,
245
],
[
245,
24,
1371
]
],
[
[
761,
63,
245
],
[
245,
40,
959
],
[
959,
24,
1371
]
],
[
[
761,
63,
473
],
[
473,
24,
1385
],
[
1385,
63,
1371
]
]
] | [
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
],
[
"Liraglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} (Compound) resembles {v} (Compound)",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
],
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Saxagliptin",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspepsia"
],
[
"Dyspepsia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} (Compound) resembles {v} (Compound)",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
],
[
"Semaglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
]
] | Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
Saxagliptin (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide and Semaglutide may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate |
DB00836 | DB13074 | 543 | 877 | [
"DDInter1088",
"DDInter1110"
] | Loperamide | Macimorelin | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxylate] and [haloperidol]. Due to pharmacological properties, loperamide has been misused and abused to self-manage opioid withdrawal symptoms and to induce euphoria.[A251610, A251625] However, loperamide is associated with a risk for experiencing a range of adverse effects, often life-threatening, if taking for non-therapeutic reasons or at doses higher than the recommended dose. | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dependently increase GH levels . Growth hormone secretagogues (GHS) represent a new class of pharmacological agents which have the potential to be used in numerous clinical applications. They include treatment for growth retardation in children and cachexia associated with chronic disease such as AIDS and cancer. Growth hormone (GH) is classically linked with linear growth during childhood. In deficiency of this hormone, AGHD is commonly associated with increased fat mass (particularly in the abdominal region), decreased lean body mass, osteopenia, dyslipidemia, insulin resistance, and/or glucose intolerance overtime. In addition, individuals with may be susceptible to cardiovascular complications from altered structures and function . Risk factors of AGHD include a history of childhood-onset GH deficiency or with hypothalamic/pituitary disease, surgery, or irradiation to these areas, head trauma, or evidence of other pituitary hormone deficiencies . While there are various therapies available such as GH replacement therapy, the absence of panhypopituitarism and low serum IGF-I levels with nonspecific clinical symptoms pose challenges to the detection and diagnosis of AGHD. The diagnosis of AGHD requires biochemical confirmation with at least 1 GH stimulation test . Macimorelin is clinically useful since it displays good stability and oral bioavailability with comparable affinity to ghrelin receptor as its endogenous ligand. In clinical studies involving healthy subjects, macimorelin stimulated GH release in a dose-dependent manner with good tolerability . Macimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market name Macrilen for oral solution. | Moderate | 1 | [
[
[
543,
24,
877
]
],
[
[
543,
24,
112
],
[
112,
23,
877
]
],
[
[
543,
24,
1320
],
[
1320,
24,
877
]
],
[
[
543,
63,
85
],
[
85,
24,
877
]
],
[
[
543,
63,
485
],
[
485,
25,
877
]
],
[
[
543,
24,
478
],
[
478,
25,
877
]
],
[
[
543,
25,
392
],
[
392,
25,
877
]
],
[
[
543,
64,
1424
],
[
1424,
25,
877
]
],
[
[
543,
24,
1399
],
[
1399,
64,
877
]
],
[
[
543,
74,
576
],
[
576,
25,
877
]
]
] | [
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Macimorelin"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
],
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Loperamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Loperamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
],
[
"Lithium carbonate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Loperamide",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methadone"
],
[
"Methadone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
]
] | Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may lead to a major life threatening interaction when taken with Macimorelin
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Macimorelin
Loperamide may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may lead to a major life threatening interaction when taken with Macimorelin
Loperamide may lead to a major life threatening interaction when taken with Quinine and Quinine may lead to a major life threatening interaction when taken with Macimorelin
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium carbonate may lead to a major life threatening interaction when taken with Macimorelin
Loperamide (Compound) resembles Methadone (Compound) and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone may lead to a major life threatening interaction when taken with Macimorelin |
DB00241 | DB06282 | 288 | 516 | [
"DDInter257",
"DDInter1053"
] | Butalbital | Levocetirizine | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervous system (CNS) depression that ranges from mild sedation to general anesthesia. Butalbital has a low degree of selectivity and a narrow therapeutic index. Typically indicated to manage tension (or muscle contraction) headaches, butalbital is often combined with one or more therapeutic agents, such as acetylsalicylic acid, acetaminophen, aspirin, and caffeine. There have not been clinical trials that evaluate the clinical efficacy of butalbital in migraines thus it is not indicated for such condition. As with other barbiturates | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
288,
24,
516
]
],
[
[
288,
24,
1031
],
[
1031,
23,
516
]
],
[
[
288,
24,
701
],
[
701,
24,
516
]
],
[
[
288,
24,
407
],
[
407,
63,
516
]
],
[
[
288,
63,
1648
],
[
1648,
24,
516
]
],
[
[
288,
1,
536
],
[
536,
24,
516
]
],
[
[
288,
40,
1023
],
[
1023,
24,
516
]
],
[
[
288,
25,
475
],
[
475,
24,
516
]
],
[
[
288,
24,
1031
],
[
1031,
24,
697
],
[
697,
24,
516
]
],
[
[
288,
24,
701
],
[
701,
23,
771
],
[
771,
62,
516
]
]
] | [
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levocetirizine"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Butalbital",
"{u} (Compound) resembles {v} (Compound)",
"Secobarbital"
],
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Butalbital",
"{u} (Compound) resembles {v} (Compound)",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Butalbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],
[
"Hyaluronidase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levocetirizine"
]
]
] | Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Levocetirizine
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Butalbital (Compound) resembles Secobarbital (Compound) and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Butalbital (Compound) resembles Pentobarbital (Compound) and Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Butalbital may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Levocetirizine |
DB00220 | DB01276 | 798 | 123 | [
"DDInter1276",
"DDInter706"
] | Nelfinavir | Exenatide | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulations.[L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. Bydureon BCise, an auto-injector extended-release formulation, remains available. | Moderate | 1 | [
[
[
798,
24,
123
]
],
[
[
798,
25,
1476
],
[
1476,
63,
123
]
],
[
[
798,
24,
1573
],
[
1573,
24,
123
]
],
[
[
798,
24,
1040
],
[
1040,
63,
123
]
],
[
[
798,
63,
1685
],
[
1685,
24,
123
]
],
[
[
798,
23,
222
],
[
222,
24,
123
]
],
[
[
798,
25,
455
],
[
455,
24,
123
]
],
[
[
798,
1,
215
],
[
215,
24,
123
]
],
[
[
798,
40,
1327
],
[
1327,
24,
123
]
],
[
[
798,
24,
1101
],
[
1101,
25,
123
]
]
] | [
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin human"
],
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Nelfinavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Nelfinavir",
"{u} (Compound) resembles {v} (Compound)",
"Indinavir"
],
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Nelfinavir",
"{u} (Compound) resembles {v} (Compound)",
"Saquinavir"
],
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Exenatide"
]
]
] | Nelfinavir may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Nelfinavir may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Nelfinavir may lead to a major life threatening interaction when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Nelfinavir (Compound) resembles Indinavir (Compound) and Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Nelfinavir (Compound) resembles Saquinavir (Compound) and Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Exenatide |
DB00213 | DB09098 | 837 | 98 | [
"DDInter1388",
"DDInter1700"
] | Pantoprazole | Somatrem | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be found in quadruple regimens for the treatment of _H. pylori_ infections along with other antibiotics including [amoxicillin], [clarithromycin], and [metronidazole], for example. Its efficacy is considered similar to other medications within the PPI class including [omeprazole], [esomeprazole], [lansoprazole], [dexlansoprazole], and [rabeprazole]. Pantoprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disposition of short stature should be considered a medical condition justifying medical treatment with such hormone therapy - especially when these hormone agents have been proven effective at increasing the height of children with or without growth hormone deficiency . | Moderate | 1 | [
[
[
837,
24,
98
]
],
[
[
837,
62,
168
],
[
168,
23,
98
]
],
[
[
837,
24,
1671
],
[
1671,
24,
98
]
],
[
[
837,
24,
159
],
[
159,
63,
98
]
],
[
[
837,
23,
785
],
[
785,
63,
98
]
],
[
[
837,
23,
1069
],
[
1069,
24,
98
]
],
[
[
837,
25,
915
],
[
915,
24,
98
]
],
[
[
837,
25,
1519
],
[
1519,
63,
98
]
],
[
[
837,
1,
1215
],
[
1215,
24,
98
]
],
[
[
837,
62,
168
],
[
168,
24,
671
],
[
671,
24,
98
]
]
] | [
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Pantoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Somatrem"
]
],
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
],
[
"Flibanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Pantoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capmatinib"
],
[
"Capmatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Pantoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Pantoprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Atazanavir"
],
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Pantoprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Velpatasvir"
],
[
"Velpatasvir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Pantoprazole",
"{u} (Compound) resembles {v} (Compound)",
"Lansoprazole"
],
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Pantoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
]
] | Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somatrem
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin and Flibanserin may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Capmatinib and Capmatinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Vandetanib and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Pantoprazole may lead to a major life threatening interaction when taken with Atazanavir and Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Pantoprazole may lead to a major life threatening interaction when taken with Velpatasvir and Velpatasvir may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Pantoprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Somatrem |
DB01064 | DB08918 | 1,148 | 41 | [
"DDInter987",
"DDInter1059"
] | Isoprenaline | Levomilnacipran | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that this isopropyl analog of epinephrine dilated the bronchi, as well as raising the heart rate and cardiac output, without vasoconstriction.[A233724,A233729] The US patent from 1943 states that this compound had a wider therapeutic index and a stronger action than [adrenaline]. Isoprenaline was granted FDA approval on 19 February 1948. | Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].[A261181, L47956] Once administered, interconversion between levomilnacipran and its stereoisomer does not occur in humans. First approved by the FDA on July 25, 2013, levomilnacipran is used to treat major depressive disorder in adults. While levomilnacipran was previously investigated and proposed as a potential treatment for stroke in Europe, the EMA decided against this use. | Moderate | 1 | [
[
[
1148,
24,
41
]
],
[
[
1148,
24,
901
],
[
901,
40,
41
]
],
[
[
1148,
21,
28975
],
[
28975,
60,
41
]
],
[
[
1148,
25,
1618
],
[
1618,
24,
41
]
],
[
[
1148,
24,
477
],
[
477,
24,
41
]
],
[
[
1148,
74,
1674
],
[
1674,
24,
41
]
],
[
[
1148,
63,
1445
],
[
1445,
24,
41
]
],
[
[
1148,
64,
702
],
[
702,
24,
41
]
],
[
[
1148,
24,
144
],
[
144,
63,
41
]
],
[
[
1148,
24,
1264
],
[
1264,
25,
41
]
]
] | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
],
[
"Milnacipran",
"{u} (Compound) resembles {v} (Compound)",
"Levomilnacipran"
]
],
[
[
"Isoprenaline",
"{u} (Compound) causes {v} (Side Effect)",
"Tension"
],
[
"Tension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Levomilnacipran"
]
],
[
[
"Isoprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Isoprenaline",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
],
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Isoprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
],
[
"Olodaterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levomilnacipran"
]
]
] | Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran (Compound) resembles Levomilnacipran (Compound)
Isoprenaline (Compound) causes Tension (Side Effect) and Tension (Side Effect) is caused by Levomilnacipran (Compound)
Isoprenaline may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Isoprenaline (Compound) resembles Orciprenaline (Compound) and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Isoprenaline may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may lead to a major life threatening interaction when taken with Levomilnacipran |
DB11166 | DB12364 | 18 | 1,421 | [
"DDInter104",
"DDInter200"
] | Antithrombin Alfa | Betrixaban | Antithrombin Alfa is a recombinant antithrombin, an anticoagulant, that is used for the prevention of thromboembolic events in patients that have hereditary deficiency of antithrombin in high risk situations. | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks for VTE . VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients . | Major | 2 | [
[
[
18,
25,
1421
]
],
[
[
18,
63,
1074
],
[
1074,
24,
1421
]
],
[
[
18,
24,
738
],
[
738,
24,
1421
]
],
[
[
18,
63,
714
],
[
714,
25,
1421
]
],
[
[
18,
64,
936
],
[
936,
25,
1421
]
],
[
[
18,
25,
405
],
[
405,
25,
1421
]
],
[
[
18,
63,
1074
],
[
1074,
24,
1004
],
[
1004,
24,
1421
]
],
[
[
18,
63,
1039
],
[
1039,
64,
529
],
[
529,
24,
1421
]
],
[
[
18,
63,
1595
],
[
1595,
24,
714
],
[
714,
25,
1421
]
],
[
[
18,
63,
222
],
[
222,
62,
1091
],
[
1091,
24,
1421
]
]
] | [
[
[
"Antithrombin Alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Antithrombin Alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
],
[
"Iodide I-123",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Antithrombin Alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Antithrombin Alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Antithrombin Alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cangrelor"
],
[
"Cangrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Antithrombin Alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
],
[
"Acalabrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Antithrombin Alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
],
[
"Iodide I-123",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyl salicylate"
],
[
"Phenyl salicylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Antithrombin Alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Antithrombin Alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Collagenase clostridium histolyticum"
],
[
"Collagenase clostridium histolyticum",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Antithrombin Alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amprenavir"
],
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
]
] | Antithrombin Alfa may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 and Iodide I-123 may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Antithrombin Alfa may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Antithrombin Alfa may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may lead to a major life threatening interaction when taken with Betrixaban
Antithrombin Alfa may lead to a major life threatening interaction when taken with Cangrelor and Cangrelor may lead to a major life threatening interaction when taken with Betrixaban
Antithrombin Alfa may lead to a major life threatening interaction when taken with Acalabrutinib and Acalabrutinib may lead to a major life threatening interaction when taken with Betrixaban
Antithrombin Alfa may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 and Iodide I-123 may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate and Phenyl salicylate may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Antithrombin Alfa may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may lead to a major life threatening interaction when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Antithrombin Alfa may cause a moderate interaction that could exacerbate diseases when taken with Collagenase clostridium histolyticum and Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may lead to a major life threatening interaction when taken with Betrixaban
Antithrombin Alfa may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban |
DB08881 | DB11799 | 868 | 627 | [
"DDInter1925",
"DDInter205"
] | Vemurafenib | Bictegravir | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program. | Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet. | Moderate | 1 | [
[
[
868,
24,
627
]
],
[
[
868,
24,
1362
],
[
1362,
24,
627
]
],
[
[
868,
63,
578
],
[
578,
24,
627
]
],
[
[
868,
64,
478
],
[
478,
24,
627
]
],
[
[
868,
24,
466
],
[
466,
63,
627
]
],
[
[
868,
25,
982
],
[
982,
63,
627
]
],
[
[
868,
25,
985
],
[
985,
24,
627
]
],
[
[
868,
25,
129
],
[
129,
25,
627
]
],
[
[
868,
24,
603
],
[
603,
25,
627
]
],
[
[
868,
25,
913
],
[
913,
64,
627
]
]
] | [
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bictegravir"
]
],
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bictegravir"
]
],
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bictegravir"
]
],
[
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bictegravir"
]
],
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bictegravir"
]
],
[
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bictegravir"
]
],
[
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bictegravir"
]
],
[
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bictegravir"
]
],
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
],
[
"Magnesium citrate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bictegravir"
]
],
[
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bictegravir"
]
]
] | Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir
Vemurafenib may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir
Vemurafenib may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir
Vemurafenib may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir
Vemurafenib may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Bictegravir
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may lead to a major life threatening interaction when taken with Bictegravir
Vemurafenib may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Bictegravir |
DB00382 | DB05294 | 62 | 1,069 | [
"DDInter1734",
"DDInter1917"
] | Tacrine | Vandetanib | A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market. | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Moderate | 1 | [
[
[
62,
24,
1069
]
],
[
[
62,
24,
1194
],
[
1194,
23,
1069
]
],
[
[
62,
24,
688
],
[
688,
24,
1069
]
],
[
[
62,
24,
384
],
[
384,
63,
1069
]
],
[
[
62,
24,
401
],
[
401,
25,
1069
]
],
[
[
62,
24,
985
],
[
985,
64,
1069
]
],
[
[
62,
63,
1494
],
[
1494,
25,
1069
]
],
[
[
62,
24,
594
],
[
594,
75,
1069
]
],
[
[
62,
24,
1194
],
[
1194,
63,
1195
],
[
1195,
40,
1069
]
],
[
[
62,
24,
112
],
[
112,
6,
8374
],
[
8374,
45,
1069
]
]
] | [
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vandetanib"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ranitidine"
],
[
"Ranitidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vandetanib"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vandetanib"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vandetanib"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palonosetron"
],
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ranitidine"
],
[
"Ranitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erlotinib"
],
[
"Erlotinib",
"{u} (Compound) resembles {v} (Compound)",
"Vandetanib"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Vandetanib"
]
]
] | Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Ranitidine and Ranitidine may cause a minor interaction that can limit clinical effects when taken with Vandetanib
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Vandetanib
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Vandetanib
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may lead to a major life threatening interaction when taken with Vandetanib
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Vandetanib
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron and Palonosetron may lead to a major life threatening interaction when taken with Vandetanib
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib (Compound) resembles Vandetanib (Compound) and Bosutinib may lead to a major life threatening interaction when taken with Vandetanib
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Ranitidine and Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib and Erlotinib (Compound) resembles Vandetanib (Compound)
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vandetanib (Compound) |
DB00861 | DB09418 | 914 | 554 | [
"DDInter551",
"DDInter1501"
] | Diflunisal | Potassium perchlorate | Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear to be associated with inhibition of prostaglandin synthesis via the arachidonic acid pathway. Diflunisal is used to relieve pain accompanied with inflammation and in the symptomatic treatment of rheumatoid arthritis and osteoarthritis. | Potassium perchlorate is an inorganic salt with the chemical formula KClO4. It is a strong oxidizer with the lowest solubility of the alkali metal perchlorates. Potassium is most commonly used in flares and automobile airbags . The use of potassium perchlorate as a component in sealing gaskets for food containers has been revoked by the FDA following the use being abandoned by the industry . Potassium perchlorate acts as a competitive inhibitor of iodine uptake by the thyroid gland and attenuates the production of the thyroid hormone. Thus the use of potassium perchlorate has been extensive for hyperthyroidism during the last 50 years, particularly in the late 1950s and early 1960s . The therapeutic use of potassium perchlorate in thyroid disorders has been ceased due to a high risk for developing aplastic anemia and nephrotic syndrome . | Moderate | 1 | [
[
[
914,
24,
554
]
],
[
[
914,
63,
176
],
[
176,
23,
554
]
],
[
[
914,
24,
1254
],
[
1254,
23,
554
]
],
[
[
914,
24,
1296
],
[
1296,
62,
554
]
],
[
[
914,
74,
1274
],
[
1274,
24,
554
]
],
[
[
914,
63,
1512
],
[
1512,
24,
554
]
],
[
[
914,
24,
848
],
[
848,
24,
554
]
],
[
[
914,
74,
1274
],
[
1274,
24,
935
],
[
935,
24,
554
]
],
[
[
914,
63,
1512
],
[
1512,
24,
935
],
[
935,
24,
554
]
],
[
[
914,
24,
948
],
[
948,
62,
176
],
[
176,
23,
554
]
]
] | [
[
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Potassium perchlorate"
]
],
[
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Potassium perchlorate"
]
],
[
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
],
[
"Insulin glulisine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Potassium perchlorate"
]
],
[
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Potassium perchlorate"
]
],
[
[
"Diflunisal",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Potassium perchlorate"
]
],
[
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Potassium perchlorate"
]
],
[
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Potassium perchlorate"
]
],
[
[
"Diflunisal",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoprofen"
],
[
"Ketoprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Potassium perchlorate"
]
],
[
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoprofen"
],
[
"Ketoprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Potassium perchlorate"
]
],
[
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Potassium gluconate"
],
[
"Potassium gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Potassium perchlorate"
]
]
] | Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a minor interaction that can limit clinical effects when taken with Potassium perchlorate
Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a minor interaction that can limit clinical effects when taken with Potassium perchlorate
Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a minor interaction that can limit clinical effects when taken with Potassium perchlorate
Diflunisal (Compound) resembles Flurbiprofen (Compound) and Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Potassium perchlorate
Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Potassium perchlorate
Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Potassium perchlorate
Diflunisal (Compound) resembles Flurbiprofen (Compound) and Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Potassium perchlorate
Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Potassium perchlorate
Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Potassium gluconate and Potassium gluconate may cause a minor interaction that can limit clinical effects when taken with Insulin glargine and Insulin glargine may cause a minor interaction that can limit clinical effects when taken with Potassium perchlorate |
DB01181 | DB12010 | 1,532 | 214 | [
"DDInter906",
"DDInter785"
] | Ifosfamide | Fostamatinib | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase.[A235008, A235013, A235018] | Moderate | 1 | [
[
[
1532,
24,
214
]
],
[
[
1532,
25,
976
],
[
976,
24,
214
]
],
[
[
1532,
63,
723
],
[
723,
24,
214
]
],
[
[
1532,
24,
879
],
[
879,
24,
214
]
],
[
[
1532,
62,
307
],
[
307,
24,
214
]
],
[
[
1532,
25,
676
],
[
676,
63,
214
]
],
[
[
1532,
24,
1017
],
[
1017,
63,
214
]
],
[
[
1532,
74,
450
],
[
450,
24,
214
]
],
[
[
1532,
23,
255
],
[
255,
24,
214
]
],
[
[
1532,
25,
1292
],
[
1292,
25,
214
]
]
] | [
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Ifosfamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
],
[
"Lumateperone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Ifosfamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Ifosfamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Ifosfamide",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Ifosfamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Delafloxacin"
],
[
"Delafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Ifosfamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
],
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
]
]
] | Ifosfamide may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone and Lumateperone may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Ifosfamide may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Ifosfamide may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Ifosfamide (Compound) resembles Cyclophosphamide (Compound) and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Ifosfamide may cause a minor interaction that can limit clinical effects when taken with Delafloxacin and Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Ifosfamide may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone may lead to a major life threatening interaction when taken with Fostamatinib |
DB05812 | DB09039 | 1,374 | 1,670 | [
"DDInter8",
"DDInter629"
] | Abiraterone | Eliglustat | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resistant prostate cancer and hormone-sensitive high-risk metastatic prostate cancer.[L40968, L40193, L47740, L47745] As abiraterone has poor oral bioavailability and is susceptible to hydrolysis by esterases, abiraterone acetate was developed as an orally bioavailable prodrug with enhanced stability and absorption.[A3811, A260835] | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher disease, the accumulation of glucosylceramide leads to the formation of Gaucher cells that infiltrate the liver, spleen, bone marrow and other organs. This leads to complications such as anemia and thrombocytopenia.[L41404,A246384] By inhibiting glucosylceramide synthase, eliglustat reduces the accumulation of glucosylceramide. Eliglustat is mainly metabolized by CYP2D6. Patients selected for eliglustat treatment undergo an FDA-cleared genotyping test to establish if they are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs). The results of this test dictate eliglustat dosing recommendations for each type of patient. There are no dosing recommendations for CYP2D6 ultra-rapid or indeterminate metabolizers.[L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease.[L41404,A7634] Enzyme replacement continues to be the standard of care for the treatment of type 1 Gaucher disease ([imiglucerase], [velaglucerase alfa], [taliglucerase alfa]); however, oral substrate reduction therapies with favourable safety profiles, such as eliglustat, represent a treatment alternative.[A246389,A7634] | Major | 2 | [
[
[
1374,
25,
1670
]
],
[
[
1374,
62,
479
],
[
479,
23,
1670
]
],
[
[
1374,
23,
1135
],
[
1135,
62,
1670
]
],
[
[
1374,
63,
121
],
[
121,
24,
1670
]
],
[
[
1374,
24,
1409
],
[
1409,
24,
1670
]
],
[
[
1374,
64,
839
],
[
839,
24,
1670
]
],
[
[
1374,
24,
119
],
[
119,
63,
1670
]
],
[
[
1374,
25,
868
],
[
868,
24,
1670
]
],
[
[
1374,
25,
982
],
[
982,
63,
1670
]
],
[
[
1374,
64,
762
],
[
762,
25,
1670
]
]
] | [
[
[
"Abiraterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
]
],
[
[
"Abiraterone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Eliglustat"
]
],
[
[
"Abiraterone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Eliglustat"
]
],
[
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
],
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
],
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Abiraterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Grepafloxacin"
],
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
],
[
"Talazoparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Abiraterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Abiraterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Abiraterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bepridil"
],
[
"Bepridil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
]
]
] | Abiraterone may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Abiraterone may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Abiraterone may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib and Talazoparib may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Abiraterone may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Abiraterone may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Abiraterone may lead to a major life threatening interaction when taken with Bepridil and Bepridil may lead to a major life threatening interaction when taken with Eliglustat |
DB00086 | DB06441 | 1,167 | 936 | [
"DDInter1712",
"DDInter283"
] | Streptokinase | Cangrelor | Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci. | Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset and offset of action. Cangrelor was approved by the FDA in June 2015 for intravenous application. | Major | 2 | [
[
[
1167,
25,
936
]
],
[
[
1167,
23,
1631
],
[
1631,
62,
936
]
],
[
[
1167,
24,
97
],
[
97,
24,
936
]
],
[
[
1167,
24,
643
],
[
643,
63,
936
]
],
[
[
1167,
63,
1595
],
[
1595,
24,
936
]
],
[
[
1167,
25,
1046
],
[
1046,
25,
936
]
],
[
[
1167,
64,
366
],
[
366,
25,
936
]
],
[
[
1167,
24,
1347
],
[
1347,
25,
936
]
],
[
[
1167,
25,
1618
],
[
1618,
64,
936
]
],
[
[
1167,
23,
1631
],
[
1631,
62,
1271
],
[
1271,
25,
936
]
]
] | [
[
[
"Streptokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cangrelor"
]
],
[
[
"Streptokinase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
],
[
"Turmeric",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cangrelor"
]
],
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaprozin"
],
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cangrelor"
]
],
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
],
[
"Desvenlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cangrelor"
]
],
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Collagenase clostridium histolyticum"
],
[
"Collagenase clostridium histolyticum",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cangrelor"
]
],
[
[
"Streptokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Caplacizumab"
],
[
"Caplacizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cangrelor"
]
],
[
[
"Streptokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eptifibatide"
],
[
"Eptifibatide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cangrelor"
]
],
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cangrelor"
]
],
[
[
"Streptokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cangrelor"
]
],
[
[
"Streptokinase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
],
[
"Turmeric",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Alteplase"
],
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cangrelor"
]
]
] | Streptokinase may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Cangrelor
Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin and Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Cangrelor
Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Cangrelor
Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Collagenase clostridium histolyticum and Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Cangrelor
Streptokinase may lead to a major life threatening interaction when taken with Caplacizumab and Caplacizumab may lead to a major life threatening interaction when taken with Cangrelor
Streptokinase may lead to a major life threatening interaction when taken with Eptifibatide and Eptifibatide may lead to a major life threatening interaction when taken with Cangrelor
Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may lead to a major life threatening interaction when taken with Cangrelor
Streptokinase may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may lead to a major life threatening interaction when taken with Cangrelor
Streptokinase may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Alteplase and Alteplase may lead to a major life threatening interaction when taken with Cangrelor |
DB01110 | DB01224 | 86 | 623 | [
"DDInter1209",
"DDInter1553"
] | Miconazole | Quetiapine | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-based products are available.[L14021, L14024, L14027, L14033, L14396] Miconazole is thought to act primarily through the inhibition of fungal CYP450 14α-lanosterol demethylase activity.[A203636, A203639] Miconazole was first synthesized in 1969 and first granted FDA approval on January 8, 1974, for sale by INSIGHT Pharmaceuticals as a topical cream.[A214523, L14021] It is currently available as a variety of prescription and over the counter products. Despite having been in clinical use for an extended period, resistance to m | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as [clozapine] and [olanzapine]. | Moderate | 1 | [
[
[
86,
24,
623
]
],
[
[
86,
63,
827
],
[
827,
1,
623
]
],
[
[
86,
24,
851
],
[
851,
1,
623
]
],
[
[
86,
6,
12523
],
[
12523,
45,
623
]
],
[
[
86,
21,
28803
],
[
28803,
60,
623
]
],
[
[
86,
24,
484
],
[
484,
63,
623
]
],
[
[
86,
64,
1181
],
[
1181,
24,
623
]
],
[
[
86,
25,
1411
],
[
1411,
24,
623
]
],
[
[
86,
24,
477
],
[
477,
24,
623
]
],
[
[
86,
63,
723
],
[
723,
24,
623
]
]
] | [
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trazodone"
],
[
"Trazodone",
"{u} (Compound) resembles {v} (Compound)",
"Quetiapine"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
],
[
"Nefazodone",
"{u} (Compound) resembles {v} (Compound)",
"Quetiapine"
]
],
[
[
"Miconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Quetiapine"
]
],
[
[
"Miconazole",
"{u} (Compound) causes {v} (Side Effect)",
"Anaemia"
],
[
"Anaemia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Quetiapine"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Miconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Terfenadine"
],
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Miconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
]
] | Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Trazodone and Trazodone (Compound) resembles Quetiapine (Compound)
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone and Nefazodone (Compound) resembles Quetiapine (Compound)
Miconazole (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Quetiapine (Compound)
Miconazole (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Quetiapine (Compound)
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine
Miconazole may lead to a major life threatening interaction when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine
Miconazole may lead to a major life threatening interaction when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine |
DB05239 | DB12015 | 866 | 1,033 | [
"DDInter425",
"DDInter53"
] | Cobimetinib | Alpelisib | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma. | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolism. Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation. There are several isoform-specific PI3K inhibitors that are under clinical development or currently approved, such as [idelalisib] used for chronic lymphocytic leukemia (CLL). Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer in combination with [fulvestrant] for postmenopausal women and male patients. To initiate alpelisib therapy, it is required that the presence of a PIK3CA mutation in the tissue and/or liquid biopsy sample collection should be confirmed via FDA-approved diagnostic tests. Alpelisib is marketed under the trade name Piqray and is available as oral tablets. Studies evaluating the therapeutic effectiveness of alpelisib in other cancers, such as ovarian cancer and colorectal cancer , are under ongoing investigations. Alpelisib was granted FDA approval on 24 May 2019. In April 2022, the FDA granted the use of alpelisib in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS) in adults and children who require systemic therapy. | Moderate | 1 | [
[
[
866,
24,
1033
]
],
[
[
866,
24,
738
],
[
738,
24,
1033
]
],
[
[
866,
25,
1510
],
[
1510,
24,
1033
]
],
[
[
866,
63,
322
],
[
322,
24,
1033
]
],
[
[
866,
64,
859
],
[
859,
24,
1033
]
],
[
[
866,
24,
982
],
[
982,
63,
1033
]
],
[
[
866,
25,
179
],
[
179,
63,
1033
]
],
[
[
866,
64,
697
],
[
697,
25,
1033
]
],
[
[
866,
25,
1604
],
[
1604,
25,
1033
]
],
[
[
866,
24,
738
],
[
738,
64,
1510
],
[
1510,
24,
1033
]
]
] | [
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Posaconazole"
],
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telotristat ethyl"
],
[
"Telotristat ethyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alpelisib"
]
],
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
],
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alpelisib"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
]
] | Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Cobimetinib may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Cobimetinib may lead to a major life threatening interaction when taken with Posaconazole and Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Cobimetinib may lead to a major life threatening interaction when taken with Telotristat ethyl and Telotristat ethyl may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Cobimetinib may lead to a major life threatening interaction when taken with Phenobarbital and Phenobarbital may lead to a major life threatening interaction when taken with Alpelisib
Cobimetinib may lead to a major life threatening interaction when taken with Lumacaftor and Lumacaftor may lead to a major life threatening interaction when taken with Alpelisib
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib |
DB00321 | DB00738 | 21 | 485 | [
"DDInter78",
"DDInter1420"
] | Amitriptyline | Pentamidine | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Moderate | 1 | [
[
[
21,
24,
485
]
],
[
[
21,
6,
12523
],
[
12523,
45,
485
]
],
[
[
21,
18,
9385
],
[
9385,
57,
485
]
],
[
[
21,
7,
9650
],
[
9650,
57,
485
]
],
[
[
21,
21,
28817
],
[
28817,
60,
485
]
],
[
[
21,
23,
112
],
[
112,
62,
485
]
],
[
[
21,
24,
971
],
[
971,
63,
485
]
],
[
[
21,
24,
322
],
[
322,
24,
485
]
],
[
[
21,
35,
1264
],
[
1264,
63,
485
]
],
[
[
21,
25,
1494
],
[
1494,
24,
485
]
]
] | [
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
]
],
[
[
"Amitriptyline",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Pentamidine"
]
],
[
[
"Amitriptyline",
"{u} (Compound) downregulates {v} (Gene)",
"MRPL19"
],
[
"MRPL19",
"{u} (Gene) is downregulated by {v} (Compound)",
"Pentamidine"
]
],
[
[
"Amitriptyline",
"{u} (Compound) upregulates {v} (Gene)",
"HMGCS1"
],
[
"HMGCS1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Pentamidine"
]
],
[
[
"Amitriptyline",
"{u} (Compound) causes {v} (Side Effect)",
"Vision blurred"
],
[
"Vision blurred",
"{u} (Side Effect) is caused by {v} (Compound)",
"Pentamidine"
]
],
[
[
"Amitriptyline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pentamidine"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
]
],
[
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
]
],
[
[
"Amitriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palonosetron"
],
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
]
]
] | Amitriptyline (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pentamidine (Compound)
Amitriptyline (Compound) downregulates MRPL19 (Gene) and MRPL19 (Gene) is downregulated by Pentamidine (Compound)
Amitriptyline (Compound) upregulates HMGCS1 (Gene) and HMGCS1 (Gene) is downregulated by Pentamidine (Compound)
Amitriptyline (Compound) causes Vision blurred (Side Effect) and Vision blurred (Side Effect) is caused by Pentamidine (Compound)
Amitriptyline may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pentamidine
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine
Amitriptyline (Compound) resembles Doxepin (Compound) and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine
Amitriptyline may lead to a major life threatening interaction when taken with Palonosetron and Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine |
DB00393 | DB11130 | 854 | 407 | [
"DDInter1295",
"DDInter1344"
] | Nimodipine | Opium | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Compared to other calcium channel blocking agents, nimodipine exhibits greater effects on cerebral circulation than on peripheral circulation. Nimodipine is used to as an adjunct to improve the neurologic outcome following subarachnoid hemorrhage from ruptured intracranial aneurysm. | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papaver somniferum_, which is more known as poppies. This plant is an integrant of the Papaveraceae family, and it is characterized by solitary leaves and capsulated fruits. Therefore, opium is a sticky brown resin obtained by collecting and drying the latex that exudes from the poppy pods. Once extracted, opium contains two main groups of alkaloids; the psychoactive constituents which are in the category of phenanthrenes and alkaloids that have no central nervous system effect in the category of isoquinolines. Morphine is the most prevalent and principal alkaloid in opium, and it is responsible for most of the harmful effects of opium. Opium has gradually been superseded by a variety of synthetic opioids and general anesthetics. Some of the isolated derivatives of opium are morphine, noscapine, strychnine, veratrine, colchicine, codeine, and quinine. Opium is a prohibited drug of abuse in most countries, but the illegal production of this drug and its derivatives keeps being registered. There is some legal production of opium in different countries for the obtention of alkaloids by extraction. | Moderate | 1 | [
[
[
854,
24,
407
]
],
[
[
854,
1,
409
],
[
409,
24,
407
]
],
[
[
854,
24,
104
],
[
104,
24,
407
]
],
[
[
854,
63,
475
],
[
475,
24,
407
]
],
[
[
854,
23,
578
],
[
578,
24,
407
]
],
[
[
854,
24,
1053
],
[
1053,
25,
407
]
],
[
[
854,
1,
409
],
[
409,
63,
104
],
[
104,
24,
407
]
],
[
[
854,
24,
104
],
[
104,
24,
409
],
[
409,
24,
407
]
],
[
[
854,
24,
849
],
[
849,
63,
409
],
[
409,
24,
407
]
],
[
[
854,
63,
475
],
[
475,
24,
409
],
[
409,
24,
407
]
]
] | [
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Nimodipine",
"{u} (Compound) resembles {v} (Compound)",
"Felodipine"
],
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Nimodipine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Opium"
]
],
[
[
"Nimodipine",
"{u} (Compound) resembles {v} (Compound)",
"Felodipine"
],
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Felodipine"
],
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Felodipine"
],
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Felodipine"
],
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
]
] | Nimodipine (Compound) resembles Felodipine (Compound) and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Nimodipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Opium
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Opium
Nimodipine (Compound) resembles Felodipine (Compound) and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Felodipine and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Felodipine and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Felodipine and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Opium |
DB00014 | DB00285 | 521 | 1,100 | [
"DDInter839",
"DDInter1927"
] | Goserelin | Venlafaxine | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal. | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder in adults. The immediate formulation of the drug, marketed as Effexor, was first approved by the FDA in 1993 and the extended-release formulation, Effexor XR, was later introduced in 1997. Venlafaxine has been used as a first-line treatment for MDD, GAD, social anxiety disorder, and panic disorder in Canada for many years. It was also considered a second-line treatment for obsessive-compulsive disorder (OCD).[A177226,A177235] Venlafaxine was also investigated in off-label uses for the prophylaxis of migraine headaches,[A413,A177229] for reduction of vasomotor symptoms associated with menopause, and for the management of neuropathic pain (although there is only minimal evidence of efficacy for this condition). | Moderate | 1 | [
[
[
521,
24,
1100
]
],
[
[
521,
24,
534
],
[
534,
1,
1100
]
],
[
[
521,
21,
29013
],
[
29013,
60,
1100
]
],
[
[
521,
23,
112
],
[
112,
62,
1100
]
],
[
[
521,
24,
1228
],
[
1228,
63,
1100
]
],
[
[
521,
25,
351
],
[
351,
63,
1100
]
],
[
[
521,
1,
774
],
[
774,
63,
1100
]
],
[
[
521,
24,
1324
],
[
1324,
24,
1100
]
],
[
[
521,
25,
1166
],
[
1166,
64,
1100
]
],
[
[
521,
25,
702
],
[
702,
25,
1100
]
]
] | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tramadol"
],
[
"Tramadol",
"{u} (Compound) resembles {v} (Compound)",
"Venlafaxine"
]
],
[
[
"Goserelin",
"{u} (Compound) causes {v} (Side Effect)",
"Diabetes mellitus"
],
[
"Diabetes mellitus",
"{u} (Side Effect) is caused by {v} (Compound)",
"Venlafaxine"
]
],
[
[
"Goserelin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Venlafaxine"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
],
[
"Lenvatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
]
],
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
]
],
[
[
"Goserelin",
"{u} (Compound) resembles {v} (Compound)",
"Degarelix"
],
[
"Degarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
]
],
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venlafaxine"
]
],
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venlafaxine"
]
]
] | Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Tramadol and Tramadol (Compound) resembles Venlafaxine (Compound)
Goserelin (Compound) causes Diabetes mellitus (Side Effect) and Diabetes mellitus (Side Effect) is caused by Venlafaxine (Compound)
Goserelin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Venlafaxine
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib and Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine
Goserelin may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine
Goserelin (Compound) resembles Degarelix (Compound) and Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine
Goserelin may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may lead to a major life threatening interaction when taken with Venlafaxine
Goserelin may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Venlafaxine |
DB00283 | DB14509 | 701 | 1,399 | [
"DDInter395",
"DDInter1081"
] | Clemastine | Lithium carbonate | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
701,
24,
1399
]
],
[
[
701,
24,
506
],
[
506,
24,
1399
]
],
[
[
701,
35,
1242
],
[
1242,
24,
1399
]
],
[
[
701,
24,
222
],
[
222,
25,
1399
]
],
[
[
701,
24,
506
],
[
506,
24,
1374
],
[
1374,
24,
1399
]
],
[
[
701,
24,
820
],
[
820,
63,
874
],
[
874,
23,
1399
]
],
[
[
701,
24,
717
],
[
717,
63,
506
],
[
506,
24,
1399
]
],
[
[
701,
35,
1242
],
[
1242,
24,
820
],
[
820,
24,
1399
]
],
[
[
701,
24,
1264
],
[
1264,
64,
874
],
[
874,
23,
1399
]
],
[
[
701,
24,
543
],
[
543,
25,
1374
],
[
1374,
24,
1399
]
]
] | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Clemastine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
],
[
"Epinephrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
],
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Clemastine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epinephrine"
],
[
"Epinephrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
]
] | Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Clemastine (Compound) resembles Cetirizine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may lead to a major life threatening interaction when taken with Lithium carbonate
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide and Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Clemastine (Compound) resembles Cetirizine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may lead to a major life threatening interaction when taken with Epinephrine and Epinephrine may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may lead to a major life threatening interaction when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate |
DB00461 | DB00704 | 598 | 267 | [
"DDInter1254",
"DDInter1263"
] | Nabumetone | Naltrexone | Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a degree of cyclooxygenase-2 selectivity (COX-2), nabumetone still produces significant adverse effects in the GI tract.[label,A178903] The molecule itself is a pro-drug with its 6-methoxy-2-naphthylacetic acid (6-MNA) metabolite acting as a potent COX inhibitor similar in structure to [naproxen]. Nabumetone was developed by Smithkline Beecham under the trade name Relafen and first received FDA approval in December, 1991. | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Moderate | 1 | [
[
[
598,
24,
267
]
],
[
[
598,
21,
28695
],
[
28695,
60,
267
]
],
[
[
598,
24,
850
],
[
850,
63,
267
]
],
[
[
598,
25,
1468
],
[
1468,
63,
267
]
],
[
[
598,
24,
1512
],
[
1512,
24,
267
]
],
[
[
598,
63,
912
],
[
912,
24,
267
]
],
[
[
598,
25,
663
],
[
663,
24,
267
]
],
[
[
598,
25,
1510
],
[
1510,
64,
267
]
],
[
[
598,
21,
28695
],
[
28695,
60,
828
],
[
828,
25,
267
]
],
[
[
598,
21,
29285
],
[
29285,
60,
522
],
[
522,
24,
267
]
]
] | [
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Nabumetone",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspnoea"
],
[
"Dyspnoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Naltrexone"
]
],
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Nabumetone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Nabumetone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Nabumetone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naltrexone"
]
],
[
[
"Nabumetone",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspnoea"
],
[
"Dyspnoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Oxycodone"
],
[
"Oxycodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naltrexone"
]
],
[
[
"Nabumetone",
"{u} (Compound) causes {v} (Side Effect)",
"Eosinophilic pneumonia"
],
[
"Eosinophilic pneumonia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Zafirlukast"
],
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
]
] | Nabumetone (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Naltrexone (Compound)
Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone
Nabumetone may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone
Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone
Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone
Nabumetone may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone
Nabumetone may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Naltrexone
Nabumetone (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Oxycodone (Compound) and Oxycodone may lead to a major life threatening interaction when taken with Naltrexone
Nabumetone (Compound) causes Eosinophilic pneumonia (Side Effect) and Eosinophilic pneumonia (Side Effect) is caused by Zafirlukast (Compound) and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone |
DB00146 | DB00312 | 160 | 1,023 | [
"DDInter265",
"DDInter1423"
] | Calcifediol | Pentobarbital | The major circulating metabolite of vitamin D3 (cholecalciferol). It is produced in the liver and is the best indicator of the body's vitamin D stores. It is effective in the treatment of rickets and osteomalacia, both in azotemic and non-azotemic patients. Calcifediol also has mineralizing properties. | A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236) | Moderate | 1 | [
[
[
160,
24,
1023
]
],
[
[
160,
24,
288
],
[
288,
40,
1023
]
],
[
[
160,
25,
1196
],
[
1196,
63,
1023
]
],
[
[
160,
36,
386
],
[
386,
24,
1023
]
],
[
[
160,
25,
1331
],
[
1331,
24,
1023
]
],
[
[
160,
24,
288
],
[
288,
40,
11265
],
[
11265,
40,
1023
]
],
[
[
160,
24,
536
],
[
536,
1,
682
],
[
682,
40,
1023
]
],
[
[
160,
25,
1196
],
[
1196,
63,
288
],
[
288,
40,
1023
]
],
[
[
160,
36,
386
],
[
386,
24,
288
],
[
288,
40,
1023
]
],
[
[
160,
25,
1331
],
[
1331,
24,
288
],
[
288,
40,
1023
]
]
] | [
[
[
"Calcifediol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentobarbital"
]
],
[
[
"Calcifediol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Butalbital"
],
[
"Butalbital",
"{u} (Compound) resembles {v} (Compound)",
"Pentobarbital"
]
],
[
[
"Calcifediol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxercalciferol"
],
[
"Doxercalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentobarbital"
]
],
[
[
"Calcifediol",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Cholecalciferol"
],
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentobarbital"
]
],
[
[
"Calcifediol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ergocalciferol"
],
[
"Ergocalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentobarbital"
]
],
[
[
"Calcifediol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Butalbital"
],
[
"Butalbital",
"{u} (Compound) resembles {v} (Compound)",
"Thiamylal"
],
[
"Thiamylal",
"{u} (Compound) resembles {v} (Compound)",
"Pentobarbital"
]
],
[
[
"Calcifediol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secobarbital"
],
[
"Secobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Thiopental"
],
[
"Thiopental",
"{u} (Compound) resembles {v} (Compound)",
"Pentobarbital"
]
],
[
[
"Calcifediol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxercalciferol"
],
[
"Doxercalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Butalbital"
],
[
"Butalbital",
"{u} (Compound) resembles {v} (Compound)",
"Pentobarbital"
]
],
[
[
"Calcifediol",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Cholecalciferol"
],
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Butalbital"
],
[
"Butalbital",
"{u} (Compound) resembles {v} (Compound)",
"Pentobarbital"
]
],
[
[
"Calcifediol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ergocalciferol"
],
[
"Ergocalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Butalbital"
],
[
"Butalbital",
"{u} (Compound) resembles {v} (Compound)",
"Pentobarbital"
]
]
] | Calcifediol may cause a moderate interaction that could exacerbate diseases when taken with Butalbital and Butalbital (Compound) resembles Pentobarbital (Compound)
Calcifediol may lead to a major life threatening interaction when taken with Doxercalciferol and Doxercalciferol may cause a moderate interaction that could exacerbate diseases when taken with Pentobarbital
Calcifediol (Compound) resembles Cholecalciferol (Compound) and Calcifediol may lead to a major life threatening interaction when taken with Cholecalciferol and Cholecalciferol may cause a moderate interaction that could exacerbate diseases when taken with Pentobarbital
Calcifediol may lead to a major life threatening interaction when taken with Ergocalciferol and Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Pentobarbital
Calcifediol may cause a moderate interaction that could exacerbate diseases when taken with Butalbital and Butalbital (Compound) resembles Thiamylal (Compound) and Thiamylal (Compound) resembles Pentobarbital (Compound)
Calcifediol may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbital (Compound) resembles Thiopental (Compound) and Thiopental (Compound) resembles Pentobarbital (Compound)
Calcifediol may lead to a major life threatening interaction when taken with Doxercalciferol and Doxercalciferol may cause a moderate interaction that could exacerbate diseases when taken with Butalbital and Butalbital (Compound) resembles Pentobarbital (Compound)
Calcifediol (Compound) resembles Cholecalciferol (Compound) and Calcifediol may lead to a major life threatening interaction when taken with Cholecalciferol and Cholecalciferol may cause a moderate interaction that could exacerbate diseases when taken with Butalbital and Butalbital (Compound) resembles Pentobarbital (Compound)
Calcifediol may lead to a major life threatening interaction when taken with Ergocalciferol and Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Butalbital and Butalbital (Compound) resembles Pentobarbital (Compound) |
DB00631 | DB01263 | 372 | 859 | [
"DDInter405",
"DDInter1494"
] | Clofarabine | Posaconazole | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed. It is not known if the drug extends life expectancy. Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated. | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Moderate | 1 | [
[
[
372,
24,
859
]
],
[
[
372,
21,
28762
],
[
28762,
60,
859
]
],
[
[
372,
63,
1101
],
[
1101,
23,
859
]
],
[
[
372,
63,
482
],
[
482,
24,
859
]
],
[
[
372,
24,
850
],
[
850,
63,
859
]
],
[
[
372,
24,
267
],
[
267,
24,
859
]
],
[
[
372,
25,
770
],
[
770,
24,
859
]
],
[
[
372,
24,
39
],
[
39,
64,
859
]
],
[
[
372,
25,
676
],
[
676,
64,
859
]
],
[
[
372,
25,
1377
],
[
1377,
25,
859
]
]
] | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Clofarabine",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Posaconazole"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Posaconazole"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Clofarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Posaconazole"
]
],
[
[
"Clofarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Posaconazole"
]
],
[
[
"Clofarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Posaconazole"
]
]
] | Clofarabine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Posaconazole (Compound)
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Posaconazole
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole
Clofarabine may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Posaconazole
Clofarabine may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Posaconazole
Clofarabine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Posaconazole |
DB00358 | DB00675 | 1,010 | 888 | [
"DDInter1140",
"DDInter1744"
] | Mefloquine | Tamoxifen | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortality; 90% of deaths from malaria occur in Africa. Individuals at the highest risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling to their place of origin. Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum. The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 196 | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole]. Tamoxifen was granted FDA approval on 30 December 1977. | Moderate | 1 | [
[
[
1010,
24,
888
]
],
[
[
1010,
24,
675
],
[
675,
25,
888
]
],
[
[
1010,
24,
543
],
[
543,
63,
888
]
],
[
[
1010,
6,
4973
],
[
4973,
45,
888
]
],
[
[
1010,
7,
7669
],
[
7669,
46,
888
]
],
[
[
1010,
18,
7623
],
[
7623,
57,
888
]
],
[
[
1010,
21,
28701
],
[
28701,
60,
888
]
],
[
[
1010,
23,
112
],
[
112,
62,
888
]
],
[
[
1010,
63,
1100
],
[
1100,
24,
888
]
],
[
[
1010,
24,
1251
],
[
1251,
24,
888
]
]
] | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tamoxifen"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
]
],
[
[
"Mefloquine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Mefloquine",
"{u} (Compound) upregulates {v} (Gene)",
"DDIT4"
],
[
"DDIT4",
"{u} (Gene) is upregulated by {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Mefloquine",
"{u} (Compound) downregulates {v} (Gene)",
"RRP12"
],
[
"RRP12",
"{u} (Gene) is downregulated by {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Mefloquine",
"{u} (Compound) causes {v} (Side Effect)",
"Discomfort"
],
[
"Discomfort",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Mefloquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tamoxifen"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
]
]
] | Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene may lead to a major life threatening interaction when taken with Tamoxifen
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen
Mefloquine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Tamoxifen (Compound)
Mefloquine (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Tamoxifen (Compound)
Mefloquine (Compound) downregulates RRP12 (Gene) and RRP12 (Gene) is downregulated by Tamoxifen (Compound)
Mefloquine (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Tamoxifen (Compound)
Mefloquine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Tamoxifen
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Mirtazapine and Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen |
DB00277 | DB09268 | 1,031 | 1,662 | [
"DDInter1791",
"DDInter1464"
] | Theophylline | Picosulfuric acid | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under several brand names such as Uniphyl and Theochron, and it is indicated mainly for asthma, bronchospasm, and COPD. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been used in European countries for many years. | Moderate | 1 | [
[
[
1031,
24,
1662
]
],
[
[
1031,
24,
1619
],
[
1619,
63,
1662
]
],
[
[
1031,
63,
342
],
[
342,
24,
1662
]
],
[
[
1031,
24,
708
],
[
708,
24,
1662
]
],
[
[
1031,
64,
534
],
[
534,
24,
1662
]
],
[
[
1031,
25,
143
],
[
143,
24,
1662
]
],
[
[
1031,
23,
898
],
[
898,
24,
1662
]
],
[
[
1031,
25,
17
],
[
17,
25,
1662
]
],
[
[
1031,
24,
33
],
[
33,
25,
1662
]
],
[
[
1031,
24,
1619
],
[
1619,
63,
1164
],
[
1164,
24,
1662
]
]
] | [
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon gamma-1b"
],
[
"Interferon gamma-1b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
],
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Theophylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tramadol"
],
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Theophylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mexiletine"
],
[
"Mexiletine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Propofol"
],
[
"Propofol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Theophylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
],
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
]
] | Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Interferon gamma-1b and Interferon gamma-1b may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Theophylline may lead to a major life threatening interaction when taken with Tramadol and Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Theophylline may lead to a major life threatening interaction when taken with Mexiletine and Mexiletine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Theophylline may cause a minor interaction that can limit clinical effects when taken with Propofol and Propofol may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Theophylline may lead to a major life threatening interaction when taken with Sotalol and Sotalol may lead to a major life threatening interaction when taken with Picosulfuric acid
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone may lead to a major life threatening interaction when taken with Picosulfuric acid
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid |
DB01042 | DB08904 | 1,307 | 375 | [
"DDInter1144",
"DDInter342"
] | Melphalan | Certolizumab pegol | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases. | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_. It was developed and manufactured by UCB Pharma, first FDA approved in 2008 and updated for a new indication on March 28, 2019. | Major | 2 | [
[
[
1307,
25,
375
]
],
[
[
1307,
63,
1461
],
[
1461,
23,
375
]
],
[
[
1307,
23,
1193
],
[
1193,
62,
375
]
],
[
[
1307,
24,
200
],
[
200,
63,
375
]
],
[
[
1307,
63,
66
],
[
66,
24,
375
]
],
[
[
1307,
24,
1430
],
[
1430,
24,
375
]
],
[
[
1307,
40,
1191
],
[
1191,
24,
375
]
],
[
[
1307,
64,
1066
],
[
1066,
25,
375
]
],
[
[
1307,
63,
552
],
[
552,
25,
375
]
],
[
[
1307,
24,
1330
],
[
1330,
64,
375
]
]
] | [
[
[
"Melphalan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Melphalan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Melphalan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Melphalan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
],
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Melphalan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Melphalan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Melphalan",
"{u} (Compound) resembles {v} (Compound)",
"Levodopa"
],
[
"Levodopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Melphalan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Melphalan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"
],
[
"Carmustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Melphalan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
],
[
"Naxitamab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
]
] | Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Melphalan may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Melphalan (Compound) resembles Levodopa (Compound) and Levodopa may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Melphalan may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Certolizumab pegol
Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may lead to a major life threatening interaction when taken with Certolizumab pegol
Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab and Naxitamab may lead to a major life threatening interaction when taken with Certolizumab pegol |
DB00305 | DB11601 | 377 | 1,270 | [
"DDInter1232",
"DDInter1889"
] | Mitomycin | Tuberculin purified protein derivative | Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix. Few other antibiotics have been discovered that work via this alkylating mechanism, making mitomycin relatively unique in the space of microbiota-derived therapies. Mitomycin's cross-linking activity has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper Tract Urothelial Cancer (LG-UTUC) - as well as adjunctly to _ab externo_ glaucoma surgeries. | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycobacterium tuberculosis* through early diagnosis and appropriate therapeutic intervention. The purified protein fraction is isolated from culture media filtrates of a human strain of Mycobacterium tuberculosis. It is included in the World Health Organization's List of Essential Medicines. | Moderate | 1 | [
[
[
377,
24,
1270
]
],
[
[
377,
24,
1531
],
[
1531,
24,
1270
]
],
[
[
377,
64,
1064
],
[
1064,
24,
1270
]
],
[
[
377,
63,
329
],
[
329,
24,
1270
]
],
[
[
377,
25,
1259
],
[
1259,
63,
1270
]
],
[
[
377,
25,
976
],
[
976,
24,
1270
]
],
[
[
377,
24,
738
],
[
738,
63,
1270
]
],
[
[
377,
24,
1531
],
[
1531,
24,
350
],
[
350,
24,
1270
]
],
[
[
377,
64,
1064
],
[
1064,
25,
350
],
[
350,
24,
1270
]
],
[
[
377,
63,
329
],
[
329,
24,
1531
],
[
1531,
24,
1270
]
]
] | [
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Mitomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bleomycin"
],
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Mitomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Mitomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Mitomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bleomycin"
],
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
]
] | Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Mitomycin may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Bleomycin and Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Mitomycin may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Mitomycin may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Mitomycin may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Bleomycin and Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative |
DB01058 | DB06414 | 978 | 655 | [
"DDInter1510",
"DDInter703"
] | Praziquantel | Etravirine | Praziquantel is a pyrazino-isoquinolein derivative from the thioxantonic group used as a broad anthelmintic spectrum. Specifically, it is known as a treatment of trematodes and cestodes infections such as schistosomiasis, taeniasis, and cysticercosis. The efficacy of praziquantel in treating parasitic flatworms infection with low cost (~US$0.20 drug cost to treat a child) makes it an integral to WHO's plan to eliminate schistosomiasis by 2030.[A263206,A263211] Despite being approved since 1980, the exact mechanism of action is yet to be elucidated. | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 100mg tablets in the treatment of adult HIV-1 infection documented to be resistant to therapy with other NNRTIs and antiretroviral agents. On March 26, 2012, approval was extended for use in treatment-experienced pediatric patients 6 to 18 years of age, weighing at least 16 kg. Etravarine must always be used in combination with other antiretroviral drugs. Etravirine exerts its effects via direct inhibition of the reverse transcriptase enzyme of human immunodeficiency virus type 1 (HIV-1), and consequently blocks DNA-dependent and RNA-dependent polymerase activity. Etravirine does not inhibit human DNA polymerase alpha, beta or gamma. Common side effects of use include mild to moderate rash within the first 6 weeks of therapy, nausea, diarrhea and peripheral neuropathy. Patients are advised to immediately contact their healthcare provider if a rash develops. In 2009, postmarketing case reports of Stevens-Johnson Syndrome, toxic epidermal necrolysis, erythema multiforme, and other hypersensitivity reactions lead to a revision of etravirine's "Warnings and Precautions," as well as notification of health care providers. In 2013, reports of Autoimmune disorders (such as Graves’ disease, polymyositis, and Guillain-Barré syndrome) in the setting of immune reconstitution, as well as more in depth information about the development of rashes in patients taking etravirine, lead to a modification of etravirine's monograph. | Moderate | 1 | [
[
[
978,
24,
655
]
],
[
[
978,
6,
10215
],
[
10215,
45,
655
]
],
[
[
978,
21,
28883
],
[
28883,
60,
655
]
],
[
[
978,
63,
1101
],
[
1101,
23,
655
]
],
[
[
978,
63,
1051
],
[
1051,
24,
655
]
],
[
[
978,
24,
868
],
[
868,
63,
655
]
],
[
[
978,
24,
1220
],
[
1220,
24,
655
]
],
[
[
978,
62,
752
],
[
752,
24,
655
]
],
[
[
978,
24,
1476
],
[
1476,
64,
655
]
],
[
[
978,
25,
129
],
[
129,
64,
655
]
]
] | [
[
[
"Praziquantel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Praziquantel",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Etravirine"
]
],
[
[
"Praziquantel",
"{u} (Compound) causes {v} (Side Effect)",
"Skin disorder"
],
[
"Skin disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Etravirine"
]
],
[
[
"Praziquantel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Etravirine"
]
],
[
[
"Praziquantel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
],
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Praziquantel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Praziquantel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Praziquantel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Praziquantel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etravirine"
]
],
[
[
"Praziquantel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etravirine"
]
]
] | Praziquantel (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Etravirine (Compound)
Praziquantel (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Etravirine (Compound)
Praziquantel may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Etravirine
Praziquantel may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Praziquantel may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Praziquantel may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Praziquantel may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Praziquantel may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may lead to a major life threatening interaction when taken with Etravirine
Praziquantel may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Etravirine |
DB01017 | DB01603 | 1,669 | 1,366 | [
"DDInter1224",
"DDInter1195"
] | Minocycline | Meticillin | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines. Minocycline was granted FDA approval on 30 June 1971. | One of the penicillins which is resistant to penicillinase but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection. | Moderate | 1 | [
[
[
1669,
24,
1366
]
],
[
[
1669,
63,
790
],
[
790,
40,
1366
]
],
[
[
1669,
24,
950
],
[
950,
40,
1366
]
],
[
[
1669,
24,
339
],
[
339,
1,
1366
]
],
[
[
1669,
63,
703
],
[
703,
1,
1366
]
],
[
[
1669,
63,
126
],
[
126,
24,
1366
]
],
[
[
1669,
40,
1572
],
[
1572,
24,
1366
]
],
[
[
1669,
24,
1096
],
[
1096,
24,
1366
]
],
[
[
1669,
63,
663
],
[
663,
25,
1366
]
],
[
[
1669,
63,
790
],
[
790,
1,
1667
],
[
1667,
40,
1366
]
]
] | [
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meticillin"
]
],
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Piperacillin"
],
[
"Piperacillin",
"{u} (Compound) resembles {v} (Compound)",
"Meticillin"
]
],
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cloxacillin"
],
[
"Cloxacillin",
"{u} (Compound) resembles {v} (Compound)",
"Meticillin"
]
],
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bacampicillin"
],
[
"Bacampicillin",
"{u} (Compound) resembles {v} (Compound)",
"Meticillin"
]
],
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbenicillin"
],
[
"Carbenicillin",
"{u} (Compound) resembles {v} (Compound)",
"Meticillin"
]
],
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meticillin"
]
],
[
[
"Minocycline",
"{u} (Compound) resembles {v} (Compound)",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meticillin"
]
],
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meticillin"
]
],
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Meticillin"
]
],
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Piperacillin"
],
[
"Piperacillin",
"{u} (Compound) resembles {v} (Compound)",
"Phenoxymethylpenicillin"
],
[
"Phenoxymethylpenicillin",
"{u} (Compound) resembles {v} (Compound)",
"Meticillin"
]
]
] | Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Piperacillin and Piperacillin (Compound) resembles Meticillin (Compound)
Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Cloxacillin and Cloxacillin (Compound) resembles Meticillin (Compound)
Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Bacampicillin and Bacampicillin (Compound) resembles Meticillin (Compound)
Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Carbenicillin and Carbenicillin (Compound) resembles Meticillin (Compound)
Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Meticillin
Minocycline (Compound) resembles Demeclocycline (Compound) and Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Meticillin
Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Meticillin
Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may lead to a major life threatening interaction when taken with Meticillin
Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Piperacillin and Piperacillin (Compound) resembles Phenoxymethylpenicillin (Compound) and Phenoxymethylpenicillin (Compound) resembles Meticillin (Compound) |
DB00332 | DB00924 | 1,089 | 1,405 | [
"DDInter970",
"DDInter454"
] | Ipratropium | Cyclobenzaprine | Ipratropium is a quaternary ammonium derivative of [atropine] that acts as an anticholinergic agent. It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption. Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its first monotherapy product was FDA approved in 1986, while the combination product of ipratropium and [albuterol] was approved in 1996.[L5894, L5891] | Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 and has been available for human use since 1977. It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.[A185039,A184982] Since its approval, it has remained relatively popular as an adjunctive, short-term treatment for acute skeletal muscle spasms secondary to musculoskeletal injury. | Moderate | 1 | [
[
[
1089,
24,
1405
]
],
[
[
1089,
24,
1302
],
[
1302,
1,
1405
]
],
[
[
1089,
24,
401
],
[
401,
63,
1405
]
],
[
[
1089,
63,
21
],
[
21,
1,
1405
]
],
[
[
1089,
24,
1264
],
[
1264,
64,
1405
]
],
[
[
1089,
6,
12523
],
[
12523,
45,
1405
]
],
[
[
1089,
21,
29574
],
[
29574,
60,
1405
]
],
[
[
1089,
24,
1219
],
[
1219,
24,
1405
]
],
[
[
1089,
35,
19
],
[
19,
24,
1405
]
],
[
[
1089,
63,
352
],
[
352,
24,
1405
]
]
] | [
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protriptyline"
],
[
"Protriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Cyclobenzaprine"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amitriptyline"
],
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Cyclobenzaprine"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cyclobenzaprine"
]
],
[
[
"Ipratropium",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Cyclobenzaprine"
]
],
[
[
"Ipratropium",
"{u} (Compound) causes {v} (Side Effect)",
"Tongue oedema"
],
[
"Tongue oedema",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cyclobenzaprine"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
],
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
]
],
[
[
"Ipratropium",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
]
]
] | Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Protriptyline and Protriptyline (Compound) resembles Cyclobenzaprine (Compound)
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Amitriptyline and Amitriptyline (Compound) resembles Cyclobenzaprine (Compound)
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may lead to a major life threatening interaction when taken with Cyclobenzaprine
Ipratropium (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Cyclobenzaprine (Compound)
Ipratropium (Compound) causes Tongue oedema (Side Effect) and Tongue oedema (Side Effect) is caused by Cyclobenzaprine (Compound)
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine
Ipratropium (Compound) resembles Hyoscyamine (Compound) and Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine |
DB01115 | DB11569 | 336 | 1,093 | [
"DDInter1291",
"DDInter1003"
] | Nifedipine | Ixekizumab | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action. The most popular of the third generation dihydropyridines is [amlodipine]. Nifedipine was granted FDA approval on 31 December 1981. | Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A has been found to be implicated in a variety of autoimmune diseases including Rheumatoid Arthritis and plaque psoriasis. Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing. Ixekizumab is comprised of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each, and has a molecular weight of 146,158 Daltons for the protein backbone of the molecule. It is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. | Moderate | 1 | [
[
[
336,
24,
1093
]
],
[
[
336,
24,
1683
],
[
1683,
24,
1093
]
],
[
[
336,
40,
376
],
[
376,
24,
1093
]
],
[
[
336,
63,
58
],
[
58,
24,
1093
]
],
[
[
336,
62,
1031
],
[
1031,
24,
1093
]
],
[
[
336,
1,
1081
],
[
1081,
24,
1093
]
],
[
[
336,
25,
1456
],
[
1456,
63,
1093
]
],
[
[
336,
63,
1057
],
[
1057,
25,
1093
]
],
[
[
336,
24,
676
],
[
676,
64,
1093
]
],
[
[
336,
24,
1011
],
[
1011,
25,
1093
]
]
] | [
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Nifedipine",
"{u} (Compound) resembles {v} (Compound)",
"Amlodipine"
],
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Nifedipine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Nifedipine",
"{u} (Compound) resembles {v} (Compound)",
"Nicardipine"
],
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Nifedipine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixekizumab"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixekizumab"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixekizumab"
]
]
] | Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Nifedipine (Compound) resembles Amlodipine (Compound) and Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Nifedipine may cause a minor interaction that can limit clinical effects when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Nifedipine (Compound) resembles Nicardipine (Compound) and Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Nifedipine may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Ixekizumab
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Ixekizumab
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Ixekizumab |
DB00204 | DB08895 | 228 | 976 | [
"DDInter580",
"DDInter1825"
] | Dofetilide | Tofacitinib | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer. | Moderate | 1 | [
[
[
228,
24,
976
]
],
[
[
228,
24,
214
],
[
214,
63,
976
]
],
[
[
228,
25,
982
],
[
982,
63,
976
]
],
[
[
228,
24,
86
],
[
86,
24,
976
]
],
[
[
228,
25,
868
],
[
868,
24,
976
]
],
[
[
228,
40,
540
],
[
540,
24,
976
]
],
[
[
228,
62,
1324
],
[
1324,
24,
976
]
],
[
[
228,
25,
1011
],
[
1011,
25,
976
]
],
[
[
228,
23,
1101
],
[
1101,
25,
976
]
],
[
[
228,
25,
1619
],
[
1619,
64,
976
]
]
] | [
[
[
"Dofetilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Dofetilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Dofetilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
],
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Dofetilide",
"{u} (Compound) resembles {v} (Compound)",
"Dronedarone"
],
[
"Dronedarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Dofetilide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Dofetilide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
]
] | Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Dofetilide may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Dofetilide may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Dofetilide (Compound) resembles Dronedarone (Compound) and Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Dofetilide may cause a minor interaction that can limit clinical effects when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Dofetilide may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Tofacitinib
Dofetilide may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Tofacitinib
Dofetilide may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may lead to a major life threatening interaction when taken with Tofacitinib |
DB04951 | DB09118 | 187 | 1,580 | [
"DDInter1477",
"DDInter1711"
] | Pirfenidone | Stiripentol | Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is proposed to primarily regulate tumor necrosis factor (TNF) pathways and modulate cellular oxidation. The FDA first approved pirfenidone alongside [nintedanib] as one of the first drugs to treat IPF. | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzymes. However, its clinical efficacy as adjunctive therapy for epilepsies stems from its inhibitory action on CYP enzymes, as stiripentol reduces the degradation of CYP-sensitive antiepileptic drugs, hence boosting their therapeutic efficacy. Stiripentol may also exhibit direct anticonvulsant properties, although the exact mechanism of action is fully understood. Approved in the US, Canada, and Europe, stiripentol is used to treat seizures associated with Dravet syndrome.[L880,L42500,L42510] It is marketed under the brand name Diacomit. | Moderate | 1 | [
[
[
187,
24,
1580
]
],
[
[
187,
24,
283
],
[
283,
63,
1580
]
],
[
[
187,
62,
168
],
[
168,
24,
1580
]
],
[
[
187,
63,
1018
],
[
1018,
24,
1580
]
],
[
[
187,
24,
1478
],
[
1478,
24,
1580
]
],
[
[
187,
25,
868
],
[
868,
24,
1580
]
],
[
[
187,
25,
1619
],
[
1619,
63,
1580
]
],
[
[
187,
24,
1362
],
[
1362,
25,
1580
]
],
[
[
187,
24,
283
],
[
283,
23,
466
],
[
466,
62,
1580
]
],
[
[
187,
62,
168
],
[
168,
24,
283
],
[
283,
63,
1580
]
]
] | [
[
[
"Pirfenidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Pirfenidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Pirfenidone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Pirfenidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Pirfenidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Pirfenidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Pirfenidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Pirfenidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Stiripentol"
]
],
[
[
"Pirfenidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Stiripentol"
]
],
[
[
"Pirfenidone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
]
] | Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Pirfenidone may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Pirfenidone may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Pirfenidone may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may lead to a major life threatening interaction when taken with Stiripentol
Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Stiripentol
Pirfenidone may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol |
DB00570 | DB09098 | 147 | 98 | [
"DDInter1936",
"DDInter1700"
] | Vinblastine | Somatrem | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disposition of short stature should be considered a medical condition justifying medical treatment with such hormone therapy - especially when these hormone agents have been proven effective at increasing the height of children with or without growth hormone deficiency . | Moderate | 1 | [
[
[
147,
24,
98
]
],
[
[
147,
63,
168
],
[
168,
23,
98
]
],
[
[
147,
24,
671
],
[
671,
24,
98
]
],
[
[
147,
24,
159
],
[
159,
63,
98
]
],
[
[
147,
25,
609
],
[
609,
24,
98
]
],
[
[
147,
62,
63
],
[
63,
24,
98
]
],
[
[
147,
63,
10
],
[
10,
24,
98
]
],
[
[
147,
23,
307
],
[
307,
24,
98
]
],
[
[
147,
25,
1155
],
[
1155,
63,
98
]
],
[
[
147,
64,
695
],
[
695,
24,
98
]
]
] | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Somatrem"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Vinblastine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Vinblastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Teniposide"
],
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapsone"
],
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Vinblastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Vinblastine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
],
[
"Tucatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Vinblastine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
]
] | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somatrem
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Vinblastine may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Vinblastine may cause a minor interaction that can limit clinical effects when taken with Teniposide and Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Vinblastine may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Vinblastine may lead to a major life threatening interaction when taken with Tucatinib and Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Vinblastine may lead to a major life threatening interaction when taken with Clozapine and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem |
DB01234 | DB11791 | 1,220 | 785 | [
"DDInter513",
"DDInter287"
] | Dexamethasone | Capmatinib | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen. | Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or overexpression - is known to occur in many types of cancer, and leads to overactivation of multiple downstream signaling pathways such as STAT3, PI3K/ATK, and RAS/MAPK. Mutations in _MET_ have been detected in non-small cell lung cancer (NSCLC), and the prevalence of _MET_ amplification in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)-naive patients with NSCLC has been reported to be 1.4% - 21%. This co-occurrence has made c-Met a desirable target in the treatment of NSCLC. Manufactured by Novartis and marketed under the brand name Tabrecta, capmatinib was granted accelerated approval by the FDA on May 6, 2020, for the treatment of NSCLC in patients whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping. The presence of the mutation must be confirmed by an FDA-approved test, such as the FoundationOne CDx assay (manufactured by Foundation Medicine, Inc.), which was approved by the FDA on the same day. As this indication was granted under an accelerated approval, its continued approval is contingent upon verification of capmatinib's benefit in confirmatory trials. Capmatinib was approved by Health Canada on June 8, 2022. | Major | 2 | [
[
[
1220,
25,
785
]
],
[
[
1220,
24,
1135
],
[
1135,
23,
785
]
],
[
[
1220,
63,
1324
],
[
1324,
24,
785
]
],
[
[
1220,
24,
868
],
[
868,
24,
785
]
],
[
[
1220,
25,
866
],
[
866,
24,
785
]
],
[
[
1220,
24,
1320
],
[
1320,
63,
785
]
],
[
[
1220,
25,
283
],
[
283,
63,
785
]
],
[
[
1220,
64,
1064
],
[
1064,
24,
785
]
],
[
[
1220,
62,
608
],
[
608,
24,
785
]
],
[
[
1220,
25,
1017
],
[
1017,
64,
785
]
]
] | [
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Capmatinib"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capmatinib"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobimetinib"
],
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Capmatinib"
]
]
] | Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Capmatinib
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Dexamethasone may lead to a major life threatening interaction when taken with Cobimetinib and Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Dexamethasone may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Dexamethasone may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Dexamethasone may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Capmatinib |
DB00570 | DB01610 | 147 | 248 | [
"DDInter1936",
"DDInter1912"
] | Vinblastine | Valganciclovir | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. | Moderate | 1 | [
[
[
147,
24,
248
]
],
[
[
147,
24,
563
],
[
563,
1,
248
]
],
[
[
147,
21,
29209
],
[
29209,
60,
248
]
],
[
[
147,
63,
1101
],
[
1101,
24,
248
]
],
[
[
147,
24,
372
],
[
372,
24,
248
]
],
[
[
147,
24,
1480
],
[
1480,
63,
248
]
],
[
[
147,
25,
507
],
[
507,
63,
248
]
],
[
[
147,
64,
1648
],
[
1648,
24,
248
]
],
[
[
147,
25,
770
],
[
770,
24,
248
]
],
[
[
147,
62,
63
],
[
63,
24,
248
]
]
] | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
],
[
"Ganciclovir",
"{u} (Compound) resembles {v} (Compound)",
"Valganciclovir"
]
],
[
[
"Vinblastine",
"{u} (Compound) causes {v} (Side Effect)",
"Anorexia"
],
[
"Anorexia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Valganciclovir"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
],
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Vinblastine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
],
[
"Samarium (153Sm) lexidronam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Vinblastine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Vinblastine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Vinblastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Teniposide"
],
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
]
] | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir (Compound) resembles Valganciclovir (Compound)
Vinblastine (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Valganciclovir (Compound)
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir
Vinblastine may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam and Samarium (153Sm) lexidronam may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir
Vinblastine may lead to a major life threatening interaction when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir
Vinblastine may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir
Vinblastine may cause a minor interaction that can limit clinical effects when taken with Teniposide and Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir |
DB00305 | DB01059 | 377 | 956 | [
"DDInter1232",
"DDInter1313"
] | Mitomycin | Norfloxacin | Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix. Few other antibiotics have been discovered that work via this alkylating mechanism, making mitomycin relatively unique in the space of microbiota-derived therapies. Mitomycin's cross-linking activity has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper Tract Urothelial Cancer (LG-UTUC) - as well as adjunctly to _ab externo_ glaucoma surgeries. | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Minor | 0 | [
[
[
377,
23,
956
]
],
[
[
377,
23,
872
],
[
872,
40,
956
]
],
[
[
377,
62,
1176
],
[
1176,
1,
956
]
],
[
[
377,
23,
1539
],
[
1539,
1,
956
]
],
[
[
377,
18,
3199
],
[
3199,
45,
956
]
],
[
[
377,
18,
8781
],
[
8781,
46,
956
]
],
[
[
377,
21,
28658
],
[
28658,
60,
956
]
],
[
[
377,
24,
1307
],
[
1307,
23,
956
]
],
[
[
377,
25,
970
],
[
970,
23,
956
]
],
[
[
377,
63,
1648
],
[
1648,
23,
956
]
]
] | [
[
[
"Mitomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norfloxacin"
]
],
[
[
"Mitomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Norfloxacin"
]
],
[
[
"Mitomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Norfloxacin"
]
],
[
[
"Mitomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Norfloxacin"
]
],
[
[
"Mitomycin",
"{u} (Compound) downregulates {v} (Gene)",
"TOP2A"
],
[
"TOP2A",
"{u} (Gene) is bound by {v} (Compound)",
"Norfloxacin"
]
],
[
[
"Mitomycin",
"{u} (Compound) downregulates {v} (Gene)",
"ST7"
],
[
"ST7",
"{u} (Gene) is upregulated by {v} (Compound)",
"Norfloxacin"
]
],
[
[
"Mitomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Norfloxacin"
]
],
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
],
[
"Melphalan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norfloxacin"
]
],
[
[
"Mitomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluorouracil"
],
[
"Fluorouracil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norfloxacin"
]
],
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norfloxacin"
]
]
] | Mitomycin may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Norfloxacin (Compound)
Mitomycin may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Norfloxacin (Compound)
Mitomycin may cause a minor interaction that can limit clinical effects when taken with Ofloxacin and Ofloxacin (Compound) resembles Norfloxacin (Compound)
Mitomycin (Compound) downregulates TOP2A (Gene) and TOP2A (Gene) is bound by Norfloxacin (Compound)
Mitomycin (Compound) downregulates ST7 (Gene) and ST7 (Gene) is upregulated by Norfloxacin (Compound)
Mitomycin (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Norfloxacin (Compound)
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan may cause a minor interaction that can limit clinical effects when taken with Norfloxacin
Mitomycin may lead to a major life threatening interaction when taken with Fluorouracil and Fluorouracil may cause a minor interaction that can limit clinical effects when taken with Norfloxacin
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Norfloxacin |
DB00014 | DB06655 | 521 | 5 | [
"DDInter839",
"DDInter1077"
] | Goserelin | Liraglutide | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal. | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor. Liraglutide was granted FDA approval on January 25, 2010. | Moderate | 1 | [
[
[
521,
24,
5
]
],
[
[
521,
24,
245
],
[
245,
24,
5
]
],
[
[
521,
24,
1296
],
[
1296,
63,
5
]
],
[
[
521,
25,
839
],
[
839,
24,
5
]
],
[
[
521,
25,
1154
],
[
1154,
63,
5
]
],
[
[
521,
25,
246
],
[
246,
25,
5
]
],
[
[
521,
24,
245
],
[
245,
23,
1103
],
[
1103,
23,
5
]
],
[
[
521,
24,
1630
],
[
1630,
63,
245
],
[
245,
24,
5
]
],
[
[
521,
24,
480
],
[
480,
62,
870
],
[
870,
24,
5
]
],
[
[
521,
24,
216
],
[
216,
24,
870
],
[
870,
24,
5
]
]
] | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Grepafloxacin"
],
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
],
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Liraglutide"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Liraglutide"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"
],
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpromazine"
],
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
]
] | Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Goserelin may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Goserelin may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Goserelin may lead to a major life threatening interaction when taken with Gatifloxacin and Gatifloxacin may lead to a major life threatening interaction when taken with Liraglutide
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a minor interaction that can limit clinical effects when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide |
DB00594 | DB00759 | 863 | 1,620 | [
"DDInter68",
"DDInter1783"
] | Amiloride | Tetracycline | A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with diuretics to spare potassium loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705) | Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells. The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml. Other formulations of tetracycline continue to be used. | Minor | 0 | [
[
[
863,
23,
1620
]
],
[
[
863,
23,
1572
],
[
1572,
40,
1620
]
],
[
[
863,
62,
964
],
[
964,
40,
1620
]
],
[
[
863,
23,
319
],
[
319,
63,
1620
]
],
[
[
863,
24,
286
],
[
286,
63,
1620
]
],
[
[
863,
23,
1572
],
[
1572,
1,
11377
],
[
11377,
40,
1620
]
],
[
[
863,
62,
964
],
[
964,
1,
1572
],
[
1572,
40,
1620
]
],
[
[
863,
23,
1545
],
[
1545,
40,
1572
],
[
1572,
40,
1620
]
],
[
[
863,
23,
319
],
[
319,
63,
1572
],
[
1572,
40,
1620
]
],
[
[
863,
24,
286
],
[
286,
63,
1572
],
[
1572,
40,
1620
]
]
] | [
[
[
"Amiloride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracycline"
]
],
[
[
"Amiloride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} (Compound) resembles {v} (Compound)",
"Tetracycline"
]
],
[
[
"Amiloride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} (Compound) resembles {v} (Compound)",
"Tetracycline"
]
],
[
[
"Amiloride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amoxicillin"
],
[
"Amoxicillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracycline"
]
],
[
[
"Amiloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracycline"
]
],
[
[
"Amiloride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} (Compound) resembles {v} (Compound)",
"Methacycline"
],
[
"Methacycline",
"{u} (Compound) resembles {v} (Compound)",
"Tetracycline"
]
],
[
[
"Amiloride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} (Compound) resembles {v} (Compound)",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} (Compound) resembles {v} (Compound)",
"Tetracycline"
]
],
[
[
"Amiloride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Oxytetracycline"
],
[
"Oxytetracycline",
"{u} (Compound) resembles {v} (Compound)",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} (Compound) resembles {v} (Compound)",
"Tetracycline"
]
],
[
[
"Amiloride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amoxicillin"
],
[
"Amoxicillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} (Compound) resembles {v} (Compound)",
"Tetracycline"
]
],
[
[
"Amiloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} (Compound) resembles {v} (Compound)",
"Tetracycline"
]
]
] | Amiloride may cause a minor interaction that can limit clinical effects when taken with Demeclocycline and Demeclocycline (Compound) resembles Tetracycline (Compound)
Amiloride may cause a minor interaction that can limit clinical effects when taken with Doxycycline and Doxycycline (Compound) resembles Tetracycline (Compound)
Amiloride may cause a minor interaction that can limit clinical effects when taken with Amoxicillin and Amoxicillin may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline
Amiloride may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline
Amiloride may cause a minor interaction that can limit clinical effects when taken with Demeclocycline and Demeclocycline (Compound) resembles Methacycline (Compound) and Methacycline (Compound) resembles Tetracycline (Compound)
Amiloride may cause a minor interaction that can limit clinical effects when taken with Doxycycline and Doxycycline (Compound) resembles Demeclocycline (Compound) and Demeclocycline (Compound) resembles Tetracycline (Compound)
Amiloride may cause a minor interaction that can limit clinical effects when taken with Oxytetracycline and Oxytetracycline (Compound) resembles Demeclocycline (Compound) and Demeclocycline (Compound) resembles Tetracycline (Compound)
Amiloride may cause a minor interaction that can limit clinical effects when taken with Amoxicillin and Amoxicillin may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline (Compound) resembles Tetracycline (Compound)
Amiloride may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline (Compound) resembles Tetracycline (Compound) |
DB01211 | DB11575 | 609 | 1,676 | [
"DDInter393",
"DDInter841"
] | Clarithromycin | Grazoprevir | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration. | Grazoprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients . Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as Grazoprevir. Grazoprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 [synthesis]. These enzymes are essential for viral replication and serve to cleave the virally encoded polyprotein into mature proteins like NS3, NS4A, NS4B, NS5A and NS5B [FDA Label]. The barrier for develoment of resistance to NS3/4A inhibitors is lower than that of NS5B inhibitors, another class of DAAs . Subtitutions at amino acid positions 155, 156, or 168 are known to confer resistance. The substitutions of the enzyme's catalytic triad consisting of H58, D82, and S139 are also likely to alter the affinity of the drug for NS3/4A or the activity of the enzyme itself. Despite this disadvantage Grazoprevir is still effective against HCV particularly when paired with . In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Grazoprevir as first line therapy in combination with for genotypes 1a, 1b, and 4 of Hepatitis C . Grazoprevir and are used with or without with the intent to cure, or achieve a sustained virologic response (SVR), after 12 weeks of daily therapy. SVR and eradication of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause mortality . Grazoprevir is available as a fixed dose combination product with (tradename Zepatier) used for the treatment of chronic Hepatitis C. Approved in January 2016 by the FDA, Zepatier is indicated for the treatment of HCV genotypes 1 and 4 with or without depending on the the presence of resistance associated amino acid substitutions in the NS5A protein and previous treatment failure with , , , or other NS3/4A inhibitors like , , or [FDA Label]. When combined together, Grazoprevir and as the combination product Zepatier have been shown to achieve a SVR between 94% and 97% for genotype 1 and 97% and 100% for genotype 4 after 12 weeks of treatment . It can be used in patients with compensated cirrhosis, human immunodeficiency virus co-infection, or severe kidney disease. | Major | 2 | [
[
[
609,
25,
1676
]
],
[
[
609,
63,
723
],
[
723,
24,
1676
]
],
[
[
609,
25,
868
],
[
868,
24,
1676
]
],
[
[
609,
24,
1151
],
[
1151,
24,
1676
]
],
[
[
609,
62,
752
],
[
752,
24,
1676
]
],
[
[
609,
25,
351
],
[
351,
63,
1676
]
],
[
[
609,
25,
1017
],
[
1017,
64,
1676
]
],
[
[
609,
24,
412
],
[
412,
25,
1676
]
],
[
[
609,
25,
1491
],
[
1491,
25,
1676
]
],
[
[
609,
24,
466
],
[
466,
64,
1676
]
]
] | [
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Grazoprevir"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Grazoprevir"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Grazoprevir"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
],
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Grazoprevir"
]
],
[
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Grazoprevir"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Grazoprevir"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Grazoprevir"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
],
[
"Eluxadoline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Grazoprevir"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Grazoprevir"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Grazoprevir"
]
]
] | Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Grazoprevir
Clarithromycin may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Grazoprevir
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Grazoprevir
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Grazoprevir
Clarithromycin may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Grazoprevir
Clarithromycin may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Grazoprevir
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline and Eluxadoline may lead to a major life threatening interaction when taken with Grazoprevir
Clarithromycin may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin may lead to a major life threatening interaction when taken with Grazoprevir
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may lead to a major life threatening interaction when taken with Grazoprevir |
DB01024 | DB13257 | 1,096 | 260 | [
"DDInter1252",
"DDInter727"
] | Mycophenolic acid | Ferrous sulfate anhydrous | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone. This regimen can be used in place of the older anti-proliferative [azathioprine] due to its stronger immunosuppressive potency. However, mycophenolic acid treatment is more expensive and requires therapeutic drug monitoring to optimize efficacy and minimize toxicity.[A249180,A249185] Mycophenolic acid is available as enteric-coated tablets of delayed-release, in an effort to improve upper gastrointestinal adverse events by delaying mycophenolic | Iron deficiency anemia is a large public health concern worldwide, especially in young children, infants, and women of childbearing age. This type of anemia occurs when iron intake, iron stores, and iron loss do not adequately support the formation of erythrocytes, also known as red blood cells. Ferrous sulfate is a synthetic agent used in the treatment of iron deficiency. It is the gold standard of oral iron therapy in the UK and many other countries.[L2234,L2246] | Minor | 0 | [
[
[
1096,
23,
260
]
],
[
[
1096,
23,
1114
],
[
1114,
23,
260
]
],
[
[
1096,
63,
1620
],
[
1620,
24,
260
]
],
[
[
1096,
24,
460
],
[
460,
24,
260
]
],
[
[
1096,
25,
1292
],
[
1292,
24,
260
]
],
[
[
1096,
23,
1114
],
[
1114,
63,
1620
],
[
1620,
24,
260
]
],
[
[
1096,
63,
1620
],
[
1620,
24,
1114
],
[
1114,
23,
260
]
],
[
[
1096,
24,
460
],
[
460,
62,
752
],
[
752,
23,
260
]
],
[
[
1096,
25,
1292
],
[
1292,
24,
1114
],
[
1114,
23,
260
]
],
[
[
1096,
63,
597
],
[
597,
24,
489
],
[
489,
24,
260
]
]
] | [
[
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ferrous sulfate anhydrous"
]
],
[
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
[
"Zinc sulfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ferrous sulfate anhydrous"
]
],
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracycline"
],
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous sulfate anhydrous"
]
],
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
],
[
"Magnesium carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous sulfate anhydrous"
]
],
[
[
"Mycophenolic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
],
[
"Deferiprone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous sulfate anhydrous"
]
],
[
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
[
"Zinc sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracycline"
],
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous sulfate anhydrous"
]
],
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracycline"
],
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc sulfate"
],
[
"Zinc sulfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ferrous sulfate anhydrous"
]
],
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
],
[
"Magnesium carbonate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ferrous sulfate anhydrous"
]
],
[
[
"Mycophenolic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
],
[
"Deferiprone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc sulfate"
],
[
"Zinc sulfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ferrous sulfate anhydrous"
]
],
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron sucrose"
],
[
"Iron sucrose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous sulfate anhydrous"
]
]
] | Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Ferrous sulfate anhydrous
Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline and Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Ferrous sulfate anhydrous
Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate and Magnesium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Ferrous sulfate anhydrous
Mycophenolic acid may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone may cause a moderate interaction that could exacerbate diseases when taken with Ferrous sulfate anhydrous
Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline and Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Ferrous sulfate anhydrous
Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline and Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Ferrous sulfate anhydrous
Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate and Magnesium carbonate may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Ferrous sulfate anhydrous
Mycophenolic acid may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone may cause a moderate interaction that could exacerbate diseases when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Ferrous sulfate anhydrous
Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Iron sucrose and Iron sucrose may cause a moderate interaction that could exacerbate diseases when taken with Ferrous sulfate anhydrous |
DB00876 | DB00959 | 1,414 | 1,486 | [
"DDInter658",
"DDInter1191"
] | Eprosartan | Methylprednisolone | Eprosartan is an angiotensin II receptor antagonist used to treat hypertension. It performs 2 actions on the renin angiotensin system. By preventing the binding of angiotensin II to AT1, vascular smooth muscle relaxes and vasodilation occurs. By inhibiting norepinephrine production, blood pressure is further reduced. | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression. The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials. | Moderate | 1 | [
[
[
1414,
24,
1486
]
],
[
[
1414,
63,
175
],
[
175,
40,
1486
]
],
[
[
1414,
63,
167
],
[
167,
1,
1486
]
],
[
[
1414,
24,
1220
],
[
1220,
1,
1486
]
],
[
[
1414,
24,
617
],
[
617,
40,
1486
]
],
[
[
1414,
21,
28997
],
[
28997,
60,
1486
]
],
[
[
1414,
24,
1344
],
[
1344,
63,
1486
]
],
[
[
1414,
24,
1479
],
[
1479,
24,
1486
]
],
[
[
1414,
63,
1648
],
[
1648,
24,
1486
]
],
[
[
1414,
1,
240
],
[
240,
24,
1486
]
]
] | [
[
[
"Eprosartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Eprosartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
]
],
[
[
"Eprosartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
]
],
[
[
"Eprosartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
]
],
[
[
"Eprosartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
]
],
[
[
"Eprosartan",
"{u} (Compound) causes {v} (Side Effect)",
"Ill-defined disorder"
],
[
"Ill-defined disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Methylprednisolone"
]
],
[
[
"Eprosartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Eprosartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Eprosartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Eprosartan",
"{u} (Compound) resembles {v} (Compound)",
"Losartan"
],
[
"Losartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
]
] | Eprosartan may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Eprosartan may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Methylprednisolone (Compound)
Eprosartan may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Methylprednisolone (Compound)
Eprosartan may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide (Compound) resembles Methylprednisolone (Compound)
Eprosartan (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is caused by Methylprednisolone (Compound)
Eprosartan may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone
Eprosartan may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone
Eprosartan may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone
Eprosartan (Compound) resembles Losartan (Compound) and Losartan may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone |
DB00289 | DB06706 | 847 | 468 | [
"DDInter132",
"DDInter985"
] | Atomoxetine | Isometheptene | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associated with ADHD including distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. Although the underlying pathophysiology that causes ADHD remains unclear, evidence suggests that dysregulation in noradrenergic and dopaminergic pathways plays a critical role in suboptimal executive functioning within prefrontal regions of the brain, which are involved in attention and memory. Atomoxetine has been shown to specifically increase NA and DA within the prefrontal cortex, but not in the nucleus accumbens (NA) or striatum. This is beneficial in the treatment of ADHD as DA activation in the subcortical NA and stri | Isometheptene is a sympathomimetic drug that causes vasoconstriction. It is used for treating migraines and tension headaches. | Moderate | 1 | [
[
[
847,
24,
468
]
],
[
[
847,
24,
480
],
[
480,
24,
468
]
],
[
[
847,
24,
144
],
[
144,
63,
468
]
],
[
[
847,
23,
222
],
[
222,
24,
468
]
],
[
[
847,
1,
939
],
[
939,
24,
468
]
],
[
[
847,
25,
1629
],
[
1629,
64,
468
]
],
[
[
847,
25,
1053
],
[
1053,
25,
468
]
],
[
[
847,
24,
480
],
[
480,
24,
1354
],
[
1354,
24,
468
]
],
[
[
847,
24,
1148
],
[
1148,
63,
1000
],
[
1000,
24,
468
]
],
[
[
847,
23,
222
],
[
222,
63,
480
],
[
480,
24,
468
]
]
] | [
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isometheptene"
]
],
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isometheptene"
]
],
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
],
[
"Olodaterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isometheptene"
]
],
[
[
"Atomoxetine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isometheptene"
]
],
[
[
"Atomoxetine",
"{u} (Compound) resembles {v} (Compound)",
"Benzphetamine"
],
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isometheptene"
]
],
[
[
"Atomoxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
],
[
"Methylene blue",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isometheptene"
]
],
[
[
"Atomoxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isometheptene"
]
],
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Droxidopa"
],
[
"Droxidopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isometheptene"
]
],
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanadrel"
],
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isometheptene"
]
],
[
[
"Atomoxetine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isometheptene"
]
]
] | Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene
Atomoxetine may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene
Atomoxetine (Compound) resembles Benzphetamine (Compound) and Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene
Atomoxetine may lead to a major life threatening interaction when taken with Methylene blue and Methylene blue may lead to a major life threatening interaction when taken with Isometheptene
Atomoxetine may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Isometheptene
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Droxidopa and Droxidopa may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Guanadrel and Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene
Atomoxetine may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene |
DB08868 | DB12159 | 1,011 | 12 | [
"DDInter737",
"DDInter609"
] | Fingolimod | Dupilumab | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.[L12654,L12657] | Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that induce inflammatory and immunological reactions in several atopic or allergic conditions, such as eczema, allergic reaction, and rhinosinusitis. Dupilumab was generated by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture. Dupilumab is commonly marketed as Dupixent, which is available as a formulation for subcutaneous injection. It was first approved by the FDA in 2017. It is currently used to treat atopic dermatitis, asthma as an add-on maintenance treatment, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis. It is used as monotherapy or in combination with other drugs, such as corticosteroids.[L7186,L7192,L41439] Dupilumab is currently under investigations for potential therapeutic use in diseases driven by allergic reactions or type 2 inflammation, such as pediatric atopic dermatitis, and chronic obstructive pulmonary disease. It is also being studied in combination with another antibody that which targets IL-33. | Major | 2 | [
[
[
1011,
25,
12
]
],
[
[
1011,
64,
599
],
[
599,
24,
12
]
],
[
[
1011,
63,
1136
],
[
1136,
24,
12
]
],
[
[
1011,
25,
287
],
[
287,
63,
12
]
],
[
[
1011,
25,
713
],
[
713,
24,
12
]
],
[
[
1011,
24,
1129
],
[
1129,
63,
12
]
],
[
[
1011,
64,
581
],
[
581,
25,
12
]
],
[
[
1011,
25,
1624
],
[
1624,
25,
12
]
],
[
[
1011,
25,
676
],
[
676,
64,
12
]
],
[
[
1011,
64,
599
],
[
599,
24,
1136
],
[
1136,
24,
12
]
]
] | [
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dupilumab"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dupilumab"
]
],
[
[
"Fingolimod",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
],
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dupilumab"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
],
[
"Diroximel fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dupilumab"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dimethyl fumarate"
],
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dupilumab"
]
],
[
[
"Fingolimod",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
],
[
"Human adenovirus e serotype 4 strain cl-68578 antigen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dupilumab"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dupilumab"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
],
[
"Rotavirus vaccine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dupilumab"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dupilumab"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
],
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dupilumab"
]
]
] | Fingolimod may lead to a major life threatening interaction when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Dupilumab
Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Dupilumab
Fingolimod may lead to a major life threatening interaction when taken with Diroximel fumarate and Diroximel fumarate may cause a moderate interaction that could exacerbate diseases when taken with Dupilumab
Fingolimod may lead to a major life threatening interaction when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Dupilumab
Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen and Human adenovirus e serotype 4 strain cl-68578 antigen may cause a moderate interaction that could exacerbate diseases when taken with Dupilumab
Fingolimod may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Dupilumab
Fingolimod may lead to a major life threatening interaction when taken with Rotavirus vaccine and Rotavirus vaccine may lead to a major life threatening interaction when taken with Dupilumab
Fingolimod may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Dupilumab
Fingolimod may lead to a major life threatening interaction when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Dupilumab |
DB00069 | DB00526 | 367 | 1,555 | [
"DDInter946",
"DDInter1355"
] | Interferon alfacon-1 | Oxaliplatin | Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional amino acid changes were made to facilitate the molecular construction, and a corresponding synthetic DNA sequence was constructed using chemical synthesis methodology. Interferon alfacon-1 differs from interferon alfa-2b at 20/166 amino acids (88% homology), and comparison with interferon-beta shows identity at over 30% of the amino acid positions. Interferon alfacon-1 is produced in Escherichia coli (E. coli) cells that have been genetically altered by insertion of a synthetically constructed sequence that codes for Interferon alfacon-1. Prior to final purification, Interferon alfacon- | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The DACH moiety also prevents cross-resistance with cisplatin and carboplatin. Although oxaliplatin has been investigated as a monotherapy, it is typically administered in combination with fluorouracil and leucovorin, known as the FOLFOX regimen, for the treatment of colorectal cancer.[A796,A797] This is an effective combination treatment both as a first-line treatment and in patients refractory to an initial fluorouracil and leucovorin combination. Ongoing trials have also shown promising results for oxaliplatin use in nonHodgkin’s lymphoma, breast cancer, mesothelioma, and non-small cell lung cancer. Oxaliplatin was approved by the FDA on January 9, 2004 and is currently marketed by Sanofi-Aventis under the trademark Eloxatin®. | Moderate | 1 | [
[
[
367,
24,
1555
]
],
[
[
367,
24,
810
],
[
810,
63,
1555
]
],
[
[
367,
24,
289
],
[
289,
24,
1555
]
],
[
[
367,
63,
1257
],
[
1257,
24,
1555
]
],
[
[
367,
64,
1648
],
[
1648,
24,
1555
]
],
[
[
367,
25,
534
],
[
534,
24,
1555
]
],
[
[
367,
25,
1477
],
[
1477,
63,
1555
]
],
[
[
367,
23,
450
],
[
450,
63,
1555
]
],
[
[
367,
25,
976
],
[
976,
64,
1555
]
],
[
[
367,
24,
908
],
[
908,
64,
1555
]
]
] | [
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
],
[
"Strontium chloride Sr-89",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cerivastatin"
],
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegfilgrastim"
],
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Interferon alfacon-1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Interferon alfacon-1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tramadol"
],
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Interferon alfacon-1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telbivudine"
],
[
"Telbivudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Interferon alfacon-1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxaliplatin"
]
]
] | Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89 and Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Cerivastatin and Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Pegfilgrastim and Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Interferon alfacon-1 may lead to a major life threatening interaction when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Interferon alfacon-1 may lead to a major life threatening interaction when taken with Tramadol and Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Interferon alfacon-1 may lead to a major life threatening interaction when taken with Telbivudine and Telbivudine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Interferon alfacon-1 may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Interferon alfacon-1 may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Oxaliplatin
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Oxaliplatin |
DB00992 | DB01118 | 842 | 33 | [
"DDInter1182",
"DDInter76"
] | Methyl aminolevulinate (topical) | Amiodarone | Methyl 5-aminolevulinate is the methyl ester of 5-aminolevulinic acid. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application (often as the hydrochloride salt) results in an accumulation of protoporphyrin IX in the skin lesions to which the cream has been applied. Subsequent illumination with red light results in the generation of toxic singlet oxygen that destroys cell membranes and thereby kills the tumour cells. It has a role as an antineoplastic agent, a photosensitizing agent, a prodrug and a dermatologic drug. It is functionally related to a 5-aminolevulinic acid. | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxicity and possibly death, amiodarone use should be reserved for its approved indications, according to prescribing information.[L3561,L11265,L11286] | Moderate | 1 | [
[
[
842,
24,
33
]
],
[
[
842,
21,
28681
],
[
28681,
60,
33
]
],
[
[
842,
63,
663
],
[
663,
24,
33
]
],
[
[
842,
24,
866
],
[
866,
63,
33
]
],
[
[
842,
24,
187
],
[
187,
64,
33
]
],
[
[
842,
75,
213
],
[
213,
25,
33
]
],
[
[
842,
21,
28681
],
[
28681,
60,
597
],
[
597,
24,
33
]
],
[
[
842,
21,
28714
],
[
28714,
60,
540
],
[
540,
1,
33
]
],
[
[
842,
63,
663
],
[
663,
24,
540
],
[
540,
1,
33
]
],
[
[
842,
24,
866
],
[
866,
64,
540
],
[
540,
1,
33
]
]
] | [
[
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
]
],
[
[
"Methyl aminolevulinate",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Amiodarone"
]
],
[
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
]
],
[
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
],
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
]
],
[
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pirfenidone"
],
[
"Pirfenidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amiodarone"
]
],
[
[
"Methyl aminolevulinate",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
],
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amiodarone"
]
],
[
[
"Methyl aminolevulinate",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
]
],
[
[
"Methyl aminolevulinate",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dronedarone"
],
[
"Dronedarone",
"{u} (Compound) resembles {v} (Compound)",
"Amiodarone"
]
],
[
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u} (Compound) resembles {v} (Compound)",
"Amiodarone"
]
],
[
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
],
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u} (Compound) resembles {v} (Compound)",
"Amiodarone"
]
]
] | Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone
Methyl aminolevulinate (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Amiodarone (Compound)
Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone
Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib and Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone
Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone and Pirfenidone may lead to a major life threatening interaction when taken with Amiodarone
Methyl aminolevulinate (Compound) resembles Aminolevulinic acid (Compound) and Methyl aminolevulinate may lead to a major life threatening interaction when taken with Aminolevulinic acid and Aminolevulinic acid may lead to a major life threatening interaction when taken with Amiodarone
Methyl aminolevulinate (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Chloramphenicol (Compound) and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone
Methyl aminolevulinate (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Dronedarone (Compound) and Dronedarone (Compound) resembles Amiodarone (Compound)
Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone and Dronedarone (Compound) resembles Amiodarone (Compound)
Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib and Cobimetinib may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone (Compound) resembles Amiodarone (Compound) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.